{"pages":[{"(R)N6-phenylisopropyladenosine":{"Created":"2007-09-19","SuperCategory":"Adenosine","Id":"nifext_5214"}},{"1,2-Dibromo-3-chloropropane":{"Synonym":["1, 2-Dibrom-3-chlor-propan","1,2-Dibromo-3-cloro-propano","1,2-Dibrom-3-chlor-propan","1,2-Dibromo-3-chloropropane","1,2-Dibromochloropropane","1,2-Dibroom-3-chloorpropaan","1-Chloro-2,3-dibromopropane","2,3-Dibromo-1-chloropropane","3-Chloro-1,2-dibromopropane","BBCP","CBCP","ClCH2CHBrCH2Br","DBCP","Dibromchlorpropan","Dibromochloropropane","Dibromochloropropane [UN2872]","Durham Nematicode EM 17.1","Fumagon","Fumazon 86","Fumazone","Fumazone 86","Fumazone 86e","Gro-tone nematode granular","Nemabrom","Nemafume","Nemagon","Nemagon 20","Nemagon 206","Nemagon 20G","Nemagon 90","Nemagon soil fumigant","Nemagone","Nemanax","Nemanex","Nemapaz","Nemaset","Nematocide","Nematocide EM 12.1","Nematocide EM 15.1","Nematocide Solution EM 17.1","Nematox","Nemazon"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0044","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0044","Abbrev":"C3H5Br2Cl","Definition":"Organic Compound;Pesticide;Organochloride;Organobromide; 1,2-Dibromo-3-chloropropane is a manufactured chemical and the active ingredient in the nematicide Nemagon, also known as Fumazone."}},{"1,2-Dibromoethane":{"Synonym":[".alpha.,.beta.-dibromoethane","1,2 Dibromoethane","1,2-Dibromo tetradeutero Ethane","1,2-Dibromaethan","1,2-Dibromoetano","1,2-Dibromoethane","1,2-Dibromoethane solution","1,2-Dibromoethane(Ethylene bromide)","1,2-Dibromomethane","1,2-Dibroomethaan","1,2-Ethylene dibromide","1,2-dibromoethane (EDB)","Aadibroom","Aethylenbromid","Alpha,beta-dibromoethane","Alpha,omega-dibromoethane","Ethylene Bromide","Bromofume","Bromuro di etile","CH2BrCH2Br","Caswell No. 439","Celmide","DBE","Ethylene Dibromide","Dibromoethane","1,2-Dibromoethane","Dibromoethylene","Dibromure d'ethylene","Dowfume","Dowfume 40","Dowfume W 85","Dowfume W-100","Dowfume W-8","Dowfume W-85","Dowfume W-90","Dowfume W85","Dowfume edb","Dwubromoetan","E-d-bee","EDB","Edabrom","Ethylene bromide","Ethylene dibromide","Ethylene dibromide [UN1605]","Fumo-gas","Garden dowfume","Glycol bromide","Glycol dibromide","Iscobrome d","Kopfume","Nefis","Nephis","Pestmaster","Pestmaster edb-85","SYM dibromoethane","SYM-dibromoethane","Sanhyuum","Soilbrom","Soilbrom 90EC","Soilbrom-100","Soilbrom-40","Soilbrom-85","Soilbrom-90","Soilbrom-90ec","Soilbrome-85","Soilfume","Unifume"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0035","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0035","Abbrev":"C2H4Br2","Definition":"Organic Compound;Pesticide;Gasoline Additive/Component;Organochloride; 1,2-Dibromoethane is a mainly synthetic chemical that also occurs in small amounts naturally in the ocean. It was once widely used as an additive in leaded gasoline and a pesticide, however, today it's use is restricted to only certain pesticides and dye preparations."}},{"1-120 Truncated Alpha-Synuclein Drosophila":{"PMID":"17376994","CurationStatus":"uncurated","Pages":"3338-3346","PublicationDate":["March 21"],"JournalVolume":"27","PublicationName":"The Journal of Neuroscience","Id":"nlx_organ_090801","JournalNumber":"12","Authors":["Magali Periquet","Tudor Fulga","Liisa Myllykangas","Michael G. Schlossmacher"],"Title":"Aggregated Alpha-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo","Figure":"1-3","Definition":"This transgenic drosophila expresses a form of alpha-synuclein that is a C-terminally truncated fragment comprising amino acids 1-120.  This form of alpha-synuclein has an enhanced ability to aggregate and thus enhanced neurotoxicity.  This mutant is used in research to determine the role of alpha-synuclein aggregation in neurodegenerative diseases, such as Parkinsons."}},{"1-D extent":{"Synonym":"1-D size","SuperCategory":"Size","Id":"PATO_0001708","Definition":"A quality inhering in a bearer by virtue of its extension in one dimension."}},{"11-dehydro-thromboxane B2":{"Created":"2007-09-19","SuperCategory":"Thromboxane","Id":"nifext_5182"}},{"129":{"Created":"2007-08-15","CurationStatus":"pending_final_vetting","SuperCategory":"Inbred mouse strain","Id":"birnlex_219","DefiningCitation":["Beck","J.A.","et al.","Genealogies of mouse inbred strains (2000)","Nature","Jan2000","v24"],"Abbrev":"129"}},{"1D polyacrylamide gel electrophoresis instrument":{"Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Polyacrylamide gel electrophoresis instrument","Id":"birnlex_2411"}},{"1D Time-series analysis software":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Time-series analysis software","Id":"birnlex_2216"}},{"2-Chloro-Adenosine 5'-diphosphate":{"Created":"2007-09-19","SuperCategory":"Adenosine 5'-diphosphate","Id":"nifext_5225"}},{"2-chloro-CPA":{"Created":"2007-09-19","SuperCategory":"N6-cyclopentyladenosine","Id":"nifext_5212"}},{"2-cyclohexylmethylidenehydrazinoadenosine":{"Synonym":"WRC 0470","Created":"2007-09-19","SuperCategory":"Adenosine","Id":"nifext_5221"}},{"2-D extent":{"Synonym":"2-D size","SuperCategory":"Size","Id":"PATO_0001709","Definition":"A quality inhering in a bearer by virtue of its extension in two dimensions."}},{"2-D shape":{"SuperCategory":"Shape","Id":"PATO_0002006","Definition":"A shape that inheres in a 2 dimensional entity, such as a cross section or projection of a 3 dimensional entity."}},{"2-methylthio adenosine 5'-diphosphate":{"Created":"2007-09-19","SuperCategory":"Adenosine 5'-diphosphate","Id":"nifext_5228"}},{"2-methylthio adenosine 5'-triphosphate":{"Created":"2007-09-19","SuperCategory":"Adenosine 5'-triphosphate","Id":"nifext_5230"}},{"2-phenylaminoadenosine":{"Synonym":"CV 1808","Created":"2007-09-19","SuperCategory":"Adenosine","Id":"nifext_5219"}},{"2-substituted-5'-N-ethylcarboxamidoadenosine":{"Created":"2007-09-19","SuperCategory":"Adenosine","Id":"nifext_5215"}},{"2D polyacrylamide gel electrophoresis instrument":{"Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Polyacrylamide gel electrophoresis instrument","Id":"birnlex_2412"}},{"2D spatial image":{"Created":"2007-03-09","CurationStatus":"uncurated","SuperCategory":"Image","Id":"birnlex_2028","Definition":"A type of image where pixel values represent a quantity measure over 2 spatial dimensions."}},{"2D Time-series analysis software":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Time-series analysis software","Id":"birnlex_2217"}},{"3 dB Frequency":{"Synonym":["-3 dB Frequency\tCutoff frequency"],"CurationStatus":"uncurated","SuperCategory":"Device parameter","Id":"oen_0001237","Has role":"Electrophysiology concept","Definition":"The frequency at which the signal voltage at the output of the filter falls to SQRT(1/2) of the amplitude of the input signal"}},{"3,3'-Dichlorobenzidine":{"Synonym":["3,3'-dichloro-(1,1'-Biphenyl)-4,4'-diamine","3,3'-Dichlorobenzidine","3,3'-Dichlorbenzidin","3,3'-Dichloro-4","4'-diaminodiphenyl","3,3'-Dichloro-4,4'-biphenyldiamine","3,3'-Dichloro-4,4'-diamino(1,1-biphenyl)","3,3'-Dichloro-4,4'-diaminobiphenyl","3,3'-Dichloro-4,4'-diaminodiphenyl","3,3'-Dichloro-p,p'-bianiline","3,3'-Dichlorobenzidin","3,3'-Dichlorobenzidina","3,3'-Dichlorobenzidine base","3,3'-Dichlorobiphenyl-4,4'-diamine","3,3'-dichloro[1,1'-biphenyl]-4,4'-diamine","3,3'-dichlorobiphenyl-4,4'-ylenediamine","3,3-Dichloro-[1,1]-biphenyl-4,4-diamine","4 ,4'-diamino-3,3'-dichlorobiphenyl","4'-Amino-3,3'-dichloro(1,1'-biphenyl)-4-ylamine","4,4'-Diamino-3,3'-dichlorobiphenyl","3,3'-dichloro-Benzidine","Curithane C126","DCB","Dichlorobenzidine","Dichlorobenzidine base","3,3'-Dichlorobenzidine","O,o'-dichlorobenzidine","Ortho,ortho'-dichlorobenzidine","3"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0040","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0040","Abbrev":"C12H10Cl2N2","Definition":"Organic Compound;Industrial Precursor/Intermediate;Aromatic Hydrocarbon;Amine;Organochloride; 3,3'-Dichlorobenzidine is a manufactured chemical used in pigments for printing inks, textiles, plastics and enamels, paint, leather, and rubber."}},{"3-D extent":{"Synonym":"3-D size","SuperCategory":"Size","Id":"PATO_0001710","Definition":"A quality inhering in a bearer by virtue of its extension in three dimensions."}},{"3-Methylthiofentanyl":{"RelatedTo":["Delta-type opioid receptor"],"Synonym":"3-Methyl-thiofentanyl,","CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:53763","Has role":"Drug","Definition":"3-Methyl-thiofentanyl is an opioid analgesic that is an analogue of fentanyl. Pharmacology: Not Available Mechanism of action: Not Available Drug type: Experimental. Illicit. Small Molecule. Drug category: Analgesics, Opioid"}},{"3D spatial image":{"Created":"2007-03-09","Synonym":["Volume"],"CurationStatus":"uncurated","SuperCategory":"Image","Curator":"Bill Bug","Id":"birnlex_2165","Definition":"A type of image where pixel values represent a quantity measure over 3 spatial dimensions."}},{"3D T1 weighted MRI scan":{"RelatedTo":"Magnetic resonance imaging","Synonym":"3D T1 weighted scan","CurationStatus":"uncurated","SuperCategory":"MRI 3D image","Id":"nlx_156814"}},{"3D T1 Weighted Scan":{"CurationStatus":"uncurated","Comment":"I don't understand why this is a type of protocol.  Does this refer to the image itself or to the process.  I recommend that we get rid of this class.","SuperCategory":"T1 weighted protocol","Id":"nlx_inv_20090243"}},{"3D Time-series analysis software":{"Synonym":"4D analysis software","Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Time-series analysis software","Id":"birnlex_2218"}},{"3D visualization software":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Data visualization software","Id":"birnlex_2220"}},{"4D visualization software":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Data visualization software","Id":"birnlex_2221"}},{"4Pi microscopy":{"EditorialNote":"Trying to unify the assay and protocol branches, as I think it leads to unnecessary duplication for search.  Decided to go with protocol","CurationStatus":"graph position temporary","SuperCategory":"Optical imaging protocol","Curator":["Maryann Martone"],"Id":"nlx_158014","Has role":"Super-resolution microscopy","Definition":"Imaging assay that utilizes a 4Pi microscope, a laser scanning fluorescence microscope with an improved axial resolution. The typical value of 500\u2013700 nm can be improved to 100\u2013150 nm, which corresponds to an almost spherical focal spot with 5\u20137 times less volume than that of standard confocal microscopy.  The improvement in resolution is achieved by using two opposing objective lenses both of which focused to the same geometrical location. Also the difference in optical path length through each of the two objective lenses is carefully aligned to be minimal. By this, molecules residing in the common focal area of both objectives can be illuminated coherently from both sides and also the reflected or emitted light can be collected coherently, i.e. coherent superposition of emitted light on the detector is possible. (adapted from Wikipedia:  http://en.wikipedia.org/wiki/Super-resolution_microscopy#4Pi)"}},{"5-HT Receptor":{"RelatedTo":"Serotonin","Synonym":["Serotonin Receptor","5 Hydroxytryptamine Receptors","5-Hydroxytryptamine Receptors","Tryptamine Receptors","5-HT Receptors","5 HT Receptors","Hydroxytryptamine receptors 05","HT 05 Receptors","5 Hydroxytryptamine Recept","Recept 5 HT","Tryptamine Recept","Recept 5 Hydroxytryptamine"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"GO:0004993","Has role":"Neurotransmitter Receptor","Is part of":"Serotonergic system","DefiningCitation":"MSH","Definition":"Cell-surface proteins that bind serotonin and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action."}},{"5-HT1A receptor":{"Created":"2007-09-19","Synonym":["1A receptor"],"CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_5890","Has role":"5-HT Receptor","Definition":"A serotonin receptor subtype found distributed through the CENTRAL NERVOUS SYSTEM where they are involved in neuroendocrine regulation of ACTH secretion. The fact that this serotonin receptor subtype is particularly sensitive to SEROTONIN AGONISTS such as BUSPIRONE suggests its role in the modulation of ANXIETY and DEPRESSION."}},{"5-HT1B receptor":{"Created":"2007-09-19","Synonym":["5-HT1B;5- HT1B; 5-HT-1B; 5-HT-1D-beta; S12; Serotonin 1D beta receptor; Serotonin receptor 1B; 5-hydroxytryptamine 1B receptor1B Receptor","5-Hydroxytryptamine; 1B Receptor","Serotonin; 1B Receptors","5-Hydroxytryptamine; 1Dbeta Receptor","Serotonin; 5 HT 1B recept; 5 HT1B Receptor; 5 HT1DBETA recept; 5 HT1Dbeta Receptor; 5 Hydroxytryptamine 1B Receptor; 5-HT(1B) Receptor; 5-HT(1Dbeta) Receptor; Receptor serotonin 5 HT 01 B; Receptor","5 Hydroxytryptamine 1B; Receptor","5-HT1B; Receptor","5-HT1Dbeta; Receptor","5-Hydroxytryptamine 1B; Receptor","Serotonin 1B; Receptor","Serotonin 1Dbeta; Receptor","Serotonin Type 1Dbeta; Receptors","5-Hydroxytryptamine 1B; Receptors"],"CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_6386","Has role":"5-HT Receptor","Definition":"A serotonin receptor subtype found at high levels in the BASAL GANGLIA and the frontal cortex. It plays a role as a terminal autoreceptor that regulates the rate of SEROTONIN release from nerve endings. This serotonin receptor subtype is closely related to and has similar drug binding properties as the 5-HT1D RECEPTOR. It is particularly sensitive to the agonist SUMATRIPAN and may be involved in mediating the drug's antimigraine effect."}},{"5-HT1D receptor":{"Created":"2007-09-19","Synonym":["5 HT1D Receptor; 5 HT1DALPHA RECEPT; 5 Hydroxytryptamine1D Receptor; 5-HT1D Receptor; 5-HT1Dalpha Receptor; 5-Hydroxytryptamine1D Receptor; Receptor","5-HT1D; Receptor","5-Hydroxytryptamine1D; Receptor","Serotonin 1D; Receptor","Serotonin 1Dalpha; Receptors"],"CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_6164","Has role":"5-HT Receptor","Definition":"A serotonin receptor subtype that is localized to the caudate nucleus; putamen; the nucleus accumbens; the hippocampus, and the raphe nuclei. It plays a role as a terminal autoreceptor that regulates the rate of serotonin release from nerve endings. This serotonin receptor subtype is closely related to and has similar drug binding properties as the 5-HT1B receptor, but is expressed at low levels. It is particularly sensitive to the agonist sumatripan and may be involved in mediating the drug's antimigrane effect."}},{"5-HT1E receptor":{"Created":"2007-09-19","Synonym":"5-HT1E; 5- HT1E; 5-HT-1E; S31; Serotonin receptor 1E; 5-hydroxytryptamine 1E receptor","CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_5267","Has role":"5-HT Receptor"}},{"5-HT1F receptor":{"Created":"2007-09-19","Synonym":"5-HT1F; 5-HT-1F; Serotonin receptor 1F; 5-hydroxytryptamine 1F receptor","CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_6354","Has role":"5-HT Receptor"}},{"5-HT2A receptor":{"Created":"2007-09-19","Synonym":"5-HT2A; 5- HT-2; 5-HT-2A; Serotonin receptor 2A; 5-hydroxytryptamine 2A receptor","CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_6741","Has role":"5-HT Receptor"}},{"5-HT2B receptor":{"Created":"2007-09-19","Synonym":"5-HT2B;5-HT-2B; Serotonin receptor 2B; 5-hydroxytryptamine 2B receptor","CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_6982","Has role":"5-HT Receptor"}},{"5-HT2C receptor":{"Created":"2007-09-19","Synonym":"5-HT2C;5- HT2C; 5-HT-2C; 5-HTR2C; 5HT-1C; Serotonin receptor 2C; 5-hydroxytryptamine 2C receptor","CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_7414","Has role":"5-HT Receptor"}},{"5-HT4 receptor":{"Created":"2007-09-19","Synonym":"5-HT4; 5- HT4; 5-HT-4; Serotonin receptor 4; 5-hydroxytryptamine 4 receptor","CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_6151","Has role":"5-HT Receptor"}},{"5-HT5A receptor":{"Created":"2007-09-19","Synonym":"5-HT5A","CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_6120","Has role":"5-HT Receptor"}},{"5-HT6 receptor":{"Created":"2007-09-19","Synonym":"5-HT6; 5-HT-6; Serotonin receptor 6; 5-hydroxytryptamine 6 receptor","CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_7153","Has role":"5-HT Receptor"}},{"5-HT7 receptor":{"Created":"2007-09-19","Synonym":"5-HT7; 5-HT- X; 5-HT-7; 5HT7; Serotonin receptor 7; 5-hydroxytryptamine 7 receptor","CurationStatus":"uncurated","SuperCategory":"Serotonin G-protein coupled receptor","Id":"nifext_6854","Has role":"5-HT Receptor"}},{"5-Methoxy-N,N-diisopropyltryptamine":{"Synonym":["5-MeO-DIPT","5-methoxy-N,N-bis(1-methylethyl)-1H-Indole-3-ethanamine","Foxy"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:48282","Has role":"Drug","Definition":"5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a tryptamine derivative and shares many similarities with schedule I tryptamine hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine, N,N-diethyltryptamine, bufotenine, psilocybin and psilocin. Since 1999, there has been a growing popularity of 5-MeO-DIPT among drug abusers. This substance is abused for its hallucinogenic effects. Pharmacology: 5-methoxy-diisopropyltryptamine, also known as 5-methoxy-N,N-diisopropyltryptamine, 5-MeO-DiPT, foxy methoxy, or just foxy, is a tryptamine that is used recreationally as a psychedelic. 5-MeO-DiPT is orally active, and dosages between 620 mg are commonly reported. Many users note an unpleasant body load accompanies higher dosages. 5-MeO-DiPT is also taken by insufflation, or sometimes it is smoked or injected. Some users also report sound distortion, also noted with the related drug, DiPT. Mechanism of action: Not Available Drug type: Experimental. Illicit. Small Molecule. Drug category: Hallucinogens"}},{"5-oxo-6,8,11,14-eicosatetraenoic acid":{"Created":"2007-09-19","SuperCategory":"Eicosanoid lipid","Id":"nifext_5165"}},{"A":{"Created":"2006-10-05","CurationStatus":"pending_final_vetting","SuperCategory":"Inbred mouse strain","Id":"birnlex_568"}},{"A current":{"RelatedTo":["Spike repolarization","Action potential"],"Synonym":["I A","IA","Ia","Inactivating potassium current"],"CurationStatus":"uncurated","SuperCategory":"Potassium current","Id":"nlx_mol_20081201","DefiningCitation":"ModelDB:3277","Definition":"\"Transient\"; inactivating potassium current, involved in delayed onset of firing; interspike interval; action potential repolarization"}},{"A mating type (yeast)":{"Synonym":"A","SuperCategory":"Saccharomyces cerevisiae mating type","Id":"PATO_0001341","Definition":"A S. cerevisiae mating type cells that secrete a pheromone that in alpha haploids stimulates processes that lead to mating."}},{"A-10 cell":{"Synonym":"A-10","Created":"2007-10-15","CurationStatus":"uncurated","SuperCategory":"Cell line","Id":"birnlex_2475","Definition":"The clonal cell line A10 was derived by B. Kimes and B. Brandt from the thoracic aorta of DB1X embryonic rat and possesses many of the properties characteristic of smooth muscle cells. The cells produce spontaneous action potentials at the stationary phase of the growth cycle and exhibit an increase in activity of the enzymes myokinase and creatine phosphokinase.  Growth Properties: adherent, A sample of a specimen consisting of a thin plane produced through the use of a microtome or other cutting device, usually produced for the purposes of histological processing and/or microscopic examination."}},{"A1 neuron":{"Has_role":"Fly_Anatomy_Ontology","CurationStatus":"uncurated","SuperCategory":"Abdominal neuron","Id":"nlx_146708","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001988","Species":"Drosophila","Definition":"Any abdominal neuron (FBbt_00001987) that is part of some larval abdominal segment 1 (FBbt_00001748)."}},{"A1 receptor":{"Created":"2007-09-19","EditorialNote":"Additional agonists from V Ralevic and G Burnstock, Pharm. Rev., v50:n3, p413 (BB).","Synonym":"A1; Adenosine A1 receptor","CurationStatus":"uncurated","SuperCategory":"Adenosine receptor","Id":"nifext_5717","Has role":"Receptor role,"}},{"A2 neuron":{"Has_role":"Fly_Anatomy_Ontology","EditorialNote":"I'm not sure that these should be listed as having the role Fly_Anatomy_Ontology.  I am uncomfortable with the use of ontology as role.  It could be \"Fly anatomy ontology term\"","CurationStatus":"uncurated","SuperCategory":"Abdominal neuron","Id":"nlx_146709","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001989","Definition":"Any abdominal neuron (FBbt_00001987) that is part of some larval abdominal segment 2 (FBbt_00001749)."}},{"A2A receptor":{"Created":"2007-09-19","EditorialNote":"Additional agonists from V Ralevic and G Burnstock, Pharm. Rev., v50:n3, p413 (BB).","Synonym":"A2A; Adenosine A2a receptor","CurationStatus":"uncurated","SuperCategory":"Adenosine receptor","Id":"nifext_7727","Has role":"Receptor role,"}},{"A2B receptor":{"Created":"2007-09-19","Synonym":"A2B; Adenosine A2b receptor","CurationStatus":"uncurated","SuperCategory":"Adenosine receptor","Id":"nifext_6025"}},{"A3 neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Abdominal neuron","Id":"nlx_146710","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001990","Definition":"Any abdominal neuron (FBbt_00001987) that is part of some larval abdominal segment 3 (FBbt_00001750)."}},{"A3 receptor":{"Created":"2007-09-19","EditorialNote":"Additional agonists from V Ralevic and G Burnstock, Pharm. Rev., v50:n3, p413 (BB).","Synonym":"A3; Adenosine A3 receptor","CurationStatus":"uncurated","SuperCategory":"Adenosine receptor","Id":"nifext_7556"}},{"A30P Alpha-Synuclein Drosophila":{"PMID":"17683129","CurationStatus":"uncurated","Pages":"3729-3738","PublicationDate":"08/07/07","JournalVolume":"6","PublicationName":"Journal Of Proteone Research","Id":"nlx_organ_090702","Authors":["Zhiyin Xun","Rena A. Sowell","Thomas C. Kaufman"],"Title":"Lifetime Proteomic Profiling of an A30P Alpha-Synuclein Drosophila Model of Parkinson's Disease","Definition":"These transgenic flies express human A30P alpha-synuclein.  The A30P mutation disrupts an alpha-helical structure in the N-terminal region of the wild type alpha-synuclein.  This mutation accelerates alpha-synuclein oligomerization, decreases the rate of mature fibril formation, reduces cellular activity, and reduces cellular affinity for lipids.  It has an early onset and a slightly faster aggregation than wild type alpha-synuclein.  Drosophila displaying this mutation show symptoms of Parkinson's disease and are used in the laboratory to study this disorder."}},{"A4 neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Abdominal neuron","Id":"nlx_146711","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001991","Definition":"Any abdominal neuron (FBbt_00001987) that is part of some larval abdominal segment 4 (FBbt_00001751)."}},{"A5 neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Abdominal neuron","Id":"nlx_146712","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001992","Definition":"Any abdominal neuron (FBbt_00001987) that is part of some larval abdominal segment 5 (FBbt_00001752)."}},{"A53T Alpha-Synuclein Drosophila":{"PMID":"11590151","CurationStatus":"uncurated","Pages":"45996-46003","PublicationDate":"12/07/01","JournalVolume":"276","PublicationName":"The Journal of Biological Chemistry","Id":"nlx_organ_090703","JournalNumber":"49","Authors":"Robert Bussel Jr. and David Eliezer","Title":"Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of Alpha-Synuclein","Figure":"1,2,3","Definition":"These mutant flies express a the human mutant A53T alpha-synuclein mutation.  This mutation alters the secondary shift of residue 53 from a positive to a negative value and thereby creates a short contiguous region of negative shifts around the site of the mutation, indicating a local preference for extended backbone configurations.  This mutation accelerates alpha-synuclein oligomerization, increases the rate of mature fibril formations, and aggregates much faster than wild type alpha-synuclein.  It has an earlier onset.  Flies expressing A53T alpha-synuclein show symptoms of Parkinson's disease and are used in the lab to study the disease."}},{"A6 neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Abdominal neuron","Id":"nlx_146713","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001993","Definition":"Any abdominal neuron (FBbt_00001987) that is part of some larval abdominal segment 6 (FBbt_00001753)."}},{"A7 neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Abdominal neuron","Id":"nlx_146714","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001994","Definition":"Any abdominal neuron (FBbt_00001987) that is part of some larval abdominal segment 7 (FBbt_00001754)."}},{"A8 neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Abdominal neuron","Id":"nlx_146715","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001995","Definition":"Any neuron (FBbt_00005106) that is part of some abdominal segment 8 (FBbt_00000029)."}},{"ABA 2009 adult mouse brain parcellation scheme":{"CurationStatus":"uncurated","ISBN":"978-0470053560","PublicationDate":"2009","SuperCategory":"Parcellation scheme","Id":"nlx_144465","Authors":["Dong"],"Species":"Mouse","Title":"The Allen Reference Atlas: A Digital Color Brain Atlas of the C57BL/6J Male Mouse","DefiningCitation":"978-0470053560","Definition":"Parcellation scheme developed by Dong et al. (2009) for the Allen Brain adult mouse atlas.  This date is based on the version 1.0 of the ontology in Bioportal http://bioportal.bioontology.org/ontologies/40133, the date of which is listed as 2009.  Note that visualizations from the Scalable Brain Atlas list this atlas as ABA 2007."}},{"ABA 2009 mouse brain parcel":{"CurationStatus":"uncurated","SuperCategory":"Parcellation scheme parcel","Id":"nlx_144466","Is part of":"ABA mouse brain parcellation scheme","Definition":"Brain regions delineated by Dong et al. (2009), with hierarchy established via the NCBO Bioportal ontology (https://bioportal.bioontology.org/ontologies/ABA-AMB)."}},{"Abacavir":{"RelatedTo":"Gag-Pol polyprotein","Synonym":["ABC","abacavir","Epzicom"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2360","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01048","Definition":"Abacavir (ABC) is the most powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. (Wikipedia) Pharmacology: Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Abacavir is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Mechanism of action: Abacavir is a carbocyclic synthetic nucleoside analogue. Intracellularly, abacavir is converted by cellular enzymes to the active metabolite carbovir triphosphate, an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-HIV Agents. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Reverse Transcriptase Inhibitors"}},{"Abarelix":{"RelatedTo":"Gonadotropin-releasing hormone receptor","Synonym":["abarelix","Plenaxis"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00106","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00106","Definition":"Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. Pharmacology: Used in the palliative treatment of advanced prostate cancer. Abarelix is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis. Mechanism of action: Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. Drug type: Approved. Biotech. Investigational. Withdrawn. Drug category: Anti-Testosterone Agents. Antineoplastic Agents"}},{"Abatacept":{"RelatedTo":["T-lymphocyte activation antigen CD86"],"Synonym":["CTLA4-Ig","CTLA4-IgG4m","CTLA4Ig","CTLA4IgG4m","RG-1046","RG-2077","RG1046","RG2077","abatacept","Orencia"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01281","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01281","Definition":"Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). It is produced through recombinant DNA technology in mammalian cells. The drug has activity as a selective costimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077). Pharmacology: Abatacept is the first in a new class of drugs known as Selective Co-stimulation Modulators. Ordinarily, full T-cell activation requires binding of the T-cell receptor to an antigen-MHC complex on the antigen-presenting cell as well as a co-stimulatory signal provided by the binding of the CD28 protein on the surface of the T-cell with the CD80/86 proteins on the surface of the antigen-presenting cell. CTLA4 is a naturally occurring protein which is expressed on the surface of T-cells some hours or days after full T-cell activation and is capable of binding to CD80/86 on antigen-presenting cells with much greater affinity than CD28. Binding of CTLA4-Ig to CD80/86 provides a negative feedback mechanism which results in T-cell deactivation. Abatacept was developed by Bristol-Myers-Squibb and is licensed in the US for the treatment of Rheumatoid Arthritis in the case of inadequate response to anti-TNF-alpha therapy. Mechanism of action: Abatacept is a selective costimulation modulator, shown to inhibit Tcell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Blockade of this interaction has been shown to inhibit the autoimmune T-Cell activation that has been implcated in the pathogenesis of rheumatoid arthritis. Drug type: Biotech. Drug category: Antirheumatic Agents"}},{"Abaxial to":{"CurationStatus":"uncurated","SuperCategory":"Relational spatial quality","Id":"PATO_0002046","Definition":"A relational spatial quality in which the bearer entity is away from or on the opposite side of the central axis."}},{"ABC transporter":{"Created":"2007-09-06","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_2568","Has role":["Integral membrane protein"]}},{"Abciximab":{"RelatedTo":["High affinity immunoglobulin gamma Fc receptor I","Low affinity immunoglobulin gamma Fc region receptor III-B","Integrin beta-3","Complement C1s subcomponent","Complement C1r subcomponent","Complement C1q subcomponent subunit A","Complement C1q subcomponent subunit B","Complement C1q subcomponent subunit C","Low affinity immunoglobulin gamma Fc region receptor III-A","Low affinity immunoglobulin gamma Fc region receptor II-a","Low affinity immunoglobulin gamma Fc region receptor II-b"],"Synonym":["7E3 antibody","ReoPro","abciximab","antiGPIIBIIIa","c7E3","ReoPro"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00054","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00054","Definition":"Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Pharmacology: Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. Mechanism of action: Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa. Drug type: Approved. Biotech. Investigational. Drug category: Anticoagulants. Antiplatelet Agents"}},{"Abdominal 10 sensory neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Sensory neuron (FBbt Term)","Id":"nlx_147337","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00002624","Fasciculates_with":"abdominal 10 intersegmental nerve"}},{"Abdominal 9 sensory neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Sensory neuron (FBbt Term)","Id":"nlx_147332","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00002619","Fasciculates_with":"abdominal 9 intersegmental nerve"}},{"Abdominal intersegmental bidendritic neuron isbp":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"abdominal intersegmental bidendritic neuron isbd","SuperCategory":"Bipolar dendrite neuron","Id":"nlx_146896","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00002181","Fasciculates_with":"abdominal transverse nerve","Definition":"Bipolar multidendritic neuron in the lateral sensory cluster of larval abdominal segments 1-7. Located at the anterior segment boundary, it emits two long dendritic branches along the segment border muscle (muscle 8) (Williams and Shepherd, 1999)."}},{"Abdominal intersegmental trachea-associated neuron istd":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Tracheal innervating neuron","Comment":["Referred to by Bodmer and Jan","1987","and FlyPNS as ltd. Confusingly","Campos-Ortega and Hartenstein","1997","use the name ltd to refer to a different multi-dendritic neuron"],"Id":"nlx_146904","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00002189","Fasciculates_with":"abdominal transverse nerve","Definition":"Trachea associated multidendritic neuron located anteriorly in the lateral sensory cluster of larval abdominal segments 1-7."}},{"Abdominal neuron":{"Has_role":"Fly_Anatomy_Ontology","CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_146707","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001987","Species":"Drosophila","Definition":"Any neuron (FBbt_00005106) that is part of some abdomen (FBbt_00000020)."}},{"Abdominal posterior fascicle neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Neuron","Id":"nlx_147164","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00002451","Fasciculates_with":"abdominal segmental nerve","Definition":"Any neuron (FBbt_00005106) that fasciculates with some abdominal segmental nerve (FBbt_00002197)."}},{"Abducens nerve fibers":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","CurationStatus":"uncurated","NeuronamesID":"593","Umlscui":"C0175450","SuperCategory":"Regional part of brain","Id":"birnlex_1689","Is part of":["Pontine tegmentum","White matter"],"Definition":"Nerve fibers arising from motor neurons in the abducens nucleus that are contained within the pontine tegmentum"}},{"Abducens nerve root":{"Created":"2007-08-20","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1277","Is part of":"Abducens nerve","Abbrev":"6n"}},{"Abducens nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":"Nucleus of the abducent nerve","CurationStatus":"uncurated","EfferentProjections":"Lateral rectus extraocular muscle","Has role":"Cranial nerve nucleus","Abbrev":"6N","Created":"2006-07-15","NeuronamesID":"580","PartiallyOverlapsWith":"Abducens nucleus of ABA 2009","Umlscui":"C0152407","SuperCategory":"Nucleus of CNS","Id":"birnlex_1366","Is part of":"Pontine tegmentum","Species":"Mammal","Definition":"Nucleus located beneath the floor of the 4th ventricle in the pontine tegmentum, containing motor neurons innervating the lateral rectus muscle of the eye (Brodal, Neurological Anatomy, 3rd ed., 1981, pg 533)"}},{"Abducens nucleus motor neuron":{"Located in":["Abducens nucleus"],"EditorialNote":"http://www.cobocards.com/pool/cardset/7099898/anatomy-7-8/","Synonym":["abducens nucleus motor cell","6th nerve motor neuron"],"CurationStatus":"uncurated","Neurotransmitter":"Acetylcholine,","ExampleImage":"Abducens nucleus motor neuron.JPG,","SuperCategory":"Neuron","Id":"nlx_16848","Species":"Vertebrata","Definition":"Motor neuron whose cell soma lies within the abducens nucleus."}},{"Abducens nucleus of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Abducens nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153532","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Medulla motor related of ABA 2009","Species":"Mouse"}},{"Abductive reasoning activity":{"Created":"2007-03-06","CurationStatus":"uncurated","SuperCategory":"Reasoning activity","Id":"birnlex_1893"}},{"Abductive reasoning function":{"Created":"2007-03-06","Synonym":"Hypothesis generation (http://www.springerreference.com/docs/html/chapterdbid/320173.html).","CurationStatus":"uncurated","SuperCategory":"Reasoning function","Id":"birnlex_1882","Definition":"Abductive reasoning involves applying norms underlying hypothesis generation (http://www.springerreference.com/docs/html/chapterdbid/320173.html)."}},{"Abnormal":{"Synonym":["atypical","aberrant"],"SuperCategory":"Deviation(from normal)","Id":"PATO_0000460"}},{"Abnormal Involuntary Movement Scale":{"Created":"2008-03-14","Related disease":"Tardive dyskinesia","CurationStatus":"uncurated","Umlscui":"C0450978","SuperCategory":"Rating scale","PublicationLink":"http://www.atlantapsychiatry.com/forms/AIMS.pdf","Id":"birnlex_3006","Has role":"Movement control assessment","DefiningCitation":["National Institute of Mental Health. Abnormal Involuntary Movement Scale. In Guy","W.","ed. (1976). ECDEU Assessment Manual. Washington DC","U.S. Department of Health","Education"],"Abbrev":"AIMS","Definition":"The AIMS is an assessment of movement dysfunctions. It is a 12-item instrument assessing abnormal involuntary movements associated with antipsychotic drugs, such as tardive dystonia and chronic akathisia, as well as 'spontaneous' motor disturbance related to the illness itself. Scoring the AIMS consists of rating the severity of movement in three main anatomic areas (facial/oral, extremities, and trunk), based on a five-point scale (0"}},{"Abnormality of the central nervous system":{"CurationStatus":"uncurated","SuperCategory":"Abnormality of the nervous system","Id":"HP:0002011","Definition":"An abnormality of the `central nervous system` (FMA:55675)."}},{"Abnormality of the nervous system":{"Synonym":["Neurologic abnormalities"],"CurationStatus":"uncurated","SuperCategory":"Phenotypic abnormality","Id":"HP:0000707","Definition":"An abnormality of the `nervous system` (FMA:7157)."}},{"Abolished":{"CurationStatus":"uncurated","Comment":"TODO: the definition is incorrect. See absent.","SuperCategory":"Occurrence quality","Id":"PATO_0001508","Definition":"A monadic quality or occurent inhering in a bearer by virtue of its inability to accomplish a biological process."}},{"Abrased":{"SuperCategory":"Texture","Id":"PATO_0001849"}},{"Absence Epilepsy":{"Synonym":["Childhood Absence Epilepsy","Akinetic Petit Mal","Pyknolepsy","Absence Seizure Disorder","Petit Mal Convulsion","Juvenile Absence Epilepsy","Absence Seizure","Pykno-Epilepsy","Atonic Absence Seizure","Minor Epilepsy"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Generalized Epilepsy","Id":"birnlex_12742","DefiningCitation":["Menkes","Textbook of Child Neurology","5th ed"],"Definition":"A childhood seizure disorder characterized by rhythmic electrical brain discharges of generalized onset. Clinical features include a sudden cessation of ongoing activity usually without loss of postural tone. Rhythmic blinking of the eyelids or lip smacking frequently accompanies the SEIZURES. The usual duration is 5-10 seconds, and multiple episodes may occur daily. Juvenile absence epilepsy is characterized by the juvenile onset of absence seizures and an increased incidence of myoclonus and tonic-clonic seizures (MeSH)."}},{"Absent from organism":{"Synonym":["absent"],"Comment":"Example: ( E","SuperCategory":"Count in organism","Id":"PATO_0000462","Definition":"Not existent; lacking."}},{"Absolute refractory state":{"RelatedTo":["Action potential"],"CurationStatus":"uncurated","SuperCategory":"Action potential characteristic","Id":"oen_0001203","Definition":"A period of time, after the firing of an action potential, where the cell can't fire a subsequent action potential.  The mechanism includes the deactivation of sodium channels."}},{"Absorption quality":{"SuperCategory":"Full-spectrum EM radiation quality","Id":"PATO_0001293","Definition":"A scalar EM radiation quality which obtains by the capacity of the bearer to absorb radiation."}},{"Abstract":{"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Citation record element","Id":"birnlex_2378"}},{"Absynninian guinea pig":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2007-08-06","CurationStatus":"raw_import","Umlscui":"C0324523","SuperCategory":"Guinea pig","Id":"birnlex_325"}},{"AC Couple":{"RelatedTo":"Device","CurationStatus":"uncurated","SuperCategory":"Device parameter","Id":"oen_0001212","Has role":"Electrophysiology concept","Definition":"The continuous removal of DC shifts during signal recordings."}},{"Academic Free License":{"Synonym":["Academic Free License 3.0"],"CurationStatus":"uncurated","SuperCategory":"Open-source license","Id":"nlx_152785","DefiningCitation":"http://opensource.org/licenses/AFL-3.0","Abbrev":"AFL","Definition":"An open source license, identical to Open Source License (OSL) 3.0 except for the reciprocal source code obligation: Under AFL 3.0, Derivative Works of AFL 3.0-licensed Original Works can be licensed under other licenses, and the Source Code of those Derivative Works need not be disclosed. In effect, then, AFL 3.0 is like the BSD license, with no reciprocal obligation to disclose source code. AFL 3.0 differs materially from OSL 3.0 only in that important underlined half-sentence in ยง 1(c), which now authorizes distribution \"under any license of your choice that does not contradict the terms and conditions, including Licensor's reserved rights and remedies, in this Academic Free License.\" In all other material respects, AFL 3.0 uses all the same definitions and, except for reciprocity, can be interpreted the same way as OSL 3.0. "}},{"Acalyptratae":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1010980","SuperCategory":"Schizophora","Id":"birnlex_308"}},{"Acamprosate":{"RelatedTo":["Glutamate (NMDA) receptor subunit 3A","Metabotropic glutamate receptor 1","Metabotropic glutamate receptor 2","Metabotropic glutamate receptor 5"],"Synonym":["3-(Acetylamino)propanesulphonic acid","3-Acetamido-1-propanesulfonic acid","N-Acetylhomotaurine","acamprosate"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:51041","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00659","Definition":"Acamprosate, also known by the brand name Campral, is a drug used for treating alcohol dependence. Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcoholism, possibly by blocking glutaminergic N-methyl-D-aspartate receptors, while gamma-aminobutyric acid type A receptors are activated. Reports indicate that acamprosate only works with a combination of attending support groups and abstinence from alcohol. Certain serious side effects include allergic reactions, irregular heartbeats, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Acamprosate should not be taken by people with kidney problems or allergies to the drug. Pharmacology: Pharmacodynamic studies have shown that acamprosate calcium reduces alcohol intake in alcohol-dependent animals in a dose-dependent manner and that this effect appears to be specific to alcohol and the mechanisms of alcohol dependence. Acamprosate calcium has negligible observable central nervous system (CNS) activity in animals outside of its effects on alcohol dependence, exhibiting no anticonvulsant, antidepressant, or anxiolytic activity. Mechanism of action: The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. in vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance. Drug type: Approved. Investigational. Small Molecule. Drug category: Alcohol Deterrents"}},{"Acanthomorpha":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1059403","SuperCategory":"Ctenosquamata","Id":"birnlex_298"}},{"Acanthopterygii":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1004153","SuperCategory":"Holacanthopterygii","Id":"birnlex_604"}},{"Acarbose":{"RelatedTo":["Maltase-glucoamylase","intestinal","Lysosomal alpha-glucosidase","Sucrase-isomaltase","intestinal"],"Synonym":[", Glucobay","Prandase"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2376","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00284","Definition":"An inhibitor of alpha glucosidase that retards the digestion and absorption of carbohydrates in the small intestine and hence reduces the increase in blood-glucose concentrations after a carbohydrate load. It is given orally to non-insulin dependent diabetes mellitus patients where diet modification or oral hypoglycemic agents do not control their condition. (From Martindale The Extra Pharmacopoeia, 31st ed) Pharmacology: Used to reduce blood gluose in patients with type 2 diabetes. Acarbose is a complex oligosaccharide that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. Acarbose binds to and inhibits alpha amylase and alpha-gluocside hydrolases. In diabetic patients, this enzyme inhibition results in a delayed glucose absorption and a lowering of postprandial hyperglycemia. Mechanism of action: Acarbose reversibly bind to pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolases. These enzymes inhibit hydrolysis of complex starches to oligosaccharides in the lumen of the small intestine and hydrolysis of oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. Drug type: Approved. Investigational. Small Molecule. Drug category: Enzyme Inhibitors. Hypoglycemic Agents"}},{"Accelerated growth":{"SuperCategory":"Peramorphic growth","Id":"PATO_0001753","Definition":"A peramorphic growth quality which is due to an increased rate."}},{"Accelerating rotarod test":{"Synonym":"accelerated rotarod test","SynonymPMID":"15082022","CurationStatus":"uncurated","SuperCategory":"Rotarod performance test","Id":"nlx_152502","DefinitionPMID":"4384609","Definition":"A rotarod test in which the speed of the rotating rod is accelerated during the trial (Adapted from Wikipedia:  http://en.wikipedia.org/wiki/Rotarod_performance_test)"}},{"Acceleration":{"SuperCategory":"Movement quality","Id":"PATO_0001028","Definition":"A physical quality inhering in a bearer by virtue of the rate of change of its velocity in either speed or direction."}},{"Acceleration factor":{"CurationStatus":"uncurated","SuperCategory":"Value","Id":"nlx_inv_20090214","Has role":"Magnetic resonance imaging attribute"}},{"Accelleration stimulus transduction":{"Synonym":["equilibrioception"],"Created":"2008-03-13","CurationStatus":"graph_position_temporary","Umlscui":"C1327475","SuperCategory":"Solid object-coupled ciliary displacement stimulus transduction","Id":"birnlex_15017","Definition":"The series of events involved in equilibrioception in which a sensory mechanical stimulus is received by a cell and converted into a molecular signal. During equilibrioception, mechanical stimuli may be in the form of input from pressure receptors or from the labyrinth system of the inner ears."}},{"Access resistance":{"RelatedTo":"Resistance to","Synonym":["access resistance"],"CurationStatus":"uncurated","Comment":"NeuroElectro Term 12","SuperCategory":"\tCellular physiology characteristic","Id":"oen_0001016","Has role":["NeuroElectro Term"],"Definition":"Sum of the electrode resistance and the resistance at the electrode-cell junction"}},{"Access service resource":{"CurationStatus":"uncurated","SuperCategory":"Service resource","Id":"nlx_97132","Definition":"Any service resource that provides access to a physical object or data, including shared resources such as high powered microscopes, patient registries, MRI machines, NMR machines, telescopes, etc."}},{"Accession number":{"Synonym":"Accession","Created":"2007-10-05","CurationStatus":"graph_position_temporary","SuperCategory":"Identifying value","Id":"birnlex_2297"}},{"Accession Number":{"Synonym":"Accession","Created":"2007-10-05","CurationStatus":"graph_position_temporary","SuperCategory":"Identifying value","Id":"birnlex_2297"}},{"Accessory abducens nucleus":{"EditorialNote":"According to Brain Info, Crosby-1962 questioned whether, in the human, it exists independently of the accessory facial nucleus.","AfferentProjectionsPMID":"11726242","CurationStatus":"uncurated","NeuronamesID":"1860","SuperCategory":"Regional part of brain","Id":"nlx_144454","Species":["Rabbit","Pig"],"AfferentProjections":"Magnocellular part of red nucleus,","DefinitionPMID":"11726242","Definition":"A small cluster of neurons in the pontine reticular formation in some mammals, containing the majority of motoneurons innervating theretractor bulbi muscles of the eye"}},{"Accessory abducens nucleus of ABA 2009":{"PartiallyOverlapsWith":"Accessory abducens nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153709","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Accessory basal amygdaloid nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":["basal amygdaloid nucleus","accessory basal nucleus of amygdala","medial part","medial principal nucleus","basomedial nucleus (De Olmos)"],"NeuronamesID":"231","CurationStatus":"uncurated","Umlscui":"C0175223","SuperCategory":"Regional part of brain","Id":"birnlex_2686","Is part of":"Basolateral nuclear complex","Abbrev":["ABA"]}},{"Accessory Code":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_00F9","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149512","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"An identifier for the accessory intended to be read by a device such as a bar-code reader."}},{"Accessory cuneate nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":["lateral cuneate nucleus","external cuneate nucleus"],"CurationStatus":"uncurated","NeuronamesID":"765","Umlscui":"C0152397","SuperCategory":"Regional part of brain","Id":"birnlex_2634","Is part of":"Medulla oblongata","Abbrev":["ACu"]}},{"Accessory facial motor nucleus of ABA 2009":{"PartiallyOverlapsWith":"Facial (accessory) nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153457","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Accessory facial nucleus of PHT00":{"CurationStatus":"uncurated","ISBN":"123582555","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"Acs7","PartiallyOverlapsWith":"Facial (accessory) nucleus","PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_59","ParcellationScheme":"PHT00 parcellation scheme","Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Accessory medullary lamina":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-04","Synonym":["accessory medullar lamina of pallidum"],"CurationStatus":"uncurated","NeuronamesID":"218","Umlscui":"C0175213","SuperCategory":"Regional part of brain","Id":"birnlex_1626","Is part of":["Globus pallidus internal segment"],"Definition":"Thin bundle of myelinated axons that divides the medial pallidal segment into outer and inner portions (Carpenter, Core Text of Neuroanatomy, 3rd ed., 1985, pg. 303)."}},{"Accessory nerve fiber bundle":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","EditorialNote":"NeuroNames uses the preferred term \"accessory nerve fibers\", but I'm trying to avoid plurals.  NN preferred term included as a synonym.","Synonym":"accessory nerve fibers","NeuronamesID":"789","CurationStatus":"uncurated","Umlscui":"C0175549","SuperCategory":"Regional part of brain","Id":"birnlex_916","Is part of":["Medulla oblongata"],"Definition":"Fibers of the accessory nerve (11th cranial nerve) contained within the medulla"}},{"Accessory nucleus":{"CurationStatus":"uncurated","SuperCategory":"Regional part of spinal cord","Id":"nlx_39810","Has role":"Cranial nerve nucleus","Is part of":"Cervical spinal cord","Definition":"Nucleus in the cervical spinal cord containing motor neurons that innervate the sternocleidomastoid and trapezius muscles in the human via nerve fibers that travel through the 11th cranial nerve (Heimer, The human brain and spinal cord, 2nd ed, 1995, pg 260)"}},{"Accessory nucleus motor neuron":{"Located_in":"accessory nucleus","Synonym":["spinal accessory nerve","acessory nucleus motor cell","11th nerve motor neuron"],"Neurotransmitter":"Acetylcholine,","CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_83979","Has role":["Principal neuron role"],"Definition":"Motor neuron whose cell soma lies within the Acessory nucleus."}},{"Accessory olfactory bulb glomerular layer of ABA 2009":{"PartiallyOverlapsWith":"Olfactory bulb (accessory) granule cell layer","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153574","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Accessory olfactory bulb granular layer of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Olfactory bulb (accessory) granule cell layer","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153204","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Accessory olfactory bulb of ABA 2009","Species":"Mouse"}},{"Accessory olfactory bulb mitral layer of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Olfactory bulb (accessory) mitral cell body layer","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153370","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Accessory olfactory bulb of ABA 2009","Species":"Mouse"}},{"Accessory olfactory bulb of ABA 2009":{"PartiallyOverlapsWith":"Olfactory bulb accessory nucleus","CurationStatus":"uncurated","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153366","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Olfactory bulb of ABA 2009","Species":"Mouse"}},{"Accessory supraoptic group of ABA 2009":{"PartiallyOverlapsWith":"Accessory supraoptic group","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153631","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Account required":{"CurationStatus":"uncurated","SuperCategory":"Registration required","Id":"nlx_152779","Has role":"Availability annotation standard","Definition":"Access to the resource requires creation of an account and login."}},{"Accumbens nucleus core nucleus neuron":{"Located in":["Core of nucleus accumbens"],"CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_151892","Species":"Vertebrata"}},{"Accumbens Nucleus of CIVM postnatal rat brain atlas":{"AtlasImage":["accumbens p80.png"],"CurationStatus":"uncurated","TomoDefiningCriteria":["he accumbens nucleus forms the major part of the ventral striatum; however","it has a unique appearance on MRI that makes it relatively easy to segment as a distinct structure from the rest of the ventral striatum. This nucleus is most easily segmented in the coronal plane of a diffusion-weighted image (DWI). The rostral border is defined by a low diffusivity (bright on DWI) region just dorsal and medial to the anterior limb of the anterior commissure.  More caudally the accumbens becomes a large circular region that completely surrounds the anterior limb of the anterior commissure. The ventral border is defined by the rostral aspect of the ventral pallidum","which appears as a horizontal line of dark (high diffusion) spots on DWI. The dorsal border between the accumbens and the rest of the striatum can be identified based on the start of the dark striations that define the caudate/putamen. The caudal extent of the accumbens ends just rostral to the decussation of the anterior commissure. In general"],"IsPartOfPMID":"23246176","TopoDefiningCriteriaPMID":"23246176","DefiningCriteria":"topography","PartiallyOverlapsWith":"Nucleus accumbens","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","SuperCategoryPMID":"23246176","Id":"nlx_151533","ParcellationScheme":"CIVM postnatal rat brain atlas parcellation scheme","Is part of":"Subpallium of CIVM postnatal rat brain atlas","OrganismPMID":"23246176","ParcellationSchemePMID":"23246176","Species":"Rat","Definition":"The accumbens nucleus forms the major part of the ventral striatum; however, it has a unique appearance on MRI that makes it relatively easy to segment as a distinct structure from the rest of the ventral striatum. This nucleus is most easily segmented in the coronal plane of a diffusion-weighted image (DWI). The rostral border is defined by a low diffusivity (bright on DWI) region just dorsal and medial to the anterior limb of the anterior commissure.  More caudally the accumbens becomes a large circular region that completely surrounds the anterior limb of the anterior commissure. The ventral border is defined by the rostral aspect of the ventral pallidum, which appears as a horizontal line of dark (high diffusion) spots on DWI. The dorsal border between the accumbens and the rest of the striatum can be identified based on the start of the dark striations that define the caudate/putamen. The caudal extent of the accumbens ends just rostral to the decussation of the anterior commissure. In general, the accumbens is brighter on DWI (lower diffusion) than surrounding tissue.","DefinitionPMID":"23246176"}},{"Accumbens nucleus shell neuron":{"Located in":["Shell of nucleus accumbens"],"CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_151893","Species":"Vertebrata"}},{"Accumulated":{"CurationStatus":"uncurated","Comment":"Need to determine whether this is strictly synonymous with an increase in number.  We submitted it to PATO:  3081064","SuperCategory":"Population Quality","Id":"sao4531544124","Definition":"Indicates an increased number of objects that implies that the increase is due to a failure to break down or remove extra objects."}},{"Acebutolol":{"RelatedTo":"Beta-1 adrenergic receptor","Synonym":["Acebutolol HCL","Acebutololo","Acetobutolol","dl-Acebutolol","Monitan","Neptal","Prent"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2379","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01193","Definition":"A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. (PubChem) Pharmacology: Acebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. In general, beta-blockers reduce the work the heart has to do and allow it to beat more regularly. Acebutolol has less antagonistic effects on peripheral vascular 2-receptors at rest and after epinephrine stimulation than nonselective beta-antagonists. Low doses of acebutolol produce less evidence of bronchoconstriction than nonselective agents like propranolol but more than atenolol. Mechanism of action: Acebutolol is a selective 1-receptor antagonist. Activation of 1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Acebutolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. Drug type: Approved. Small Molecule. Drug category: Adrenergic beta-Antagonists. Anti-Arrhythmia Agents. Antihypertensive Agents"}},{"Acenocoumarol":{"RelatedTo":["Serum albumin","Vitamin K epoxide reductase complex subunit 1"],"Synonym":["Acenocoumarin","Acenocoumarolum (inn-latin)","Nicoumalone","Nicumalon","Nitrophenylacetylethyl-4-hydroxycoumarine","Nitrovarfarian","Nitrowarfarin","Ascumar","Neositron","Sincoumar","Sinkumar","Sinthrom","Sinthrome","Sintrom","Syncoumar","Syncumar","Syntrom"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01418","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01418","Definition":"A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233) Pharmacology: Acenocoumarol is a coumarin that is used as an anticoagulant. Its actions and uses are similar to those of warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233) Mechanism of action: Acenocoumarol inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots. Drug type: Approved. Small Molecule. Drug category: Anticoagulants. Coumarin and Indandione Derivatives"}},{"Acepromazine":{"Synonym":["10-(3-dimethylaminopropyl)phenothiazin-3-yl methyl ketone","10-(3-dimethylaminopropyl)phenothiazine-3-ethylone","ACP","Ace","Acetylpromazine","Acezine 2"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:44932","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01614","Definition":"Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic. Pharmacology: Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic. Mechanism of action: Not Available Drug type: Approved. Small Molecule. Drug category: Antipsychotic Agents. Dopamine Antagonists. Sedatives and Hypnotics"}},{"Aceprometazine":{"RelatedTo":"Histamine H1 receptor","Synonym":["10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone","Aceprometazina (inn-spanish)","Aceprometazinum (inn-latin)","Acepromethazine"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01615","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01615","Definition":"Aceprometazine (INN) is a prescription drug with neuroleptic and anti-histamine properties. It is not widely prescribed. It may be used in combination with meprobamate for the treatment of sleep disorders. This combination is available in France under the trade name Mepronizine. (Wikipedia) Pharmacology: Aceprometazine is a drug with neuroleptic and anti-histamine properties. It is not widely prescribed. Mechanism of action: Not Available Drug type: Approved. Small Molecule. Drug category: Antihistamines. Sedatives and Hypnotics"}},{"Acetaminophen":{"RelatedTo":["Prostaglandin G/H synthase 1"],"Synonym":["APAP","Acetaminofen","Paracetamol","Paracetamolo","Paracetanol","Abenol","Abensanil","Acamol","Accu-Tap","Acephen","Aceta Elixir","Aceta Tablets","Acetagesic","Acetalgin","Actamin","Actimol","Algotropyl","Allay","Alpiny","Alpinyl","Alvedon","Amadil","Aminofen","Anacin","Anacin-3","Anaflon","Anapap","Anelix","Anhiba","Apacet","Apadon","Apamid","Apamide","Atasol","Banesin","Bayer Select","Bickie-mol","Bucet","Butapap","Calpol","Captin","Cetadol","Clixodyne","Co-Gesic","Conacetol","Dafalgan","Dapa","Dapa X-S","Darvocet","Datril","Dimindol","Dirox","Disprol","Dolene AP-65","Doliprane","Dolprone","Drixoral Plus","Dularin","Dymadon","Dypap","Elixodyne","Enelfa","Eneril","Eu-Med","Excedrin","Exdol","Febridol","Febrilix","Febrinol","Febro-Gesic","Febrolin","Fendon","Feverall","Fevor","Finimal","Gelocatil","Genapap","Genebs","Hedex","Homoolan","Hy-Phen","Injectapap","Janupap","Korum","Lestemp","Liquagesic","Liquiprin","Lonarid","Lyteca","Momentum","Multin","NAPA","Napafen","Napap","Naprinol","Nealgyl","Nebs","Neopap","Neotrend","Nobedon","Norco","Oraphen-PD","Ortensan","Pacemo","Painex","Paldesic","Panadol","Panaleve","Panasorb","Panets","Panex","Panofen","Papa-Deine","Paracet","Parapan","Paraspen","Parelan","Parmol","Pasolind","Pasolind N","Pedric","Phenaphen","Phenaphen Caplets","Phendon","Phrenilin","Phrenilin Forte","Prompt","Propacet 100","Proval #3","Pyrinazine","Redutemp","Rivalgyl","Robigesic","Rounox","SK-Apap","Salzone","Sedapap","Servigesic","Snaplets-FR","St","Joseph Fever Reducer","Suppap","Synalgos-Dc-A","Tabalgin","Talacen","Tapanol","Tapar","Tavist Allergy/Sinus/Headache","Temlo","Tempanal","Tempra","Tencon","Tibinide","Tibizide","Tisin","Tisiodrazida","Tizide","Tralgon","Triaprin","Tussapap","Tycolet","Tylenol","Ultracet","Valadol","Valgesic","Valorin","Valorin Extra"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"DB00316","Has role":"Drug","Is part of":"Vicodin","DefiningCitation":"http://www.drugbank.ca/drugs/DB00316","Definition":"Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage. (PubChem) Pharmacology: Acetaminophen (USAN) or Paracetamol (INN) is a popular analgesic and antipyretic drug that is used for the relief of fever, headaches, and other minor aches and pains. It is a major ingredient in numerous cold and flu medications and many prescription analgesics. It is extremely safe in standard doses, but because of its wide availability, deliberate or accidental overdoses are not uncommon. Acetaminophen, unlike other common analgesics such as aspirin and ibuprofen, has no anti-inflammatory properties or effects on platelet function, and so it is not a member of the class of drugs known as non-steroidal anti-inflammatory drugs or NSAIDs. In normal doses acetaminophen does not irritate the lining of the stomach nor affect blood coagulation, the kidneys, or the fetal ductus arteriosus (as NSAIDs can). Like NSAIDs and unlike opioid analgesics, acetaminophen does not cause euphoria or alter mood in any way. Acetaminophen and NSAIDs have the benefit of being completely free of problems with addiction, dependence, tolerance and withdrawal. Acetaminophen is used on its own or in combination with pseudoephedrine, dextromethorphan, chlorpheniramine, diphenhydramine, doxylamine, codeine, hydrocodone, or oxycodone. Mechanism of action: Acetaminophen is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1 and COX-2, enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory affects. While aspirin acts as an irreversible inhibitor of COX and directly blocks the enzyme's active site, studies have found that acetaminophen indirectly blocks COX, and that this blockade is ineffective in the presence of peroxides. This might explain why acetaminophen is effective in the central nervous system and in endothelial cells but not in platelets and immune cells which have high levels of peroxides. Studies also report data suggesting that acetaminophen selectively blocks a variant of the COX enzyme that is different from the known variants COX-1 and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action is still poorly understood, but future research may provide further insight into how it works. Drug type: Approved. Small Molecule. Drug category: Analgesics, Non-Narcotic. Antipyretics"}},{"Acetate":{"Created":"2007-09-19","SuperCategory":"Carboxylic acid","Id":"nifext_5232"}},{"Acetazolamide":{"RelatedTo":["Carbonic anhydrase 1","Carbonic anhydrase 2","Aquaporin-1","Carbonic anhydrase 12"],"Synonym":["Acetamidothiadiazolesulfonamide","Acetazolamid","Acetazolamide Sodium","Acetazolamine","Acetazoleamide","Acetozalamide","Carbonic Anhydrase Inhibitor 6063","Acetamox","Acetazolam","Ak-Zol","Apo-Acetazolamide","Atenezol","Cidamex","Dazamide","Defiltran","Dehydratin","Diacarb","Diakarb","Diamox","Diamox Sequels","Didoc","Diluran","Diuramid","Diureticum-Holzinger","Diuriwas","Diutazol","Donmox","Duiramid","Edemox","Eumicton","Fonurit","Glaupax","Glupax","Natrionex","Nephramid","Nephramide","Phonurit","Sk-Acetazolamide","Storzolamide"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:27690","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00819","Definition":"One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) Pharmacology: Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion, in the treatment of certain convulsive disorders and in the promotion of diuresis in instances of abnormal fluid retention. Acetazolamide is not a mercurial diuretic. Rather, it is a nonbacteriostatic sulfonamide possessing a chemical structure and pharmacological activity distinctly different from the bacteriostatic sulfonamides. Mechanism of action: The anticonvulsant activity of Acetazolamide may depend on a direct inhibition of carbonic anhydrase in the CNS, which decreases carbon dioxide tension in the pulmonary alveoli, thus increasing arterial oxygen tension. The diuretic effect depends on the inhibition of carbonic anhydrase, causing a reduction in the availability of hydrogen ions for active transport in the renal tubule lumen. This leads to alkaline urine and an increase in the excretion of bicarbonate, sodium, potassium, and water. Drug type: Approved. Small Molecule. Drug category: Anticonvulsants. Carbonic Anhydrase Inhibitors. Diuretics"}},{"Acetic acid":{"Synonym":["ethoic acid","acetic acid","Essigsaeure","CH3-COOH","Ethanoic acid","Acetic acid","ACETIC ACID","C2H4O2"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"CHEBI:15366","Is part of":"Cholinergic system","DefiningCitation":"NCI Thesaurus and CHEBI","Abbrev":"HOAc","Definition":"A synthetic carboxylic acid with antibacterial and antifungal properties. Although its mechanism of action is not fully known, undissociated acetic acid may enhance lipid solubility allowing increased fatty acid accumulation on the cell membrane or in other cell wall structures. Acetic acid, as a weak acid, can inhibit carbohydrate metabolism resulting in subsequent death of the organism (NCI Thesaurus)."}},{"Acetohexamide":{"RelatedTo":"ATP-sensitive inward rectifier potassium channel 1","Synonym":["Acetohexamid","Cyclamide","Dimelin","Dimelor","Dymelor","Gamadiabet","Hypoglicil","Metaglucina","Minoral","Ordimel"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:28052","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00414","Definition":"A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. (PubChem) Pharmacology: Acetohexamide is an intermediate-acting, first-generation oral sulfonylurea. It lowers blood sugar by stimulating the pancreatic beta cells to secrete insulin and by helping the body use insulin efficiently. The pancreas must produce insulin for this medication to work. Acetohexamide has one-third the potency of chlorpropamide, and twice the potency of tolbutamide; however, similar hypoglycemic efficacy occurs with equipotent dosage of sulfonylureas. Mechanism of action: Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin. Drug type: Approved. Small Molecule. Drug category: Hypoglycemic Agents. Sulfonylureas"}},{"Acetohydroxamic Acid":{"RelatedTo":["Urease alpha subunit"],"Synonym":["AHA","Acethydroxamsaure","Acetic acid","oxime","Acetohydroxamate","Acetohydroximic acid","Acetyl hydroxyamino","Acetylhydroxamic acid","Cetohyroxamic acid","Methylhydroxamic acid","N-Hydroxyacetamide"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:27777","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00551","Definition":"Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly. It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections. Pharmacology: Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly. Mechanism of action: Acetohydroxamic Acid reversibly inhibits the bacterial enzyme urease. This inhibits the hydrolysis of urea and production of ammonia in urine infected with urea-splitting organisms, leading to a decrease in pH and ammonia levels. As antimicrobial agents are more effective in such conditions, the effectiveness of these agents is amplified, resulting in a higher cure rate. Drug type: Approved. Small Molecule. Drug category: Enzyme Inhibitors"}},{"Acetophenazine":{"RelatedTo":["D(1A) dopamine receptor"],"Synonym":"Tindal","CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2401","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB01063","Definition":"Acetophenazine is an antipsychotic drug of moderate-potency. It is used in the treatment of disorganized and psychotic thinking. It is also used to help treat false perceptions (e.g. hallucinations or delusions). It primarily targets the dopamine D2 receptor. Pharmacology: Acetophenzine is a phenothiazine antipsychotic intended for the management of schizophrenia and other psychotic disorders. Mechanism of action: Acetophenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. Drug type: Approved. Small Molecule. Drug category: Antipsychotics"}},{"Acetyl Coenzyme A":{"Synonym":["acetyl coenzyme A"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"CHEBI:15351","Has role":["Coenzyme"],"Is part of":"Cholinergic system","DefiningCitation":"NCI Thesaurus and CHEBI","Abbrev":"Acetyl-CoA","Definition":"The condensation product of coenzyme A and acetic acid which participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. In addition, Acetyl Coenzyme A acts as a biological acetylating agent (definition from NCI Thesaurus and concept from CHEBI)."}},{"Acetylcholine":{"CurationStatus":"uncurated","SuperCategory":"Biomolecule","Id":"sao185580330","Has role":"Neurotransmitter,","Is part of":"Cholinergic system","DefiningCitation":"MSH","Abbrev":"ACh","Definition":"A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications (MSH)."}},{"Acetylcholine (muscarinic) receptor":{"Created":"2007-09-19","Synonym":["mAChR","Muscarinic ACh receptor","Muscarinic AChR","MAChR"],"CurationStatus":"uncurated","SuperCategory":"G-protein coupled receptor","Id":"sao2062447305","Has role":"Acetylcholine Receptor","Definition":"One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology.Year introduced: 1984(1977) - adapted from MeSH"}},{"Acetylcholine Receptor":{"RelatedTo":"Acetylcholine","Synonym":["cholinergic receptor"],"CurationStatus":"uncurated","SuperCategory":"Neurotransmitter Receptor","Id":"sao1700719022","Is part of":"Cholinergic system","Definition":"Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology (MSH)."}},{"Acetylcholine-gated channel (nicotinic)":{"Created":"2007-09-19","Synonym":["Nicotinic acetylcholine receptor"],"CurationStatus":"uncurated","SuperCategory":"Cationic cys-loop ligand-gated ion channel","Id":"nifext_5249","Has role":["Acetylcholine Receptor"],"Abbrev":"nAChR","Definition":"This is an acetylcholine binding, cationic channel, which is primarily found on the muscle tissue of vertebrates."}},{"Acetylcholinesterase":{"Synonym":"Acetylcholine esterase","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"sao1842089031","Is part of":"Cholinergic system","Abbrev":["AChE","ACE","AcChE","AChase","Ach-E"],"Definition":"An enzyme that catalyzes the hydrolysis of acetylcholine to choline and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. (MSH)"}},{"Acetyldigitoxin":{"RelatedTo":"Sodium/potassium-transporting ATPase alpha-1 chain","Synonym":[", Acigoxin","Acylanid"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00511","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00511","Definition":"Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure. Pharmacology: The main pharmacological effects of acetyldigitoxin are on the heart. Extracardiac effects are responsible for many of the adverse effects. Its main cardiac effects are 1) a decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter, and 2) an increase of force of contraction via inhibition of the Na+/K+ ATPase pump. Mechanism of action: Acetyldigitoxin binds to a site on the extracellular aspect of the -subunit of the Na+/K+ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na+/K+ pump leads to increased Na+ levels, which in turn slows down the extrusion of Ca2+ via the Na+/Ca2+ exchange pump. Increased amounts of Ca2+ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by acetyldigitoxin. This is a different mechanism from that of catecholamines. Acetyldigitoxin also increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias. Drug type: Approved. Small Molecule. Drug category: Anti-Arrhythmia Agents. Cardiotonic Agents. Enzyme Inhibitors"}},{"Aciclovir":{"RelatedTo":["Purine nucleoside phosphorylase","DNA polymerase"],"Synonym":["9-Hyroxyethoxymethylguanine","AC2","Aciclovier","Aciclovir Sodium","Acycloguanosine","Acyclovir","Acyclovir Sodium","Wellcome-248u","Alti-Acyclovir","Avirax","Vipral","Virorax","Zovir"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2453","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00787","Definition":"A guanosine analog that acts as an antimetabolite.  Viruses are especially susceptible. Used especially against herpes. (PubChem) Pharmacology: Aciclovir (INN) or acyclovir (USAN, former BAN) is a synthetic deoxyguanosine analog and it is the prototype antiviral agent that is activated by viral thymidine kinase. The selective activity of aciclovir is due to its affinity for the thymidine kinase enzyme encoded by HSV and VZV. Mechanism of action: Viral (HSV-1, HSV-2 and VZV) thymidine kinase converts aciclovir to the aciclovir monophosphate, which is then converted to the diphosphate by cellular guanylate kinase, and finally to the triphosphate by phosphoglycerate kinase, phosphoenolpyruvate carboxykinase, and pyruvate kinase. Aciclovir triphosphate competitively inhibits viral DNA polymerase and competes with the natural deoxyguanosine triphosphate, for incorporation into viral DNA. Once incorporated, aciclovir triphosphate inhibits DNA synthesis by acting as a chain terminator. Drug type: Approved. Small Molecule. Drug category: Antiviral Agents. Nucleosides and Nucleotides"}},{"Acidic":{"SuperCategory":"Medium acidity","Id":"PATO_0001429","Definition":"An acidity inhering in a solution by virtue of its high concentration of H+ ions."}},{"Acidity":{"Synonym":"pH","SuperCategory":"Concentration of","Id":"PATO_0001842","Definition":"A quality inhering in an entity by virtue of containing acid (hydrogen ions)."}},{"Acitretin":{"RelatedTo":["Retinoic acid receptor RXR-beta","Retinoic acid receptor gamma-1","Retinoic acid receptor beta","Retinoic acid receptor gamma-2","Retinoic acid receptor RXR-alpha","Serum albumin","Retinoic acid receptor alpha"],"Synonym":[", Acetretin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:50172","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00459","Definition":"An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. (PubChem) Pharmacology: Acitretin is a retinoid. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Acitretin works by inhibiting the excessive cell growth and keratinisation (process by which skin cells become thickened due to the deposition of a protein within them) seen in psoriasis. It therefore reduces the thickening of the skin, plaque formation and scaling. Mechanism of action: The mechanism of action of acitretin is unknown, however it is believed to work by targeting specific receptors (retinoid receptors) in the skin which help normalize the growth cycle of skin cells. Drug type: Approved. Small Molecule. Drug category: Keratolytic Agents"}},{"Acknowledgement requested":{"Synonym":"Attribution requested","CurationStatus":"uncurated","SuperCategory":"Unspecified license","Id":"nlx_152579","Definition":"No license has been specified but owner has requested acknowledgement, usually with specific instructions."}},{"Acknowledgement required":{"Synonym":["Attribution"],"CurationStatus":"uncurated","SuperCategory":"Unspecified license","Id":"nlx_152580","Definition":"No license has been specified but owner has required attribution, usually with specific instructions on how to do so."}},{"Acoelomata":{"Created":"2007-11-30","CurationStatus":"pending_final_vetting","Umlscui":"C1004399","SuperCategory":"Bilateria","Id":"birnlex_7198"}},{"Acoustic startle response test":{"RelatedTo":["Pre-pulse inhibition paradigm"],"Synonym":["acoustic startle"],"CurationStatus":"uncurated","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_152225","Has role":"Auditory function test","Definition":"Test of the acoustic startle reflex response, an exaggerated flinching response to unexpected auditory stimuli."}},{"Acquisition":{"RelatedTo":"BIRN-INCF Derived Data Project,","CurationStatus":"uncurated","SuperCategory":"XCEDE term","Id":"nlx_151397","Definition":"An entity that was generated by a research or analysis related activity"}},{"Acquisition Contrast":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_9209","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149513","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Indication of acquisition contrast used with frames in the SOP Instance."}},{"Acquisition Date":{"ValueRepresentation":"DA","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0022","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149514","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"The start date of the acquisition of data that resulted in this image."}},{"Acquisition Datetime":{"ValueRepresentation":"DT","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_002A","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149515","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DT","Definition":"The date and time that the acquisition of data that resulted in this image started. Note: The synchronization of this time with an external clock is specified in the Synchronization Module in Acquisition Time Synchronized (0018,1800)."}},{"Acquisition Device Type Code Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0022_0015","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149516","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Describes the type of acquisition device. A single item shall be present in the sequence."}},{"Acquisition Duration":{"ValueRepresentation":"FD","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9073","CurationStatus":"uncurated","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149517","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FD","Definition":"The time in seconds needed to run the prescribed pulse sequence. Required if Image Type (0008,0008) Value 1 is ORIGINAL or MIXED. May be present otherwise."}},{"Acquisition Matrix":{"ValueRepresentation":"US","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1310","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149518","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Dimensions of the acquired frequency /phase data before reconstruction. Multi-valued: frequency rowsfrequency columnsphase rowsphase columns."}},{"Acquisition Number":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0012","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149519","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"A number identifying the single continuous gathering of data over a period of time that resulted in this image."}},{"Acquisition Start Condition":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0073","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149520","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Description of how the data collection was started. Acquisition Start Condition (0018,0073) is the method of starting acquisition data collection."}},{"Acquisition Start Condition Data":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0074","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149521","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Count density, change in count density, or physiological triggers causing data collection to start."}},{"Acquisition Termination Condition":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0071","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149522","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Description of how the data collection was stopped."}},{"Acquisition Termination Condition Data":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0071","CurationStatus":"uncurated","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149523","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Description of how the data collection for the series was stopped."}},{"Acquisition Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_0032","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149524","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"The start time for the acquisition of data that resulted in this image. "}},{"Acquisition Time Synchronized":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1800","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149525","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Acquisition Datetime (0008,002A) synchronized with external time reference."}},{"Acquisitions in Series":{"RelatedTo":"BIRN-INCF Derived Data Project","SuperCategory":"DICOM term","Id":"nlx_149526","Has role":"BIRN-INCF Derived Data Project","Is part of":"Resource:DICOM standard","Definition":"TBD"}},{"Acquisitions in Study":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_1004","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149527","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Number of image data acquisitions used in performing the study."}},{"Acrolein":{"Synonym":["2 Propenal","2-Propen-1-one","2-Propenal (Acrylaldehyde)","2-Propenal homopolymer","2-Propenaldehyde","Acquinite","Acraldehyde","Acraldehydeacroleina","Acrolein","Acrolein inhibited","Acrolein inhibited [UN1092]","Acroleina","Acroleine","Acrylaldehyd","Acrylaldehyde","Acrylic aldehyde","Acrylic aldehyde inhibited","Akrolein","Akroleina","Aldehyde acrylique","Acrylic Aldehyde","Allyl Aldehyde","Ethylene Aldehyde","Aldeide acrilica","Allyl aldehyde","Aqualin","Aqualine","Biocide","Caswell No. 009","Crolean","Ethylene aldehyde","MagnAcide","MagnAcide h","MagnAcide h and b","Papite","Polyacrolein","Prop-2-en-1-al","Propenal","Propenal inhibited","Propenaldehyde","Propylene aldehyde","Slimicide","Trans-acrolein","prop-2-en-1-al"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0037","Has role":["Toxin"],"DefiningCitation":"http://t3db.org/toxins/T3D0037","Abbrev":"C<sub>3<\/sub>H<sub>4<\/sub>O","Definition":"Organic Compound;Industrial Precursor/Intermediate;Aldehyde; Acrolein is the simplest unsaturated aldehyde. It is produced widely via the oxidation of propene but is most often immediately reacted with other products due to its instability and toxicity. Acrolein is used as a pesticide to control algae, weeds, bacteria, and mollusks. It is also used to make other chemicals. Small amounts of acrolein can be formed when trees, tobacco, other plants, gasoline, and oil are burned."}},{"Actin":{"SuperCategory":"Cytoskeletal Protein","Id":"sao925531236","Definition":"Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle (MSH)."}},{"Actin Associated Protein":{"SuperCategory":"Cytoskeletal Associated Protein","Id":"sao811908115"}},{"Actin Binding Protein":{"CurationStatus":"uncurated","SuperCategory":"Actin Associated Protein","Id":"sao1785445428","Definition":"Diverse family of cytoskeletal proteins which bind actin, thereby stabilizing or destabilizing microfilaments, anchoring them to other cell structure, or subserving intracellular translocation and motility (CSP)."}},{"Actin Bundling Protein":{"SuperCategory":"Actin Associated Protein","Id":"sao1281431356"}},{"Actin Filament":{"CurationStatus":"pending final vetting","SuperCategory":"Microfilament","Id":"sao1588493326","Definition":"A filamentous structure formed of a two-stranded helical polymer of the protein actin and associated proteins. Actin filaments are a major component of the contractile apparatus of skeletal muscle and the microfilaments of the cytoskeleton of eukaryotic cells. The filaments, comprising polymerized globular actin molecules, appear as flexible structures with a diameter of 5-9 nm. They are organized into a variety of linear bundles, two-dimensional networks, and three dimensional gels. In the cytoskeleton they are most highly concentrated in the cortex of the cell just beneath the plasma membrane (Gene Ontology)."}},{"Actinodromous":{"SuperCategory":"Branched (PATO 0000402)","Id":"PATO_0001967","Definition":"A shape inhering in a bearer by virtue of having three or more primary branches diverging radially from a single point."}},{"Actinomorphic":{"SuperCategory":"Radial symmetry","Id":"PATO_0001328","Definition":"A symmetry quality inhering in a bearer by virtue of being capable of division into symmetrical halves by any longitudinal plane passing through the axis."}},{"Actinopteri":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C1210427","SuperCategory":"Actinopterygii","Id":"birnlex_478"}},{"Actinopterygii":{"Created":"2007-07-27","CurationStatus":"pending_final_vetting","Umlscui":"C0998822","SuperCategory":"Euteleostomi","Id":"birnlex_482"}},{"Action imitation task":{"Created":"4/27/2010 8:37","CurationStatus":"uncurated","Contributor":"Antonia Hamilton","CAO_Id":"CAO_00795","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Action_imitation_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146017","Definition":"A task in which a participant sees another person perform an action and later performs the same action him-herself.  Imitation can be immediate or delayed.  It can be instructed or elicited implicitly (without the participantand's conscious awareness).  The actions imitated can be familar-meaningful actions or unfamilar-meaningless actions."}},{"Action observation paradigm":{"Created":"2006-06-01","Synonym":"Action Observation","CurationStatus":"uncurated","SuperCategory":"Behavioral Experimental Paradigm","Id":"birnlex_2003","Definition":"A behavioral paradigm in which subjects view images of moving body parts (Brain Map)."}},{"Action observation task":{"Created":"5/31/2011 15:54","CurationStatus":"uncurated","Contributor":"Carinna Torgerson","CAO_Id":"CAO_00796","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Action_observation_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146018","Definition":"Subjects view images of actions in order to learn the action themselves."}},{"Action potential":{"Synonym":["Firing","Spike"],"EditorialNote":"Image from squid giant axon, Huxley, 1959","CurationStatus":"uncurated","ExampleImage":"Picture 4.png,","SuperCategory":"Membrane potential","Id":"PATO_0001463","Has role":"Electrophysiology concept","DefiningCitation":"ModelDB:3645","Xref":"D000200","Definition":"A large, brief, all-or-nothing, regenerative electrical potential, that propagates along the axon, muscle fiber, or some dendrites.  Action potentials are usually generated at the axon hillock and propagate uni-directionally down the axon.  Adapted from Nicholls, Martin and Wallace 3rd edition.","Abbrev":"AP"}},{"Action potential characteristic":{"RelatedTo":"Action potential","CurationStatus":"uncurated","SuperCategory":"Cellular physiology characteristic","Id":"nlx_152523","Has role":"Electrophysiology concept"}},{"Action Potential Initiation":{"RelatedTo":["Initial Segment"],"CurationStatus":"uncurated","SuperCategory":"Action potential characteristic","Id":"oen_0001094","DefiningCitation":"ModelDB:3541","Definition":"A process where the membrane voltage at the axon hillock or an equivalent region is raised above the threshold for generating an action potential or spike."}},{"Activated":{"SuperCategory":"Functional Quality for Microglia","Id":"sao5413665309","Definition":"Microglial activation, e.g., in brain injury, is characterized by enlargement, changes in shape, and increased synthesis of cytokines such as IL-1. There are three subtypes: primed, enlarged, phagocytic"}},{"Active":{"SuperCategory":"Behavioral quality of a process","Id":"PATO_0001707","Definition":"having marked activity."}},{"Active dendrite":{"CurationStatus":"pending final vetting","Comment":["Changed the supercategory from Cellular morphology characteristic to dendrite.  This should not be classified as a morphology characteristic","as it is referencing function and not structure.  However"],"SuperCategory":"Dendrite","Curator":["Maryann Martone"],"Id":"oen_0001092","Has role":"Electrophysiology concept","Definition":"Dendrites with active conductances which can influence the affects of synaptic inputs and are sometimes  capable of generating action potentials."}},{"Active Source Diameter":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0218","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149528","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Diameter of active Source (mm)."}},{"Active Source Length":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_021A","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149529","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"Length of active Source (mm)."}},{"Active Zone Cytomatrix":{"SuperCategory":"Pre-synaptic Active Zone Component","Id":"sao1470121605","Definition":"Filamentous matrix immediately internal to the plasma membrane docking zone (Zhai and Bellen, 2004)."}},{"Active Zone Dense Projection":{"SuperCategory":"Pre-synaptic Active Zone Component","Id":"sao494258938","Definition":"Electron dense projection extending from the cytomatrix into the cytoplasm on which synaptic vesicles are tethered (Zhai and Bellen, 2004)."}},{"Active Zone Plasma Membrane":{"SuperCategory":"Pre-synaptic Active Zone Component","Id":"sao2038461087","Definition":"Plasma membrane juxtaposed to the PSD where synaptic vesicle fusion occurs (Zhai and Bellen, 2004)."}},{"Activity (of a radionuclide)":{"Synonym":"radioactivity","SuperCategory":"Radiation quality","Id":"PATO_0001740","Definition":"A radiation quality inhering in a radioactive substance by virtue of its transformation (disintegration) rate."}},{"Activity pattern":{"RelatedTo":"Action potential","CurationStatus":"pending final vetting","Comment":"Moved the Supercategory to:  Pattern.  Look here for a definition of pattern: https://bioportal.bioontology.org/ontologies/SIO/?p","SuperCategory":"Pattern","Curator":["Maryann Martone"],"Id":"oen_0001091","Has role":"Electrophysiology concept","DefiningCitation":"ModelDB:3543","Definition":"In neurons, neural circuits or neural models refers to spatial or temporal patterns (or both) of spiking activity."}},{"Actual Human Performers Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_4035","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149530","Has role":"Scan-related personnel attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"The list of current human performers that are actually involved or responsible for performing the Workitem. Zero or more items may be included in this sequence. Note: Initially this list will be empty. "}},{"Aculeata":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998588","SuperCategory":"Apocrita","Id":"birnlex_400"}},{"Acupuncture task":{"Synonym":"acupuncture paradigm","Created":"4/28/2011 12:08","CurationStatus":"uncurated","Contributor":"Brenda Gregory","CAO_Id":"CAO_00729","SuperCategory":"Behavioral Experimental Paradigm","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Acupuncture_task","Id":"birnlex_2011","Has role":"Cognitive Atlas Concept","Xref":"COGPO_00048","Definition":"subjects are stimulated with Chinese acupuncture (CAO).A behavioral paradigm where subjects are stimulated with Chinese acupuncture, a procedure in which thin needles are passed through the skin to specific points (BIRNLEX)."}},{"Acute":{"SuperCategory":"Process quality","Id":"PATO_0000389","Definition":"Having a sudden onset, sharp rise, and short course."}},{"Acute angle":{"SuperCategory":"Angular placement","Id":"PATO_0001051","Definition":"Angular placement that is at an angle which is less than 90 degrees."}},{"Acute binge drug administration paradigm":{"Synonym":["Acute binge","Acute binge administration"],"CurationStatus":"uncurated","SuperCategory":"Acute drug administration paradigm","Id":"nlx_inv_100808","Has role":"NIF annotation standard for treatment type","Definition":"A drug administration paradigm where multiple doses of a drug are given during one experimental session limited by a 24 hour period of time or less."}},{"Acute Disseminated Encephalomyelitis":{"Created":"2007-10-05","Synonym":["Postinfectious Encephalomyelitis","Immune-Mediated Encephalomyelitis"],"CurationStatus":"uncurated","SuperCategory":"Demyelinating Autoimmune Disease","Id":"birnlex_12510","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"An acute or subacute inflammatory process of the CENTRAL NERVOUS SYSTEM characterized histologically by multiple foci of perivascular demyelination. Symptom onset usually occurs several days after an acute viral infection or immunization, but it may coincide with the onset of infection or rarely no antecedent event can be identified. Clinical manifestations include CONFUSION, somnolence, FEVER, nuchal rigidity, and involuntary movements. The illness may progress to COMA and eventually be fatal (MeSH)."}},{"Acute drug administration paradigm":{"Synonym":["acute","acute drug","acute drug paradigm"],"CurationStatus":"uncurated","Comment":["We will consider acute any drug paradigm where the drug is given during one experimental session.  However it should be noted that each experimental session may involve multiple doses or drug doses and behavioral paradigms.  Typically"],"SuperCategory":"Drug administration paradigm","Id":"nlx_inv_100807","Has role":"NIF annotation standard for treatment type","Definition":"A drug administration paradigm where a drug is given during one experimental session (once during the experiment, or multiple times) within a 24 hour period."}},{"Acute Hemorrhagic Leukoencephalitis":{"Synonym":["Hemorrhagic Necrotizing Encephalomyelitis","Leukoencephalitis Acuta Hemorrhagica","Acute Necrotizing Hemorrhagic Encephalomyelitis","Hurst's Disease","Acute Necrotizing Encephalitis"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Demyelinating Autoimmune Disease","Id":"birnlex_12513","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"A fulminant and often fatal demyelinating disease of the brain which primarily affects young adults and children. Clinical features include the rapid onset of weakness, SEIZURES, and COMA. It may follow a viral illness or MYCOPLASMA PNEUMONIAE infections but in most instances there is no precipitating event. Pathologic examination reveals marked perivascular demyelination and necrosis of white matter with microhemorrhages (MeSH)."}},{"Acute Traumatic Stress Disorder":{"Synonym":"Acute Stress Disorder","Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Traumatic Stress Disorder","Id":"birnlex_12680","Definition":"A class of traumatic stress disorders that is characterized by the significant dissociative states seen immediately after overwhelming trauma. By definition it cannot last longer than 1 month, if it persists, a diagnosis of post-traumatic stress disorder ( STRESS DISORDERS, POST-TRAUMATIC) is more appropriate (MeSH)."}},{"Adalimumab":{"RelatedTo":["Tumor necrosis factor","High affinity immunoglobulin gamma Fc receptor I","Low affinity immunoglobulin gamma Fc region receptor III-B","Complement C1s subcomponent","Complement C1r subcomponent","Complement C1q subcomponent subunit A","Complement C1q subcomponent subunit B","Complement C1q subcomponent subunit C","Low affinity immunoglobulin gamma Fc region receptor III-A","Low affinity immunoglobulin gamma Fc region receptor II-a","Low affinity immunoglobulin gamma Fc region receptor II-b"],"Synonym":["Ig gamma-1 chain C region"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00051","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00051","Definition":"Anti-TNF antibody, expressed in mammalian cell culture, 1330 residues, MW"}},{"Adamantinous Craniopharyngioma":{"Synonym":["Craniopharyngioma"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Craniopharyngioma","Id":"birnlex_12614","Definition":"The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations (MeSH)."}},{"Adapalene":{"RelatedTo":["Retinoic acid receptor RXR-beta","Retinoic acid receptor gamma-1","Retinoic acid receptor beta","Retinoic acid receptor gamma-2","Retinoic acid receptor RXR-alpha","Retinoic acid receptor alpha"],"Synonym":["Adapaleno (INN-Spanish)","Adapalenum (INN-Latin)","Adaferin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:31174","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00210","Definition":"Adapalene is a topical retinoid primarily used in the treatment of acne and is also used (off-label) to treat keratosis pilaris as well as other skin conditions. It is currently marketed by Galderma under the trade names Differin in some countries, and Adaferin in India. (Wikipedia) Pharmacology: Adapalene is a chemically stable retinoid-like compound. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes all of which represent important features in the pathology of acne vulgaris. Mechanism of action: Mechanistically, adapalene binds to specific retinoic acid nuclear receptors but does not bind to the cytosolic receptor protein. Although the exact mode of action of adapalene is unknown, it is suggested that topical adapalene may normalize the differentiation of follicular epithelial cells resulting in decreased microcomedone formation. Drug type: Approved. Small Molecule. Drug category: Anti-Inflammatory Agents, Non-Steroidal. Dermatologic Agents"}},{"Adaptation ratio":{"RelatedTo":["Spike Frequency Adaptation"],"Synonym":"adaptation percent","CurationStatus":"uncurated","Comment":"NeuroElectro Term 27","SuperCategory":"Action potential characteristic","Id":"oen_0001000","Has role":["NeuroElectro Term"],"Definition":"Ratio of durations between early and late AP inter-spike intervals"}},{"Adaxial to":{"SuperCategory":"Relational spatial quality","Id":"PATO_0002047","Definition":"A relational or spatial quality in which the bearer entity is located on the side nearest to the axis of an organ or organism."}},{"Addiction":{"CurationStatus":"uncurated","SuperCategory":"Disease of mental health","Id":"nlx_92731","Definition":"A compulsion to repeat a behaviour regardless of its consequences (http://www.sciencedaily.com/articles/a/addiction.htm)."}},{"Additional Patient History":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0010_21B0","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149531","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LT","Definition":"Additional information about the patient's medical history."}},{"Adefovir Dipivoxil":{"RelatedTo":"P protein (Includes: DNA-directed DNA polymerase","Synonym":["ADV","Adefovir","Adefovir pivoxil","Adefovirdipivoxl","GS-840","PMEA","adefovir dipivoxil","bis-POM PMEA","Hepsera"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00718","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00718","Definition":"Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is a failed treatment for HIV. (Wikipedia) Pharmacology: Adefovir dipivoxil a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The concentration of adefovir that inhibited 50% of viral DNA synthesis (IC50) in vitro ranged from 0.2 to 2.5 M in HBV transfected human hepatoma cell lines. The combination of adefovir with lamivudine showed additive anti-HBV activity. Mechanism of action: Adefovir dipivoxil is a prodrug of adefovir. Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. The inhibition constant (Ki) for adefovir diphosphate for HBV DNA polymerase was 0.1 M. Adefovir diphosphate is a weak inhibitor of human DNA polymerases  and  with Ki values of 1.18 M and 0.97M, respectively. Drug type: Approved. Investigational. Small Molecule. Drug category: Antiviral Agents. Reverse Transcriptase Inhibitors"}},{"Adenine":{"RelatedTo":["Adenine phosphoribosyltransferase","DNA","S-methyl-5-thioadenosine phosphorylase","Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase","Ribosome-inactivating protein alpha-trichosanthin","Ribosome-inactivating protein momordin I","Ricin","Antiviral protein I","Low molecular weight phosphotyrosine protein phosphatase","Acetyl-CoA carboxylase","Antiviral protein S","Uncharacterized protein YML079W","MTA/SAH nucleosidase","Adenine phosphoribosyltransferase","Purine trans deoxyribosylase","Serine/threonine-protein kinase SKY1","A/G-specific adenine glycosylase","Peroxisomal trans-2-enoyl-CoA reductase","Antiviral protein DAP-30","Seed lectin subunit I"],"Synonym":["1H-Purin-6-amine","6-Aminopurine","Adenin","Adeninimine","Vitamin B4","Leuco-4"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:16708","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00173","Definition":"A purine base and a fundamental unit of adenine nucleotides. (PubChem) Pharmacology: Adenine (sometimes known as vitamin B4) combines with the sugar ribose to form adenosine, which in turn can be bonded with from one to three phosphoric acid units, yielding AMP, ADP and ATP . These adenine derivatives perform important functions in cellular metabolism. Adenine is one of four nitrogenous bases utilized in the synthesis of nucleic acids. A modified form of adenosine monophosphate (cyclic AMP) is an imporant secondary messenger in the propagation of many hormonal stimuli. Adenine is an integral part of the structure of many coenzymes. Adenosine (adenine with a ribose group) causes transient heart block in the AV node of the heart. In individuals suspected of suffering from a supraventricular tachycardia (SVT), adenosine is used to help identify the rhythm. Certain SVTs can be successfully terminated with adenosine. Mechanism of action: Adenine forms adenosine, a nucleoside, when attached to ribose, and deoxyadenosine when attached to deoxyribose, and it forms adenosine triphosphate (ATP), a nucleotide, when three phosphate groups are added to adenosine. Adenosine triphosphate is used in cellular metabolism as one of the basic methods of transferring chemical energy between reactions. In older literature, adenine was sometimes called Vitamin B4Not Available Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Dietary supplement. Micronutrient"}},{"Adenine Nucleotide Transporter":{"SuperCategory":"Protein","Id":"sao2077117136","Definition":"Transports adenine nucleotides (AMP, ADP, and ATP) across membranes (Gene Ontology)."}},{"Adenohypophysis":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","Synonym":"anterior lobe of pituitary","NeuronamesID":"390","CurationStatus":"uncurated","Umlscui":["C1280369"],"SuperCategory":"Regional part of brain","Id":"birnlex_1581","Is part of":"Hypophysis","Abbrev":["AHP"],"DefinitionPMID":"22080957","Definition":"The adenohypophysis, which consists of the anterior and intermediate lobes of the pituitary gland, contains several types of endocrine cells, which secrete systemic hormones such as adenocorticotropic hormone (ACTH), GH, LH/FSH, TSH and prolactin in response to hypothalamus-derived releasing hormones (PMID:     22080957)."}},{"Adenomatous":{"CurationStatus":"uncurated","SuperCategory":"Morphology","Id":"PATO_0002090","Definition":"A morphology quality inhering in a tumour by virtue of the bearer's exhbiting the morphological characteristics of a glandular epithelial cell."}},{"Adenosine":{"RelatedTo":["Adenylate cyclase type 1","Adenosine A3 receptor"],"Synonym":["2'-Deoxyadenosine","Adenine Deoxy Nucleoside","Adenine Deoxyribonucleoside","Adenine Deoxyribose","Adenine Nucleoside","Adenine Riboside","Adenyldeoxyriboside","Deoxyadenosine","Desoxyadenosine","MEDR-640","USAF CB-10","adenosine","Adenocard","Adenocor","Adenoscan","Adenosin","Adensoine","Boniton","Myocol","Nucleocardyl","Pallacor"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:16335","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00640","Definition":"A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. (PubChem) Pharmacology: Adenosine is an endogenous nucleoside occurring in all cells of the body and is not chemically related to other antiarrhythmic drugs. Adenosine is indicated for the conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). Adenosine is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenosine is not blocked by atropine. Mechanism of action: Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome. Drug type: Approved. Investigational. Small Molecule. Drug category: Analgesics. Anti-Arrhythmia Agents. Antiarrhythmic Agents. Cardiac drugs. Vasodilator Agents"}},{"Adenosine 3',5'-cyclic monophosphate":{"Created":"2007-09-19","SuperCategory":"Purine Nucleotide","Id":"nifext_5196"}},{"Adenosine 5'-diphosphate":{"Created":"2007-09-19","SuperCategory":"Purine Nucleotide","Id":"nifext_5197"}},{"Adenosine 5'-monophosphate":{"Created":"2007-09-19","SuperCategory":"Purine Nucleotide","Id":"nifext_5195"}},{"Adenosine 5'-O-(2-fluoro)-diphosphate":{"Created":"2007-09-19","SuperCategory":"Adenosine 5'-diphosphate","Id":"nifext_5226"}},{"Adenosine 5'-O-(2-thio)-diphosphate":{"Created":"2007-09-19","SuperCategory":"Adenosine 5'-diphosphate","Id":"nifext_5227"}},{"Adenosine 5'-O-(3-thio)-triphosphate":{"Created":"2007-09-19","SuperCategory":"Adenosine 5'-triphosphate","Id":"nifext_5229"}},{"Adenosine 5'-triphosphate":{"Created":"2007-09-19","SuperCategory":"Purine Nucleotide","Id":"nifext_5198"}},{"Adenosine monophosphate":{"RelatedTo":["Glycogen phosphorylase","liver form","Adenine phosphoribosyltransferase","5'-AMP-activated protein kinase subunit beta-1","Adenylate cyclase type 1","Acetyl-coenzyme A synthetase","cytoplasmic","AMP deaminase 1","cAMP-specific 3',5'-cyclic phosphodiesterase 4B","Long-chain-fatty-acid--CoA ligase 1","5'-AMP-activated protein kinase catalytic subunit alpha-1","Acetyl-coenzyme A synthetase 2-like","mitochondrial","5'-AMP-activated protein kinase subunit beta-2","DNA","cAMP response element-binding protein","Proto-oncogene serine/threonine-protein kinase Pim-1","cAMP-specific 3',5'-cyclic phosphodiesterase 4D","Histidine triad nucleotide-binding protein 1","Fructose-1,6-bisphosphatase 1"],"Synonym":["5'-AMP","5'-Adenosine monophosphate","5'-Adenylic acid","AMP","Adenosine 5'-(dihydrogen phosphate)","Adenosine 5'-monophosphate","Adenosine 5'-phosphate","Adenosine 5'-phosphoric acid","Adenosine phosphate","Adenosine-5'-Monophosphate","Adenosine-5'-monophosphoric acid","Adenosine-5-monophosphoric acid","Adenylate","Adenylic acid","Phosphentaside","Adenovite","Cardiomone","Lycedan","My-B-Den","Phosaden"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00131","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00131","Definition":"Adenylic acid. Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. (PubChem) Pharmacology: Adenosine monophosphate, also known as 5'-adenylic acid and abbreviated AMP, is a nucleotide that is found in RNA. It is an ester of phosphoric acid with the nucleoside adenosine. AMP consists of the phosphate group, the pentose sugar ribose, and the nucleobase adenine. AMP is used as a dietary supplement to boost immune activity, and is also used as a substitute sweetener to aid in the maintenance of a low-calorie diet. Mechanism of action: Nucleotides such as Adenosine-5'-Monophosphate affect a number of immune functions, including the reversal of malnutrition and starvation-induced immunosuppression, the enhancement of T-cell maturation and function, the enhancement of natural killer cell activity, the improvement of delayed cutaneous hypersensitivity, helping resistance to such infectious agents as Staphylococcus aureus and Candida albicans, and finally the modulation of T-cell responses toward type 1 CD4 helper lymphocytes or Th1 cells. Studies have shown that mice fed a nucleotide-free diet have both impaired humoral and cellular immune responses. The addition of dietary nucleotides normalizes both types of responses. RNA, a delivery form of nucleotides, and ribonucleotides were used in these studies. The mechanism of the immune-enhancing activity of nucleic acids/nucleotides is not clear. Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Dietary supplement. Micronutrient"}},{"Adenosine receptor":{"Created":"2007-09-19","CurationStatus":"uncurated","SuperCategory":"G-protein coupled receptor","Id":"nifext_5716","Has role":["Receptor role"]}},{"Adenosine triphosphate":{"RelatedTo":["Proto-oncogene tyrosine-protein kinase ABL1","Beta-adrenergic receptor kinase 2","ATP-binding cassette sub-family A member 1","AFG3-like protein 2","AFG3-like protein 1","NEDD8-activating enzyme E1 regulatory subunit","ATP-binding cassette transporter sub-family C member 8","Asparagine synthetase (glutamine-hydrolyzing)","Cytosolic purine 5'-nucleotidase","Activin receptor type-1","Adenylate cyclase type 1","Apoptotic protease-activating factor 1","Beta-adrenergic receptor kinase 1","Acetyl-coenzyme A synthetase","cytoplasmic","ALK tyrosine kinase receptor","RAC-alpha serine/threonine-protein kinase","A-Raf proto-oncogene serine/threonine-protein kinase","Tyrosine-protein kinase ABL2","Serine/threonine-protein kinase ALS2CR7","Serine/threonine-protein kinase receptor R3","ATP-binding cassette transporter sub-family C member 9","ADP/ATP translocase 1","Long-chain-fatty-acid--CoA ligase 1","Activin receptor type 1B","Argininosuccinate synthase","Anti-Muellerian hormone type-2 receptor","5'-AMP-activated protein kinase catalytic subunit alpha-1","Bile salt export pump","Acetyl-coenzyme A synthetase 2-like","mitochondrial","Arsenical pump-driving ATPase","Activated CDC42 kinase 1","Multidrug resistance protein 1","Canalicular multispecific organic anion transporter 1"],"Synonym":["5'-ATP","ATP","Adenosine 5'-triphosphate","Adenosine 5'-triphosphoric acid","Adenosine","5'-(tetrahydrogen triphosphate)","Adenosine-5'-triphosphate","Adenylpyrophosphoric acid","Triphosphoric acid adenosine ester","Adephos","Adetol","Adynol","Atipi","Atriphos","Cardenosine","Fosfobion","Glucobasin","Myotriphos","Phosphobion","Striadyne","Triadenyl"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00171","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00171","Definition":"An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. (PubChem) Pharmacology: Adenosine triphosphate (ATP) is the nucleotide known in biochemistry as the \"molecular currency\" of intracellular energy transfer; that is, ATP is able to store and transport chemical energy within cells. ATP also plays an important role in the synthesis of nucleic acids. The total quantity of ATP in the human body is about 0.1 mole. The energy used by human cells requires the hydrolysis of 200 to 300 moles of ATP daily. This means that each ATP molecule is recycled 2000 to 3000 times during a single day. ATP cannot be stored, hence its consumption must closely follow its synthesis. Mechanism of action: ATP is able to store and transport chemical energy within cells. ATP also plays an important role in the synthesis of nucleic acids. ATP can be produced by various cellular processes, most typically in mitochondria by oxidative phosphorylation under the catalytic influence of ATP synthase. The total quantity of ATP in the human body is about 0.1 mole. The energy used by human cells requires the hydrolysis of 200 to 300 moles of ATP daily. This means that each ATP molecule is recycled 2000 to 3000 times during a single day. ATP cannot be stored, hence its consumption must closely follow its synthesis. Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Dietary supplement. Micronutrient"}},{"Adequate stimulus":{"CurationStatus":"uncurated","SuperCategory":"Electrophysiology concept","Id":"oen_0001099","Definition":"The particular type of stimulus energy to which a sensory receptor cell is sensitive"}},{"Adhesivity":{"Synonym":["stickiness"],"Comment":["The definition is general enough to cover adhesion arising from different kinds of chemical bonding/forces"],"SuperCategory":"Quality of related physical entities","Id":"PATO_0001431","Definition":"An emergent molecular relational quality that arises from the molecular attraction exerted between two entities in contact."}},{"Adinazolam":{"RelatedTo":"Translocator protein","Synonym":["Adinazolamum (INN-Latin)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00546","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00546","Definition":"Adinazolam (Deracyn) is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed. Pharmacology: Adinazolam is a benzodiazepine derivative used to treat anxiety, status epilepticus, and for sedation induction and anterograde amnesia. Adinazolam binds with high affinity to the GABA benzodiazepine receptor complex. Considerable evidence suggest that the central pharmacologic/therapeutic actions of alprazolam are mediated via interaction with this receptor complex. Mechanism of action: Adinazolam binds to peripheral-type benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways. Drug type: Approved. Small Molecule. Drug category: Anti-anxiety Agents. Antidepressive Agents"}},{"Adjustment Disorder":{"Synonym":["Anniversary Reaction","Reactive Disorder","Reactive Depression"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Mental Disorder","Id":"birnlex_12670","Definition":"Maladaptive reactions to identifiable psychosocial stressors occurring within a short time after onset of the stressor. They are manifested by either impairment in social or occupational functioning or by symptoms (depression, anxiety, etc.) that are in excess of a normal and expected reaction to the stressor (MeSH)."}},{"Administration Route Code Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0302","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149532","Has role":"Imaging procedure attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence that identifies the Administration Route. This sequence shall contain exactly one item."}},{"Admission ID":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0038_0010","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149533","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Identification number of the visit as assigned by the healthcare provider."}},{"Admitting Date":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0038_0020","CurationStatus":"uncurated","Comment":"general term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149534","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"The date the individual (patient or healthy) was admitted."}},{"Admitting Diagnoses Code Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_1084","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149535","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"A sequence that conveys the admitting diagnosis (diagnoses). One or more Items may be included in this Sequence."}},{"Admitting Diagnoses Description":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_1080","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149536","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Description of the admitting diagnosis (diagnoses)."}},{"Admitting Time":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0038_0021","CurationStatus":"uncurated","Comment":"general term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149537","Has role":"Patient attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"The time the patient was admitted."}},{"Adolescent":{"CurationStatus":"uncurated","SuperCategory":"Maturity","Id":"PATO_0001189","Definition":"A maturity quality inhering in a bearer by virtue of its being between the onset of puberty and adulthood."}},{"Adolescent cat":{"Synonym":"Cat adolescent","CurationStatus":"uncurated","SuperCategory":"Cat","Id":"nlx_organ_109077","Definition":"A cat 5.5 to 8 months old, with the day of birth defined as day 0."}},{"Adolescent chimpanzee":{"Synonym":"Chimpanzee adolescent","CurationStatus":"uncurated","SuperCategory":"Chimpanzee","Id":"nlx_organ_109084","Definition":"A chimpanzee 5 to 16 years old."}},{"Adolescent human":{"Synonym":"Human adolescent","CurationStatus":"uncurated","SuperCategory":"Human","Id":"nlx_organ_109055","Definition":"The period of life beginning with the appearance of secondary sex characteristics and terminating with the cessation of somatic growth. The years usually referred to as adolescence lie between 13 and 18 years of age but for our purposes have been extended to anything under 21 years of age when adulthood has been considered reached. (Adapted from MeSH)"}},{"Adolescent mouse":{"Synonym":"Mouse adolescent","CurationStatus":"uncurated","Comment":"This definition is a guess at the top end (less than 8 weeks).","SuperCategory":"Mouse","Id":"nlx_organ_109065","Definition":"A mouse over 5 weeks old but less than 8 weeks old, with the day of birth defined as day 0."}},{"Adolescent rat":{"Synonym":"Rat adolescent","CurationStatus":"uncurated","SuperCategory":"Rat","Id":"nlx_organ_109071","Definition":"A rat 29 to 35 days old, with the day of birth defined as day 0."}},{"ADP amplitude":{"RelatedTo":["Membrane potential","Action potential"],"Synonym":["after-depolarization potential amplitude","afterdepolarization potential amplitude","ADP magnitude","ADP amplitude","ADP size","ADP peak amplitude"],"CurationStatus":"uncurated","Comment":"NeuroElectro Term 24","SuperCategory":"Action potential characteristic","Id":"oen_0001004","Has role":["NeuroElectro Term"],"Definition":"Amplitude from first AP onset to maximum voltage, typically more depolarized that the resting membrane potential"}},{"ADP duration":{"RelatedTo":["Membrane potential","Time","Action potential"],"Synonym":["after-depolarization potential duration","afterdepolarization potential duration"],"CurationStatus":"uncurated","Comment":"NeuroElectro Term 25","SuperCategory":"Action potential characteristic","Id":"oen_0001003","Has role":["NeuroElectro Term"],"Definition":"Duration from first AP onset to maximum ADP"}},{"Adrenergic system":{"CurationStatus":"uncurated","SuperCategory":"Catecholamine system","Id":"nlx_anat_1005023","Definition":"any molecule, protein, cell, tissue or organ that is related to epinephrine (also known as adrenaline)."}},{"Adrenoceptor receptor":{"RelatedTo":["Epinephrine"],"Created":"2007-09-19","Synonym":["Alpha-adrenergic receptor","Alpha adrenergic receptor","Beta-adrenergic receptor"],"CurationStatus":"uncurated","SuperCategory":"G-protein coupled receptor","Id":"nifext_6234","Has role":["Neurotransmitter Receptor"],"Definition":"Class of G-protein receptors that are activated by catecholamines."}},{"Adrenocorticotropic hormone":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5084"}},{"Adrenoleukodystrophy":{"Created":"2007-10-05","Synonym":["Schilder-Addison Complex","X-Linked Adrenoleukodystrophy","Adrenomyeloneuropathy"],"CurationStatus":"uncurated","SuperCategory":"Hereditary Central Nervous System Demyelinating Diseases","Id":"birnlex_12527","Definition":"An X-linked recessive disorder characterized by the accumulation of saturated very long chain fatty acids in the LYSOSOMES of ADRENAL CORTEX and the white matter of CENTRAL NERVOUS SYSTEM. This disease occurs almost exclusively in the males. Clinical features include the childhood onset of ATAXIA; NEUROBEHAVIORAL MANIFESTATIONS; HYPERPIGMENTATION; ADRENAL INSUFFICIENCY; SEIZURES; MUSCLE SPASTICITY; and DEMENTIA. The slowly progressive adult form is called adrenomyeloneuropathy. The defective gene ABCD1 is located at Xq28, and encodes the adrenoleukodystrophy protein ( ATP-BINDING CASSETTE TRANSPORTERS) (MeSH)."}},{"Adrenomedullin":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5136"}},{"Adult":{"CurationStatus":"uncurated","SuperCategory":"Maturity","Id":"birnlex_681","Definition":"A maturity quality inhering in an individual by virtue of the individual having attained sexual maturity and full growth."}},{"Adult anterior LK leucokinin neuron":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"adult ALK neuron","Comment":["These neurons are not labelled by a leucokinin antibody (de Haro et al."],"FBbt_Id":"FBbt_00110059","Created":"2011-12-12T10:24:58Z","Contributor":"mmc46","SuperCategory":"Adult leucokinin neuron of the central nervous system","SomaLocation":"adult protocerebrum","Id":"nlx_149018","Is part of":"Adult protocerebrum","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","Definition":"Adult neuron that expresses leucokinin (FBgn0028418) and whose cell body is located superficially in the posterior side of the median protocerebrum (de Haro et al., 2010).","hasDBXref":"VFB:FBbt_00110059"}},{"Adult attachment interview":{"Created":"8/15/2011 10:52","CurationStatus":"uncurated","Contributor":"Corey White","CAO_Id":"CAO_00797","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Adult_attachment_interview","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146019","Definition":"Standardized interview used to assess developmental and attachment history."}},{"Adult Caenorhabditis elegans":{"Synonym":["Caenorhabditis elegans adult","C. elegans adult","C elegans adult","Adult C. elegans"],"CurationStatus":"uncurated","SuperCategory":"Caenorhabditis_elegans","Id":"WBls:0000041","Definition":"The stage after an animal is fully-developed and reaches maturity. (C. elegans development: http://purl.org/obo/owl/WBls#WBls_0000041)"}},{"Adult cat":{"Synonym":"Cat adult","CurationStatus":"uncurated","SuperCategory":"Cat","Id":"nlx_organ_109025","Definition":"A cat with age greater than or equal to 9 months, with the day of birth defined as day 0."}},{"Adult deuterocerebrum DC tachykinin neuron":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"adult TC1 neuron","Comment":["Tachykinin expression was observed by in situ hybridization and immunostaining (Winther et al."],"FBbt_Id":"FBbt_00110046","Created":"2011-12-08T02:39:29Z","Contributor":"mmc46","SuperCategory":"Adult tachykinin neuron of the central nervous system","SomaLocation":"adult deuterocerebrum","Id":"nlx_149005","Is part of":"Adult brain","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","Definition":"Adult neuron that expresses tachykinin (FBgn0037976) whose cell body is located in the cortex of the anterior deuterocerebrum close to the antennal lobes. There are about 8 pairs of cell bodies per hemisphere (Winther et al., 2003).","hasDBXref":"VFB:FBbt_00110046"}},{"Adult dMP2 ILP7 neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-06-14T02:34:33Z","Contributor":"sr544","SuperCategory":"Neurosecretory neuron","Comment":["The adult dMP2 ILP7 neurons probably develops from the embryonic / larval dMP2 ILP7 neurons","though some remodelling occurs (Miguel-Aliaga et al."],"Id":"nlx_148840","Is part of":"Thoracico-abdominal ganglion","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100539","Definition":"An adult dMP2 neuron that expresses ILP7. There are two per abdominal segment, all projecting to the hindgut. These projections have ILP7 positive swellings and connect to the anterior intestines and the rectum. Their terminals are also sites of ILP7 localization (Miguel-Aliaga et al., 2008)."}},{"Adult DN period neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Adult pacemaker neuron","Comment":["Kaneko et al.","(1997) suggest that the larval DN period neurons could be the same cells as the adult DN period neurons based on position of the soma. However","they further comment that these cells do not continuously express Period (FBgn0003068) throughout the developmental stages","making developmental profiling difficult. Furthermore","antiphase cycling of Period observed in larval DN period neuron-2 was not found in either the pupal or adult DN period neuron-2","suggesting that these cells would have to change their Period cycling phase during metamorphosis if they are the same cells. Because of this uncertainty"],"Id":"nlx_147362","Is part of":"Adult brain","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00003628","hasDBXref":"VFB:FBbt_00003628","Definition":"Period (FBgn0003068) expressing neuron of the adult brain whose cell body is located in the posterior, dorsal-most cortex."}},{"Adult dorsomedial neurosecretory cell":{"Overlaps_some":["adult tritocerebrum","superior lateral protocerebrum","hypocerebral ganglion"],"Has_role":"Fly_Anatomy_Ontology","Created":"2012-03-02T12:32:50Z","Synonym":"MNC","Contributor":"mmc46","SomaLocation":"adult pars intercerebralis","SuperCategory":"Dorsomedial neurosecretory cell","Id":"nlx_149065","Is part of":"Adult pars intercerebralis","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00110107","Definition":"Neurosecretory cell of the pars intercerebralis that extend ventrally and branch before exiting the brain. It extends thin branches laterally in the dorsal protocerebrum, shorter branches along the cell neurites in the dorsal part of the median bundle and extensive arborizations in the tritocerebrum (Enell et al., 2010). The two branches follow the aorta and innervate the corpus cardiacum in the ring gland and the hypocerebral ganglion, near the cardiac valve of the midgut. One of the branches follows the stalk of the crop, whilst the other bifurcates, with each of these branches extending along each side of the midgut (Cao and Brown, 2001). Located in a bilateral cell body cluster of five to seven cells in each hemisphere (Cao and Brown, 2001, Broughton et al., 2005)."}},{"Adult drosophila":{"Synonym":"Drosophila adult","CurationStatus":"uncurated","SuperCategory":"Drosophila","Id":"FBdv:00005369","Definition":"A developmental stage in the drosophila life-cycle that starts at the end of pharate adult stage P15(ii) / P-stage / pharate adult stage P15 / pharate adult stage. (Definition aligned with Drosophila development: http://purl.org/obo/owl/FBdv#FBdv_00005369)"}},{"Adult drosophila melanogaster":{"Synonym":"Drosophila melanogaster adult","CurationStatus":"uncurated","SuperCategory":"Drosophila melanogaster","Id":"nlx_organ_109027","Definition":"A drosophila 14 days old or older, with the day of birth defined as day 0."}},{"Adult gorilla":{"Synonym":"Gorilla adult","CurationStatus":"uncurated","SuperCategory":"Gorilla","Id":"nlx_organ_109026","Definition":"A gorilla 13 years old and over."}},{"Adult human":{"EditorialNote":"For the NIF project, we define adult human using the NIH criteria for involvement of children in research projects, where children are defined as < 21 yrs of age.","Synonym":"Human adult","CurationStatus":"pending final vetting","SuperCategory":"Human","Id":"nlx_52049","Definition":"A person having attained full growth or maturity, defined as 21 years of age or older. (Based on definition of adult from the National Institutes of Health CRISP database)"}},{"Adult labial interneuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Interneuron (FBbt Term)","Id":"nlx_147747","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004037","Fasciculates_with":"adult labial nerve"}},{"Adult labial motor neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Motor neuron (FBbt Term)","Id":"nlx_147752","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004042","Fasciculates_with":"adult labial nerve"}},{"Adult labial sensory neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Sensory neuron (FBbt Term)","Id":"nlx_147739","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004029","Fasciculates_with":"adult labial nerve"}},{"Adult lateral horn LHKL leucokinin neuron":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"LHLK","Has_synaptic_terminal_in":["calyx of adult mushroom body"],"FBbt_Id":"FBbt_00110058","Created":"2011-12-08T02:39:29Z","Develops_from":"larval lateral horn LHKL leucokinin neuron","Contributor":"mmc46","SuperCategory":"Adult leucokinin neuron of the central nervous system","SomaLocation":"cortex of lateral horn","Id":"nlx_149017","Is part of":"Adult brain","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","Definition":"Adult neuron that expresses leucokinin (FBgn0028418) and whose large cell body is located in the lateral horn. Its thin processes run ventrally before bifurcating into two main collateral branches which innervate the superior lateral and median protocerebrum, the region around the mushroom body pedunculus and the mushroom body calyx. There is one neuron per hemisphere (de Haro et al., 2010).","hasDBXref":"VFB:FBbt_00110058"}},{"Adult leucokinin neuron of the central nervous system":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-12-12T11:28:23Z","Contributor":"mmc46","SuperCategory":"Leucokinin neuron","Id":"nlx_149023","Is part of":"Adult central nervous system","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00110064","Definition":"An adult neuron that expresses leucokinin (FBgn0028418) and that is located in the central nervous system (de Haro et al., 2010)."}},{"Adult leucokinin SELK neuron of the subesophageal ganglion":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"adult SELK neuron","Has_synaptic_terminal_in":["adult subesophageal ganglion"],"FBbt_Id":"FBbt_00110056","Created":"2011-12-08T02:39:29Z","Contributor":"mmc46","SuperCategory":"Adult leucokinin neuron of the central nervous system","SomaLocation":"adult subesophageal ganglion","Id":"nlx_149015","Is part of":"Adult central nervous system","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","Definition":"Adult neuron that expresses leucokinin (FBgn0028418) whose cell body is located in the ventromedial subesophageal ganglion. The axon collaterals in the brain innervate the subesophageal ganglion ipsi- and contralaterally, the tritocerebrum and fasciculate with the maxillary and labral nerve. Four axons extend along the cervical connective to the ventral nerve cord. The axons that extend along the ventral nerve cord connect to the leucokinin ABLK neurons. There are two to three pairs of neurons (de Haro et al., 2010).","Fasciculates_with":["adult labral nerve","cervical connective"]}},{"Adult mouse":{"Synonym":"Mouse adult","CurationStatus":"uncurated","SuperCategory":"Mouse","Id":"birnlex_461","Definition":"A mouse with age greater than or equal to 8 weeks, with the day of birth defined as day 0, and weight >/"}},{"Adult neurogenesis":{"Synonym":"Neurogenesis","CurationStatus":"uncurated","SuperCategory":"Biological process","Id":"nlx_83525","Definition":"(birth of neurons) is the process by which neurons are created. Most active during pre-natal development, neurogenesis is responsible for populating the growing brain. - definition adapted from Wikipedia"}},{"Adult olfactory receptor neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2009-12-09T05:03:55Z","Synonym":"adult odorant receptor neuron","SuperCategory":"Olfactory receptor neuron (FBbt Term)","Id":"nlx_148091","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007386","Definition":"Any olfactory receptor neuron (FBbt_00005926) that is part of some adult (FBbt_00003004)."}},{"Adult olfactory receptor neuron Ir64a":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-11-03T01:56:34Z","Synonym":"Ir64a","Contributor":"mmc46","SuperCategory":"Antennal olfactory receptor neuron","Comment":["This neuron was indirectly shown to be olfactory by recording calcium changes in the antennal lobe during an odorant-response assay using wildtype flies and mutants in which ORN Ir64a were silenced (Ai et al."],"Id":"nlx_148987","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","Has_presynaptic_layer_in":["antennal lobe glomerulus DC4"],"FBbt_Id":"FBbt_00110019","Fasciculates_with":"antennal commissure","Definition":"Bilateral olfactory receptor neuron that expresses the ionotropic glutamate receptor (Ir) 64a (FBgn0035604) and the co-receptor Ir8a (FBgn0052704). Its axon branches, with one branch innervating the ipsilateral antennal lobe glomeruli DL4 and DP1 medial compartment and the other fasciculating with the antennal commissure and innervating the contralateral antennal lobe glomeruli DC4 and DP1 medial compartment (Ai et al., 2010, Silbering et al., 2011). Its dendrite transduces signals from the grooved sensillum of chamber III of the sacculus (Shanbhag et al., 1995)."}},{"Adult optic lobe OL tachykinin neuron":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"adult OL neuron","Comment":["Tachykinin expression was observed by in situ hybridization and immunostaining (Winther et al."],"FBbt_Id":"FBbt_00110047","Created":"2011-12-08T02:39:29Z","Contributor":"mmc46","SuperCategory":"Adult tachykinin neuron of the central nervous system","SomaLocation":"optic lobe","Id":"nlx_149006","Is part of":"Optic lobe","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","Definition":"Adult neuron that expresses tachykinin (FBgn0037976) and whose cell body is located at the base of the optic lobe. There are about 10 pairs of cell bodies per hemisphere (Winther et al., 2003).","hasDBXref":"VFB:FBbt_00110047"}},{"Adult pacemaker neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-07-13T01:58:17Z","Contributor":"sr544","SuperCategory":"Pacemaker neuron","Id":"nlx_148513","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100163","Definition":"Pacemaker neuron that is part of the adult nervous system."}},{"Adult Pdf neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-07-16T11:09:46Z","Contributor":"sr544","SuperCategory":"Pdf neuron","Id":"nlx_148521","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100171","Definition":"Pdf expressing neuron that is part of the adult."}},{"Adult Pelizaeus-Merzbacher Disease":{"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Pelizaeus-Merzbacher Disease","Id":"birnlex_12550"}},{"Adult protocerebral LPP1 tachykinin neuron":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"adult LPP1 neuron","Comment":["Tachykinin expression was observed by in situ hybridization and immunostaining (Winther et al."],"FBbt_Id":"FBbt_00110044","Created":"2011-12-08T02:39:29Z","Contributor":"mmc46","SuperCategory":"Adult tachykinin neuron of the central nervous system","SomaLocation":"adult protocerebrum","Id":"nlx_149003","Is part of":"Adult brain","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","Definition":"Adult neuron that expresses tachykinin (FBgn0037976) and  whose cell body is located in the posterior protocerebrum. One cluster of around 12 cell bodies is found per hemisphere (Winther et al., 2003).","hasDBXref":"VFB:FBbt_00110044"}},{"Adult protocerebral LPP2 tachykinin neuron":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"adult LPP2 neuron","Comment":["Tachykinin expression was observed by in situ hybridization and immunostaining (Winther et al."],"Has_synaptic_terminal_in":["fan-shaped body"],"FBbt_Id":"FBbt_00110043","Created":"2011-12-08T02:39:29Z","Contributor":"mmc46","SuperCategory":"Adult tachykinin neuron of the central nervous system","SomaLocation":"protocerebrum","Id":"nlx_149002","Is part of":"Adult brain","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","Definition":"Adult neuron that expresses tachykinin (FBgn0037976), whose cell body is located in the lateral posterior protocerebrum and that innervates the superior median protocerebrum and the fan-shaped body. One cluster of around 10 cell bodies is found per hemisphere (Winther et al., 2003).","hasDBXref":"VFB:FBbt_00110043"}},{"Adult protocerebral MPP tachykinin neuron":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"adult MPP neuron","Comment":["Tachykinin expression was observed by in situ hybridization and immunostaining (Winther et al."],"FBbt_Id":"FBbt_00110045","Created":"2011-12-08T02:39:29Z","Contributor":"mmc46","SuperCategory":"Adult tachykinin neuron of the central nervous system","SomaLocation":"adult protocerebrum","Id":"nlx_149004","Is part of":"Adult brain","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","Definition":"Adult neuron that expresses tachykinin (FBgn0037976) and whose cell body is located in the median posterior protocerebrum. One cluster of around 3 cell bodies is found per hemisphere (Winther et al., 2003).","hasDBXref":"VFB:FBbt_00110045"}},{"Adult rat":{"Synonym":"Rat adult","CurationStatus":"uncurated","SuperCategory":"Rat","Id":"birnlex_479","Definition":"A rat > or equal to 60 days old (day of birth defined as day 0) or > /"}},{"Adult tachykinin neuron of the central nervous system":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-12-12T11:28:23Z","Contributor":"mmc46","SuperCategory":"Tachykinin neuron","Id":"nlx_149020","Is part of":"Adult central nervous system","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00110061","Definition":"An adult neuron that expresses tachykinin (FBgn0037976) and that is located in the central nervous system (Winther et al., 2003)."}},{"Adult tachykinin neuron of the thoracic-abdominal ganglion":{"Has_role":"Fly_Anatomy_Ontology","Created":"2011-12-08T02:39:29Z","Contributor":"mmc46","SomaLocation":"thoracico-abdominal ganglion","SuperCategory":"Adult tachykinin neuron of the central nervous system","Id":"nlx_149010","Is part of":"Thoracico-abdominal ganglion","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00110051","Definition":"Adult neuron that expresses tachykinin (FBgn0037976) whose cell body is located in the thoracic-abdominal ganglion. There are 10 to 12 pairs in the prothoracic, 5 to 6 in the mesothoracic, 8 to 12 in the metathoracic and 1 to 2 in the abdominal neuromeres (Winther et al., 2003)."}},{"Adult tritocerebral TC1 tachykinin neuron":{"Has_role":"Fly_Anatomy_Ontology","Synonym":"tritocerebral neuron TC1","Comment":"Tachykinin expression was observed by in situ hybridization and immunostaining.","Has_synaptic_terminal_in":"fan-shaped body","FBbt_Id":"FBbt_00110050","Created":"2011-12-08T02:39:29Z","Contributor":"mmc46","SuperCategory":"Adult tachykinin neuron of the central nervous system","SomaLocation":"adult tritocerebrum","Id":"nlx_149009","Is part of":"Adult tritocerebrum","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","Definition":"Adult neuron that expresses tachykinin (FBgn0037976), whose cell body is located in the tritocerebrum and which innervates, among other regions, the fan-shaped body. One cluster of around 16 cell bodies is found per hemisphere (Winther et al., 2003).","hasDBXref":"VFB:FBbt_00110050"}},{"Adult xenopus":{"Synonym":"Xenopus adult","CurationStatus":"uncurated","SuperCategory":"Xenopus","Id":"nlx_organ_109024","Definition":"A xenopus of age greater than or equal to 1 year, with the day of birth defined as day 0 or the stage of being a fully formed animal, following Nieuwkoop and Faber stage 66 (Xenopus ontology: http://purl.org/obo/owl/XAO#XAO_1000009)."}},{"Advanced phase":{"Synonym":"increased incidence","SuperCategory":"Phase","Id":"PATO_0000500","Definition":"A phase which is earlier than the natural start time."}},{"Aeolididina":{"Created":"2008-02-02","CurationStatus":"pending_final_vetting","Umlscui":"C1031710","SuperCategory":"Nudibranchia","Id":"birnlex_7243"}},{"Aerobic":{"SuperCategory":"Sensitivity to oxygen","Id":"PATO_0001455","Definition":"A quality inhering in a bearer by virtue of its dependence on oxygen."}},{"Aerobic (for occurrence)":{"SuperCategory":"Sensitivity of occurrent to oxygen","Id":"PATO_0001459","Definition":"A quality inhering in a biological process by virtue of the process unfolding in a location with oxygen."}},{"Affective assessment":{"Created":"2008-03-14","CurationStatus":"uncurated","SuperCategory":"Mental state assessment","Id":"birnlex_3000","Definition":"An neuropsychiatric instrument consisting of a series of patient-answer and/or clinician-answered questions designed to assess the affective state of the patient.  Typically score ranges are mapped to particular stages or states along an affective continuum such as depressive state."}},{"Affective neuroscience":{"CurationStatus":"uncurated","SuperCategory":"Neuroscience","Id":"nlx_inv_100603","Definition":"Branch of neuroscience involving the study of the neural mechanisms of emotion.This interdisciplinary field combines neuroscience with the psychological study of personality, emotion, and mood. - definition adapted from Wikipedia"}},{"Affective Psychotic Disorder":{"Synonym":["Reactive Psychotic Depression","Psychotic Mood Disorder"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Mood Disorder","Id":"birnlex_12753","Definition":"Disorders in which the essential feature is a severe disturbance in mood (depression, anxiety, elation, and excitement) accompanied by psychotic symptoms such as delusions, hallucinations, gross impairment in reality testing, etc. (MeSH)."}},{"Afferent":{"Synonym":"input","CurationStatus":"uncurated","SuperCategory":"Role","Id":"nlx_15593","Definition":"An axon that is incoming into a brain region.  Could also refer to the neuron that gives rise to the axon.(A connection, or a pathway to a node. A node can be an individual neuron, a neuron class, a gray matter region, or a site. Afferent and its complementary term efferent were used for the first time by Unzer, 1771, to indicate toward or away from the central nervous system or other non-neural tissues. Adapted from Swanson, 2014)."}},{"Affinity chromotography instrument":{"Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Gravity-driven liquid chromotography instrument","Id":"birnlex_2409"}},{"African Biobank":{"CurationStatus":"uncurated","SuperCategory":"Biobank","Id":"nlx_152010","Abbrev":"African Biobank","Definition":"A cryogenic storage facility located in Africa used to archive biological samples for use in research and experiments or transplantation. Ranging in size from individual refrigerators to warehouses, African biobanks are maintained by institutions such as hospitals, universities, nonprofit organizations, and pharmaceutical companies. (Adapted from Wikipedia)"}},{"African-American":{"Synonym":["Black Americans","Afro-Americans"],"CurationStatus":"uncurated","Id":"nlx_92585","Definition":"Citizens or residents of the United States who have origins in any of the black populations of Africa. In the United States, the terms are generally used for Americans with at least partial Sub-Saharan African ancestry. Most African Americans are the direct descendants of captive Africans who survived the slavery era within the boundaries of the present United States, although some are\u2013or are descended from\u2013immigrants from African, Caribbean, Central American or South American nations. They make up the single largest racial minority in the United States and form the second largest racial group after whites in the United States. (Wikipedia)"}},{"After-potential":{"CurationStatus":"uncurated","SuperCategory":"Action potential characteristic","Id":"oen_0001258","Definition":"A transient hyperpolarization or depolarization following the action potential."}},{"Agalsidase beta":{"Synonym":["Agalsidase alfa","Alpha-D- galactoside galactohydrolase","Alpha-D-galactosidase A","Alpha-galactosidase A precursor","Melibiase","agalsidase beta","Fabrazyme","Fabrazyme (Genzyme Corp)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00103","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00103","Definition":"Recombinant human alpha-galactosidase A. The mature protein is composed of 2 subunits of 398 residues. Protein is glycosylated and produced by CHO cells Pharmacology: Used in the treatment of Fabry disease, an X-linked genetic disorder of glycosphingolipid metabolism. The disease is characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A, which leads to progressive accumulation of glycosphingolipids, predominantly GL-3, in many body tissues. Clinical manifestations of Fabry disease include renal failure, cardiomyopathy, and cerebrovascular accidents. Fabrazyme is intended to provide an exogenous source of alpha-galactosidase A and to limit the accumulation of these glycolipids in the tissues. Mechanism of action: Alpha-galactosidase A catalyzes the hydrolysis of globotriaosylceramide (GL-3) and other a-galactyl-terminated neutral glycosphingolipids, such as galabiosylceramide and blood group B substances to ceramide dihexoside and galactose. Drug type: Approved. Biotech. Investigational. Drug category: Enzyme Replacement Agents"}},{"Agarose gel electrophoresis instrument":{"Created":"2007-10-11","CurationStatus":"graph_position_temporary","SuperCategory":"Gel electrophoresis instrument","Id":"birnlex_2406"}},{"Age":{"SuperCategory":"Time","Id":"PATO_0000011","Definition":"A time quality inhering in a bearer by virtue of how long it has existed."}},{"Age associated cellular inclusion":{"Comment":["Need to look this one up and see what this really meant.  At the least"],"SuperCategory":"Cellular Inclusion","Id":"sao2017162875"}},{"Age-related macular degeneration":{"Synonym":["Age related maculopathy","Senile macular degeneration"],"Created":"2007-11-18","CurationStatus":"uncurated","Umlscui":"C0242383","SuperCategory":"Macular degeneration","Id":"birnlex_12812"}},{"Aged":{"Synonym":"elderly","CurationStatus":"uncurated","SuperCategory":"Maturity","Id":"nlx_21994","Definition":"A maturity quality inhering in an organism by virtue of the organism having passed sexual maturity and full growth and now being in its later stage of life. This is characterized by changes that happen over time and can include physical, psychological, and social change."}},{"Aged cat":{"Synonym":"Cat aged","CurationStatus":"uncurated","SuperCategory":"Adult cat","Id":"nlx_organ_109104","Definition":"A cat 10 years old or more."}},{"Aged mouse":{"Synonym":"Mouse aged","CurationStatus":"uncurated","SuperCategory":"Adult mouse","Id":"nlx_organ_109098","Definition":"A mouse 2 to 3 years old."}},{"Aged rat":{"Synonym":"Rat aged","CurationStatus":"uncurated","SuperCategory":"Adult rat","Id":"nlx_organ_109101","Definition":"A rat 3 to 4 years old."}},{"Agent delivery process":{"Created":"2006-05-15","CurationStatus":"uncurated","SuperCategory":"Planned process","Id":"birnlex_2124","Definition":"The process by which an experimental agent is delivered to an organism or part of organism."}},{"Aggregate field theory":{"CurationStatus":"uncurated","SuperCategory":"Electrophysiology theory","Id":"oen_0001101","Definition":"A theory of brain function, which states that individual mental functions or behaviors are performed by the brain as a whole, rather than by discrete portions of the brain."}},{"Aggregate Object":{"SuperCategory":"Object aggregate","Id":"sao3826089237"}},{"Aggregate regional part of brain":{"CurationStatus":"uncurated","Comment":"We'll use this category differently than \"Composite brain structure spanning multiple base parts\" which should be used for structures like the medial lemniscus that are found in different brain locations","SuperCategory":"Regional part of brain","Id":"nlx_anat_20090509","Definition":"A regional part of brain consisting of multiple brain regions that are not related through a simple volummetric part of hierarchy, e.g., basal ganglia."}},{"Aggregated":{"CurationStatus":"uncurated","SuperCategory":"Irregular spatial pattern","Id":"PATO_0001629","Definition":"Gathered or tending to gather into a mass or whole."}},{"Aging":{" limit":"1000","RelatedTo":"Development","Synonym":"Ageing","CurationStatus":"uncurated","SuperCategory":"Biological process"," format":"CSV","Id":"GO:0007568","Definition":"is the state or process of aging"}},{"Agnate half brother":{"Synonym":"Consanguine half brother","Created":"2008-03-14","CurationStatus":"definition_incomplete","SuperCategory":"Half brother","Id":"birnlex_7400","Definition":"An agnate half brother is a half brother that shares the same father with their sibling (Wikipedia)."}},{"Agnate half sister":{"Synonym":"Consanguine half sister","Created":"2008-03-14","CurationStatus":"definition_incomplete","SuperCategory":"Half sister","Id":"birnlex_7400_2","Definition":"An agnate half sister is a half sister that shares the same father with their sibling (Wikipedia)."}},{"Agonist role":{"RelatedTo":"Drug","Synonym":["Agonist","agonista","agonists"],"CurationStatus":"uncurated","SuperCategory":"Pharmacological role","Id":"CHEBI:48705","Definition":"Substance which binds to cell receptors normally responding to naturally occurring substances and which produces a response of its own."}},{"Agoraphobia":{"Created":"2007-10-05","CurationStatus":"http://purl.org/nbirn/birnlex/ontology/annotation/BIRNLex_annotation_properties.owl#uncurated","SuperCategory":"Anxiety Disorder","Curator":"Bill Bug","Id":"birnlex_12672","Definition":"Anxiety about being in places or situations from which escape might be difficult or embarrassing or in which help may not be available in the event of having a panic attack. The anxiety leads to a pervasive avoidance of being alone outside the home., Obsessive, persistent, intense fear of open places."}},{"Agranular insular area dorsal part layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  dorsal part  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153036","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area dorsal part layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  dorsal part  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152956","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area dorsal part layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  dorsal part  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153684","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area dorsal part layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  dorsal part  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153083","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area dorsal part of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  dorsal part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153218","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153080","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area posterior part layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  posterior part  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153039","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area posterior part layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  posterior part  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152943","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area posterior part layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  posterior part  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153676","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area posterior part layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  posterior part  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152907","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area posterior part of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  posterior part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153208","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area ventral part layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  ventral part  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153290","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area ventral part layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  ventral part  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153191","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area ventral part layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  ventral part  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152979","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area ventral part layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  ventral part  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153323","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Agranular insular area ventral part of ABA 2009":{"PartiallyOverlapsWith":"Agranular insular area  ventral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153610","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"AHP amplitude":{"RelatedTo":["Membrane Potential","Action Potential"],"Synonym":["after-hyperpolarization potential amplitude","afterhyperpolarization potential amplitude","AHP magnitude","AHP amplitude","AHP size","AHP peak amplitude"],"SuperCategory":"Action potential characteristic","Comment":"NeuroElectro Term 16","Id":"oen_0001009","Has role":"NeuroElectro Term","Definition":"Amplitude from first AP onset to minimum voltage, not explicitly fast or slow"}},{"AHP duration":{"RelatedTo":["Membrane Potential","Time","Action Potential"],"Synonym":["after-hyperpolarization potential duration","afterhyperpolarization potential duration","t<sub>amp<\/sub>","AHP dur"],"SuperCategory":"Action potential characteristic","Comment":"NeuroElectro Term 10","Id":"oen_0001021","Has role":"NeuroElectro Term","Definition":"Time to the maximal afterhyperpolarization following an AP"}},{"AIDS":{"Synonym":["Acquired Immune Deficiency Syndrome","Acquired immuno deficiency syndrome"],"CurationStatus":"uncurated","SuperCategory":"Infectious disease","Id":"nlx_24143","Abbrev":"AIDS","Definition":"Disease of the human immune system caused by the human immunodeficiency virus (HIV)."}},{"Air Kerma Rate Reference Date":{"ValueRepresentation":"DA","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_022C","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149538","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DA","Definition":"Reference date of Reference Air Kerma Rate (300A,022A) of Isotope."}},{"Air Kerma Rate Reference Time":{"ValueRepresentation":"TM","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_022E","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149539","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"TM","Definition":"Reference time of Air Kerma Rate (300A,022A) of Isotope."}},{"Akinetic-Rigid Variant of Huntington Disease":{"Synonym":["Akinetic-Rigid Variant"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Huntingtons disease","Id":"birnlex_12504"}},{"Alar central lobule":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Lobular parts of the cerebellar cortex","Id":"birnlex_907"}},{"Albedo":{"Comment":["Typically used for light"],"SuperCategory":"Radiation reflective quality","Id":"PATO_0001295","Definition":"A reflective quality restricted to a particular wavelength."}},{"Albendazole":{"RelatedTo":["Tubulin alpha chain"],"Synonym":[", Albenza","Eskazole","Valbazen"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:16664","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00518","Definition":"A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) Pharmacology: Albendazole is a broad-spectrum anthelmintic. The principal mode of action for albendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules. Mechanism of action: Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies. Drug type: Approved. Small Molecule. Drug category: Anthelmintics. Anticestodal Agents. Antiprotozoal Agents. Tubulin Modulators"}},{"Alclometasone":{"RelatedTo":["Corticosteroid-binding globulin"],"Synonym":["Alclometasone dipropionate"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00240","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00240","Definition":"Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent. (Wikipedia) Pharmacology: Alclometasone is a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Alclometasone is a selective glucocorticoid receptor agonist. Mechanism of action: The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Alclometasone also binds the corticosteroid receptor. Drug type: Approved. Small Molecule. Drug category: Anti-inflammatory Agents. Antipruritic Agents. Corticosteroids. Glucocorticoids"}},{"Alcohol Amnestic Disorder":{"Synonym":["Alcohol-Induced Amnestic Psychosis","Alcohol-Induced Amnestic Syndrome","Alcohol Amnestic Syndrome","Alcohol-Induced Dysmnesic Syndrome"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Alcohol-Related Disorder","Id":"birnlex_12700","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"A mental disorder associated with chronic ethanol abuse ( ALCOHOLISM) and nutritional deficiencies characterized by short term memory loss, confabulations, and disturbances of attention (MeSH)."}},{"Alcohol drug abuse and mental health administration":{"CurationStatus":"uncurated","SuperCategory":"Government granting agency","Id":"nlx_inv_1005013","Is part of":"United States Department of Health and Human Services granting agency","Abbrev":"ADAMHA","Definition":"ADAMHA is now transferred to the newly-organized SAMSHA.http://www.samhsa.gov/grants/"}},{"Alcohol Withdrawal Delirium":{"Synonym":["Alcohol Withdrawal Associated Autonomic Hyperactivity","Alcohol Withdrawal Hallucinosis","Delirium Tremens"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Alcohol-Related Disorder","Id":"birnlex_12702","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"An acute organic mental disorder induced by cessation or reduction in chronic alcohol consumption. Clinical characteristics include CONFUSION; DELUSIONS; vivid HALLUCINATIONS; TREMOR; agitation; insomnia; and signs of autonomic hyperactivity (e.g., elevated blood pressure and heart rate, dilated pupils, and diaphoresis). This condition may occasionally be fatal. It was formerly called delirium tremens (MeSH)."}},{"Alcohol-nonpreferring rat":{"RelatedTo":"Wistar Rat","Synonym":["NP line","Alcohol non-preferring rat","Alcohol non preferring rat"],"CurationStatus":"uncurated","SuperCategory":"Inbred rat strain","Id":"nlx_14436","DefiningCitation":"http://rgd.mcw.edu/tools/strains/strains_view.cgi?id","Abbrev":"NP","Definition":"An inbred rat developed at Indiana University for low-alcohol-preferring behavior through bidirectional selective breeding of Wistar rats. These have low voluntary oral consumption of alcohol which results in low blood alcohol. The NP line of rat, as it is referred to, show a preference ratio of less than 0.5:1 for an EtOH solution over water. These rat lines also demonstrate distinct physiological and behavioral phenotypes in response to alcohol. RGD ID "}},{"Alcohol-preferring rat":{"RelatedTo":"Wistar Rat","Synonym":["P line"],"CurationStatus":"uncurated","SuperCategory":"Inbred rat strain","Id":"nlx_43003","DefiningCitation":"http://rgd.mcw.edu/tools/strains/strains_view.cgi?id","Abbrev":"P","Definition":"An inbred rat developed at Indiana University for high-alcohol-preferring behavior through bidirectional selective breeding of Wistar rats. These have high voluntary oral consumption of alcohol which leads to high blood alcohol. The P line of rat, as it is referred to, prefers an EtOH solution over water at least at 2:1 ratio. These rat lines also demonstrate distinct physiological and behavioral phenotypes in response to alcohol. RDG ID "}},{"Alcohol-Related Addiction":{"CurationStatus":"uncurated","SuperCategory":"Alcohol-Related Disorder","Id":"nlx_24732"}},{"Alcohol-Related Disorder":{"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Substance-Related Disorder","Id":"birnlex_12699","Definition":"Disorder related to or resulting from abuse or mis-use of alcohol (MeSH)."}},{"Alcohol-Related Withdrawal":{"CurationStatus":"uncurated","SuperCategory":"Alcohol-Related Disorder","Id":"nlx_64478"}},{"Alcoholic Intoxication":{"Synonym":"Drunkenness","Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Alcohol-Related Disorder","Id":"birnlex_12703","Definition":"An acute brain syndrome which results from the excessive ingestion of ETHANOL or ALCOHOLIC BEVERAGES (MeSH)."}},{"Alcoholic Psychosis":{"EditorialNote":"This class will utlimately be moved to a position reflecting the effected function, as opposed to one reflecting causation (BB: 2007-10-08)","Created":"2007-10-08","CurationStatus":"graph_position_temporary","SuperCategory":"Alcohol-Related Disorder","Id":"birnlex_12707","Definition":"A group of mental disorders associated with organic brain damage and caused by poisoning from alcohol (MeSH)."}},{"Alcoholism":{"RelatedTo":"Alcohol","Created":"2007-10-08","Synonym":["Alcohol abuse"],"CurationStatus":"uncurated","Id":"birnlex_12704","DefiningCitation":"Morse and Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4","Definition":"A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic (MeSH)."}},{"Aldesleukin":{"RelatedTo":["Interleukin-2 receptor subunit beta","Interleukin-2 receptor alpha chain"],"Synonym":["IL-2","Interleukin-2 precursor","T-cell growth factor","TCGF","aldesleukin","Proleukin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00041","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00041","Definition":"Proleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways:a) proleukin is not glycosylated because it is derived from E. coli ; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. Pharmacology: Used to treat renal cell carcinoma, proleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. Mechanism of action: Proleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells. Drug type: Approved. Biotech. Investigational. Drug category: Antineoplastic Agents"}},{"Aldrin":{"Synonym":["Aldocit","Aldrex","Aldrex 30","Aldrex 30 E.C.","Aldrex 40","Aldrin dust","Aldrin mixture DRY (dot","Aldrin mixture liquid (dot)","Aldrin cast solid (dot)","Aldrin liquid [NA2762]","Aldrin solid [NA2761]","Aldrin-r","Aldrine","Aldrite","Aldron","Aldrosol","Algran","Altox","Caswell No. 012","Compound 118","Drinox","HHDN","HHPN","Hexachlorohexahydro-endo,exo-dimethanonaphthalene","Kortofin","Latka 118","Murald","Octalene","RCRA waste no. P004","Seedrin","Soilgrin"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0024","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0024","Abbrev":"C12H8Cl6","Definition":"Organic Compound;Pesticide;Organochloride; Aldrin is a chlorinated hydrocarbon used as an insecticide. Once in the insect, aldrin is oxidized into dieldrin, a neurotoxin. Due to the toxicity and ability of bioaccumulate of dieldrin, the use of aldrin is now banned in most parts of the world."}},{"Alefacept":{"RelatedTo":["High affinity immunoglobulin gamma Fc receptor I","T-cell surface antigen CD2","Low affinity immunoglobulin gamma Fc region receptor III-B","Complement C1r subcomponent","Complement C1q subcomponent subunit A","Complement C1q subcomponent subunit B","Complement C1q subcomponent subunit C","Low affinity immunoglobulin gamma Fc region receptor III-A","Low affinity immunoglobulin gamma Fc region receptor II-a","Low affinity immunoglobulin gamma Fc region receptor II-b"],"Synonym":["ASP0485"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00092","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00092","Definition":"Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. Pharmacology: Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes. Mechanism of action: Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen. Drug type: Approved. Biotech. Investigational. Drug category: Immunomodulatory Agents. Immunosuppressive Agents"}},{"Alemtuzumab":{"RelatedTo":["CAMPATH-1 antigen","High affinity immunoglobulin gamma Fc receptor I","Low affinity immunoglobulin gamma Fc region receptor III-B","Complement C1r subcomponent","Complement C1q subcomponent subunit A","Complement C1q subcomponent subunit B","Complement C1q subcomponent subunit C","Low affinity immunoglobulin gamma Fc region receptor III-A","Low affinity immunoglobulin gamma Fc region receptor II-a","Low affinity immunoglobulin gamma Fc region receptor II-b"],"Synonym":["alemtuzumab","Campath","Campath (ILEX Pharmaceuticals LP)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00087","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00087","Definition":"Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Pharmacology: Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. Mechanism of action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. Drug type: Approved. Biotech. Investigational. Drug category: Antineoplastic Agents"}},{"Alendronate":{"RelatedTo":["Farnesyl pyrophosphate synthetase","Tyrosine-protein phosphatase non-receptor type 4"],"Synonym":["Acide Alendronique (INN-French)","Acido Alendronico (INN-Spanish)","Acidum Alendronicum (INN-Latin)","Alendronate Sodium","Alendronic acid","Adronat","Alendros","Arendal","Fosamax"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00630","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00630","Definition":"A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis. (PubChem) Pharmacology: Alendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Paget's disease, and to prevent osteoporosis in postmenopausal women. Mechanism of action: The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass. Drug type: Approved. Small Molecule. Drug category: Antihypocalcemic Agents. Antiresorptives. Bisphosphonates. Bone Density Conservation Agents"}},{"Alexander Disease":{"RelatedTo":"astrocyte","Created":"2007-10-05","Synonym":"Alexander's Disease","CurationStatus":"uncurated","SuperCategory":"Hereditary Central Nervous System Demyelinating Diseases","Id":"birnlex_12528","Definition":"A rare inherited disorder of myelin formation. Alexander disease is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of cytoplasmic inclusions called Rosenthal fibers. The fibers contain GLIAL FIBRILLARY ACIDIC PROTEIN in association with ALPHA-CRYSTALLIN B CHAIN. Rosenthal fibers are found predominantly in ASTROCYTES located in the subependymal, subpial, and periventricular areas of the BRAIN (MeSH)."}},{"Alfentanil":{"RelatedTo":["Serum albumin","Mu-type opioid receptor","Alpha-1-acid glycoprotein 1","Multidrug resistance protein 1"],"Synonym":["Alfentanilum (INN-Latin)","Alfentanyl"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00802","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00802","Definition":"A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. (PubChem) Pharmacology: Alfentanil is a synthetic opioid analgesic. Alfentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, alfentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Alfentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Alfentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Mechanism of action: Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Alfentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. Drug type: Approved. Illicit. Small Molecule. Drug category: Analgesics. Analgesics, Opioid. Anesthetics. Anesthetics, Intravenous. Narcotics. Opiate Agonists"}},{"Alfuzosin":{"RelatedTo":["Alpha-1A adrenergic receptor","Alpha-1B adrenergic receptor"],"Synonym":["Alfusosine","alfuzosin","Uroxatral"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:51141","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00346","Definition":"Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. (Wikipedia) Pharmacology: Alfuzosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, alfuzosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, alfuzosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of alfuzosin results from a decrease in systemic vascular resistance and the parent compound alfuzosin is primarily responsible for the antihypertensive activity. Mechanism of action: Alfuzosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. Drug type: Approved. Investigational. Small Molecule. Drug category: Adrenergic alpha-Antagonists. Antihypertensive Agents"}},{"Alglucerase":{"RelatedTo":"D-glucosyl-N-acylsphingosine","Synonym":["Acid beta-glucosidase","Beta-glucocerebrosidase","D-glucosyl-N-acylsphingosine glucohydrolase","Glucosylceramidase precursor"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00088","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00088","Definition":"Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW"}},{"Alglucosidase alfa":{"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01272","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01272","Definition":"Alglucosidase alfa consists of the human enzyme acid a-glucosidase (GAA), encoded by the most predominant of nine observed haplotypes of this gene. Alglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen. Pharmacology: Pompe disease (glycogen storage disease type II, GSD II, glycogenosis type II, acid maltase deficiency) is an inherited disorder of glycogen metabolism caused by the absence or marked deficiency of the lysosomal enzyme GAA. In the infantile-onset form, Pompe disease results in intralysosomal accumulation of glycogen in various tissues, particularly cardiac and skeletal muscles, and hepatic tissues, leading to the development of cardiomyopathy, progressive muscle weakness, and impairment of respiratory function. In the juvenile- and adult-onset forms, intralysosomal accumulation of glycogen is limited primarily to skeletal muscle, resulting in progressive muscle weakness. Death in all forms is usually related to respiratory failure. Alglucosidase alfa provides an exogenous source of GAA. Binding to mannose-6-phosphate receptors on the cell surface has been shown to occur via carbohydrate groups on the GAA molecule, after which it is internalized and transported into lysosomes, where it undergoes proteolytic cleavage that results in increased enzymatic activity. It then exerts enzymatic activity in cleaving glycogen. Mechanism of action: Alglucosidase alfa is designed to act as an exogenous source of GAA, acting to correct GAA deficiency that is the hallmark of Pompe disease. Alglucosidase alfa binds to mannose-6-phosphate receptors on the cell surface via carbohydrate groups on the GAA molecule, after which it is internalized and transported into lysosomes, where it undergoes proteolytic cleavage that results in increased enzymatic activity. It then exerts enzymatic activity in cleaving glycogen. Drug type: Approved. Biotech. Drug category: Enzyme Replacement Agents"}},{"Algorithm":{"EditorialNote":"This is a proxy class to be replaced by its OBI equivalent, once there is an official release built off BFO v1.1 that can be successfully classified using Pellet v1.5.0 in Protege.","Created":"2007-10-05","CurationStatus":"http://purl.org/nbirn/birnlex/ontology/annotation/BIRNLex_annotation_properties.owl#graph_position_temporary","SuperCategory":"Information entity","Curator":"Bill Bug","Id":"birnlex_11009","Definition":"an algorithm is a plan which describes inputs, output of mathematical functions as well as workflow of execution for achieving an predefined objective. Algorithms are realized usually by means of implementation as computer programs for execution by automata."}},{"Algorithm execution":{"Created":"2006-06-01","CurationStatus":"curation_complete","SuperCategory":"Data transformation","Id":"birnlex_2174","Definition":"A transformation that applies an algorithm with specified parameters on a data set on a specific computing platform."}},{"Aligned with":{"Synonym":["aligned"],"SuperCategory":"Alignment","Id":"PATO_0001653","Definition":"A alignment quality between two entities in which the bearer is in proper spatial positioning with respect to an additional entity."}},{"Alignment":{"SuperCategory":"Relational spatial quality","Id":"PATO_0001652","Definition":"A relational spacial quality inhering in a bearer by virtue of its spatial positioning with respect to an additional entity."}},{"Alignment software":{"Synonym":"Image registration software","Created":"2007-10-09","CurationStatus":"uncurated","Comment":"change label to \"Image alignment software\"","SuperCategory":"Image analysis software","Id":"birnlex_2229","Definition":"Software application that performs image spatial transformation for the purposes of image 'Registration'. NITRC","Xref":"NITRC_388"}},{"Aliskiren":{"RelatedTo":["Renin"],"Synonym":["Rasilez","SPP 100","aliskiren","Rasilez"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01258","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01258","Definition":"Aliskiren is a renin inhibitor. It was approved by the U.S. Food and Drug Administration in 2007 for the treatment of hypertension. Pharmacology: Aliskiren is a nonpeptide renin inhibitor marketed under the trade name Tekturna by Novartis. Mechanism of action: Renin is secreted by the kidney in response to decreases in blood volume and renal perfusion.  Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) and non-ACE pathways. Ang II is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla and prejunctional nerve endings. It also promotes aldosterone secretion and sodium reabsorption. Together, these effects increase blood pressure. Ang II also inhibits renin release, thus providing a negative feedback to the system.  This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS). Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known. All agents that inhibit the RAAS, including renin inhibitors, suppress the negative feedback loop, leading to a compensatory rise in plasma renin concentration. When this rise occurs during treatment with ACE inhibitors and ARBs, the result is increased levels of PRA. During treatment with aliskiren, however, the effect of increased renin levels is blocked, so that PRA, Ang I and Ang II are all reduced, whether aliskiren is used as monotherapy or in combination with other antihypertensive agents. PRA reductions in clinical trials ranged from approximately 50%-80%, were not dose-related and did not correlate with blood pressure reductions. The clinical implications of the differences in effect on PRA are not known. Drug type: Approved. Investigational. Small Molecule. Drug category: Antihypertensive Agents"}},{"Alitretinoin":{"RelatedTo":["Retinoic acid receptor RXR-beta","Retinoic acid receptor gamma-1","Retinoic acid receptor beta","Retinoic acid receptor gamma-2","Retinoic acid receptor RXR-alpha","Cellular retinoic acid-binding protein 1","Retinoic acid receptor alpha","Retinoic acid receptor RXR-gamma"],"Synonym":["ALRT-1057","BAL4079","Retinoic Acid","alitretinoin","Panretin","Panretin Gel","Panretyn","Panrexin","Renova","Retin-A","Retin-A Micro"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:50648","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00523","Definition":"An important regulator of gene expression during growth and development, and in neoplasms. Tretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic. It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. It has also been approved for use in promyelocytic leukemia (leukemia, promyelocytic, acute). (PubChem) Pharmacology: Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Mechanism of action: Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents. Keratolytic Agents"}},{"Alive":{"SuperCategory":"Viability","Id":"PATO_0001421","Definition":"A viability quality inhering in a bearer by virtue of its condition before death."}},{"Alkaline":{"SuperCategory":"Medium acidity","Id":"PATO_0001430","Definition":"An acidity inhering in a solution by virtue of its low concentration of H+ ions."}},{"Alkyl nitrite":{"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"nlx_chem_100301","Has role":["Drug of abuse role","Inhalant"],"Definition":"With a long history of safe medical use in treating angina, as well as an antidote to cyanide poisoning, several alkyl nitrites which are used in over-the-counter products, such as air fresheners and video head cleaners, are often inhaled with the goal of enhancing sexual pleasure and have also been part of the club culture from the 1970s disco scene to the 1980s and 1990s rave scene. (Adapted from Wikipedia)"}},{"Allocortex":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_143557"}},{"Allodynia":{"CurationStatus":"Graph position temporary","SuperCategory":"Pain disorder","Id":"nlx_137","Definition":"A condition in which ordinary, non-painful stimuli evoke pain."}},{"Allograft inflammatory factor 1":{"Synonym":["Ionized calcium-binding adapter molecule 1"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_51537","Has role":["Calcium Binding Protein"],"DefiningCitation":["Imai et al. Biophys. Biochem. Res. Commun."],"Abbrev":["MRF-1"],"Definition":"a small 17-kDa protein consisting of 147 amino acids. It contains two EF hand motifs in the central third of the molecule."}},{"Allopolyploidy":{"SuperCategory":"Polyploid","Id":"PATO_0001379","Definition":"A polyploidy quality inhering in a bearer by virtue of containing chromosomes derived form different species."}},{"Allopurinol":{"RelatedTo":"Xanthine dehydrogenase/oxidase","Synonym":["Allopurinol Sodium","Allopurinolum (INN-Latin)","Alopurinol (INN-Spanish)","7HP","Adenock","Ailural","Allo-Puren","Allohexal","Allopur","Allozym","Allural","Aloprim","Aloral","Alositol","Aluline","Anoprolin","Anzief","Apo-Allopurinol","Apulonga","Apurin","Apurol","Atisuril","Bleminol","Bloxanth","Caplenal","Cellidrin","Cosuric","Dabrosin","Dabroson","Dura Al","Embarin","Epidropal","Epuric","Foligan","Geapur","Gichtex","Gotax","HPP","Hamarin","Hexanuret","Ketanrift","Ketobun-A","Ledopur","Lopurin","Lysuron","Milurit","Miniplanor","Monarch","Nektrohan","Progout","Purinol","Remid","Riball","Sigapurol","Suspendol","Takanarumin","Urbol","Uricemil","Uriprim","Uripurinol","Uritas","Urobenyl","Urolit","Urosin","Urtias","Urtias 100","Xanturat","Zyloprim"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:40279","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00437","Definition":"A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. (PubChem) Pharmacology: Allopurinol, a structural analog of the natural purine base hypoxanthine, is used to prevent gout and renal calculi due to either uric acid or calcium oxalate and to treat uric acid nephropathy, hyperuricemia, and some solid tumors. Mechanism of action: Allopurinol inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid. Elevated concentrations of oxypurine and oxypurine inhibition of xanthine oxidase through negative feedback results in a decrease in the concentrations of uric acid in the blood and urine. Allopurinol also facilitates the incorporation of hypoxanthine and xanthine into DNA and RNA, resulting in further reductions of serum uric acid concentrations. Drug type: Approved. Small Molecule. Drug category: Antimetabolites. Enzyme Inhibitors. Enzyme Inhibitors Antimetabolites. Free Radical Scavengers. Gout Suppressants"}},{"Allow Lossy Compression":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2200_000F","CurationStatus":"uncurated","Comment":"general term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149540","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"A code the signals whether lossy compression is allowed."}},{"Allow Media Splitting":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2200_0007","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149541","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"A code the signals whether media splitting is allowed."}},{"Almitrine":{"RelatedTo":"Sodium/potassium-transporting ATPase alpha-1 chain","Synonym":["Almitrine bismesylate","Almitrine dimesylate","Almitrine mesylate","Doxil","Duxil"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01430","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01430","Definition":"A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. (PubChem) Pharmacology: Almitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. Mechanism of action: Almitrine enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. Drug type: Approved. Small Molecule. Drug category: Respiratory System Agents"}},{"Almotriptan":{"RelatedTo":["5-hydroxytryptamine 1D receptor"],"Synonym":["almotriptan","Almogran"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00918","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00918","Definition":"Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Almotriptan does not prevent migraine attacks. Pharmacology: Almotriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Almotriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Almotriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Almotriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Almotriptan in humans. Mechanism of action: Almotriptan binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-inflammatory Agents. Anti-migraine Agents. Selective Serotonin Agonists. Serotonin Agonists. Vasoconstrictor Agents"}},{"Alosetron":{"RelatedTo":"5-hydroxytryptamine 3 receptor","Synonym":["Alosetron HCl"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00969","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00969","Definition":"Alosetron is a 5-HT3 antagonist used for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women only. Alosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the gastrointestinal tract. Pharmacology: Alosetron is a potent and selective antagonist of the serotonin 5-HT3 receptor type. Activation of these receptors affects the regulation of visceral pain, colonic transit, and GI secretions. By blocking these receptors, alosetron is able to effectively control IBS. Mechanism of action: Alosetron is a potent and selective 5-HT3 receptor antagonist. 5-HT3 receptors are nonselective cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of visceral pain, colonic transit and gastrointestinal secretions, processes that relate to the pathophysiology of irritable bowel syndrome (IBS). 5-HT3 receptor antagonists such as alosetron inhibit activation of non-selective cation channels which results in the modulation of the enteric nervous system. Drug type: Approved. Small Molecule. Withdrawn. Drug category: Gastrointestinal Agents. Serotonin Antagonists"}},{"Alouatta":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2007-08-02","CurationStatus":"raw_import","Umlscui":"C0002184","SuperCategory":"Alouattinae","Id":"birnlex_460"}},{"Alouatta caraya":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB).","Created":"2007-08-02","CurationStatus":"raw_import","Umlscui":"C0999507","SuperCategory":"Alouatta","Id":"birnlex_343"}},{"Alouattinae":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB)., GBIF does not include subfamilies under Primates.  It tends to skip from Order (Primate), to Family to Genus.","Created":"2007-08-02","CurationStatus":"raw_import","Umlscui":"C1300329","SuperCategory":"Atelidae","Id":"birnlex_454"}},{"Alpha 3 Acetylcholine Receptor":{"RelatedTo":["Acetylcholine","Nicotine","Carbachol","Epibatidine","Dimethylphenylpiperazinium","Varenicline","Mecamylamine","Trimetaphan","Hexamethonium","Bupropion","Dextromethorphan","Ibogaine"],"Synonym":["Neuronal Acetylcholine Receptor Subunit Alpha-3","CHRNA3","NACHRA3","Cholinergic receptor","nicotinic"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"sao99825125","Has role":["Acetylcholine Receptor"],"Is part of":"Cholinergic system","DefiningCitation":["NCBI"],"Definition":"Neuronal acetylcholine receptor subunit alpha-3 is encoded by the human CHRNA3 gene. This protein plays a role in ion transport. After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Neuronal AChR is composed of two different types of subunits: alpha and beta. Alpha-3 subunit can be combined to beta-2 or beta-4 to give rise to functional receptors. Interacts with RIC3; which is required for proper folding and assembly. (Adapted from NCBI and Swiss-Prot)."}},{"Alpha 7 Acetylcholine Receptor":{"RelatedTo":["Acetylcholine","Nicotine","Epibatidine","Dimethylphenylpiperazinium","Mecamylamine","Memantine"],"Synonym":["Acra7","Acetylcholine Receptor Alpha 7","CHRNA7","Cholinergic receptor nicotinic alpha 7","Neuronal acetylcholine receptor subunit alpha-7"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"sao138926812","Has role":["Acetylcholine Receptor","Neurotransmitter Receptor"],"Is part of":"Cholinergic system","DefiningCitation":"PRotein Ontology and Wikipedia","Abbrev":"NACHRA7","Definition":"This receptor it a protein that is a translation product of the CHRNA7 gene or a 1:1 ortholog thereof. NACHRA7 is a type of nicotinic acetylcholine receptor, consisting entirely of ฮฑ7 subunits. As with other nicotinic acetylcholine receptors, functional ฮฑ7 receptors are pentameric [i.e., (ฮฑ7)5 stoichiometry]. It is located in the brain, where activation yields post- and presynaptic excitation, mainly by increased Ca2+ permeability. (Definition provided by PRotein Ontology and Wikipedia)."}},{"Alpha Actinin":{"SuperCategory":"Protein","Id":"sao1659393491","Definition":"Cytoskeletal protein present in Z lines of muscle fibrils and at sites of non-muscle cell contact with a substrate (CSP)."}},{"Alpha bungarotoxin":{"RelatedTo":"Cholinergic system","Synonym":"ฮฑ-bungarotoxin","CurationStatus":"uncurated","SuperCategory":"Bungarotoxin","Id":"nlx_mol_200906148","Definition":"A type of bungarotoxin derived from the venom of the Taiwanese cobra Bugarus multicinctus.  It is a peptide of 74 amino acids that bind to the nicotinic acetylcholine receptor with high affiniฮฑ-bungarotoxinty."}},{"Alpha mating type (yeast)":{"Synonym":"alpha","SuperCategory":"Saccharomyces cerevisiae mating type","Id":"PATO_0001344","Definition":"A S. cerevisiae mating type cells that secrete a pheromone that stimulates haploids."}},{"Alpha synuclein positive inclusion":{" limit":"1000","EditorialNote":"Need to ask Stephen how to create this class from the \"Is part of\" relation","CurationStatus":"uncurated__noeditsection__Inferred classA list of all cellular inclusions with part alpha synuclein protein \"[[:Category:Alpha-Synuclein Protein","SuperCategory":"Cellular Inclusion"," format":"category","Id":"nlx_143539","Definition":"A cellular inclusion that contains alpha synuclein"}},{"Alpha Tanycyte":{"SuperCategory":"Tanycyte","Id":"sao971374186"}},{"Alpha Tubulin":{"SuperCategory":"Tubulin","Id":"sao335197072","Definition":"One of two globular polypeptides forming microtubules."}},{"Alpha wave":{"Synonym":["Alpha-wave","Alpha","Alpha oscillation","Alpha activity","Alpha rhythm","Alpha rhythms","Alpha Rhythm Electroencephalography","Alpha Rhythm Encephalography","Alpha Rhythms","ALPHA RHYTHM EEG"],"CurationStatus":"uncurated","SuperCategory":"Oscillation","PublicationLink":"http://www.scholarpedia.org/article/Alpha_rhythm","Id":"NEMO_5512000","Definition":"an electromagnetic oscillation in the frequency range of 8\u201312 Hz arising from synchronous and coherent (in phase / constructive) electrical activity.  In mammals, thalamic pacemaker cells exhibit alpha oscillations (adapted from Wikipedia)."}},{"Alpha-1-proteinase inhibitor":{"RelatedTo":"Leukocyte elastase","Synonym":["Alpha 1-antitrypsin","Alpha-1 protease inhibitor","Alpha-1-antiproteinase","Alpha-1-antitrypsin precursor","Aralast (Baxter)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00058","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00058","Definition":"Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation. Pharmacology: Prevents excessive accumulation of active neutrophil elastase and consequent proteolysis of elastin tissues in alveolar lung structures. This prevents the development of emphysema. Mechanism of action: Alpha-1 proteinase inhibitor is a serine protease inhibitor (Serpin). It primarily inhibits the action of the serine protease called elastase (also plasmin and thrombin). The reactive center loop (RCL) of alpha-1 proteinase inhibitor extends out from the body of the protein and directs binding to the target protease. The protease cleaves the serpin at the reactive site, establishing a covalent linkage between the carboxyl group of the serpin reactive site and the serine hydroxyl of the protease. The resulting inactive serpin-protease complex is highly stable. Drug type: Approved. Biotech. Drug category: Enzyme Replacement Agents"}},{"Alpha-ketoglutarate":{"Synonym":"a-ketoglutarate","Created":"2007-09-19","SuperCategory":"Carboxylic acid","Id":"nifext_5234"}},{"Alpha-Linolenic Acid":{"RelatedTo":["BC2697302","Sodium/calcium exchanger 1","Transient receptor potential cation channel subfamily V member 1","Fatty acid-binding protein","Delta-6 fatty acid desaturase"],"Synonym":["(9Z,12Z,15Z)-Octadecatrienoic acid","9,12,15-Octadecatrienoic acid","ALA","alpha-Linolenate"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:27432","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00132","Definition":"Alpha-linolenic acid (ALA) is a polyunsaturated omega-3 fatty acid. It is a component of many common vegetable oils and is important to human nutrition. (Wikipedia) Pharmacology: Alpha Linolenic Acid (ALA) is an 18-carbon polyunsaturated fatty acid with three double bonds. It is also called an omega-3 fatty acid, and is essential for all mammals. Alpha-linolenic acid (or omega 3 fatty acid) intake can decrease the risk of cardiovascular diseases by 1) preventing arrhythmias that can lead to sudden cardiac death, 2) decreasing the risk of thrombosis (blood clot formation) that can lead to heart attack or stroke, 3) decreasing serum triglyceride levels, 4) slowing the growth of atherosclerotic plaque, 5) improving vascular endothelial function, 6) lowering blood pressure slightly, and 7) decreasing inflammation. ALA deficiencies can lead to visual problems and sensory neuropathy. Scaly and hemorrhagic skin or scalp inflammations may also develop. Mechanism of action: Alpha Linolenic Acid or ALA is considered an essential fatty acid because it is required for human health, but cannot be synthesized by humans. It is in fact  a plant-derived fatty acid. Humans can synthesize other omega-3 fatty acids from ALA, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA is a precursor of the series-3 prostaglandins, the series-5 leukotrienes and the series-3 thromboxanes. These eicosanoids have anti-inflammatory and anti-atherogenic properties. ALA metabolites may also inhibit the production of the pro-inflammatory eicosanoids, prostaglandin E2 (PGE2) and leukotriene B4 (LTB4), as well as the pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta). Omega-3 fatty acids like ALA and its byproducts can modulate the expression of a number of genes, including those involved with fatty acid metabolism and inflammation. They regulate gene expression through their effects on the activity of transcription factors including NF-kappa B and members of the peroxisome proliferator-activated receptor (PPAR) family. Incorporation of ALA and its metabolites in cell membranes can affect membrane fluidity and may play a role in anti-inflammatory activity, inhibition of platelet aggregation and possibly in anti-proliferative actions of ALA. Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Dietary supplement. Micronutrient"}},{"Alpha-melanocyte stimulating hormone":{"Synonym":"a-melanocyte stimulating hormone","Created":"2007-09-19","SuperCategory":"Melanocyte stimulating hormone","Id":"nifext_5081"}},{"Alpha-Synuclein DNA":{"SuperCategory":"DNA","Id":"sao5396594119","Definition":"The alpha-Synuclein gene is mapped to human chromosome 4q21.3-q22 and organized as seven exons, five of which are protein-coding."}},{"Alpha-Synuclein Fibril":{"SuperCategory":"Fibril","Id":"sao7474011676","Definition":"Insoluble fibrils that form in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Alpha-synuclein is the primary structural component."}},{"Alpha-Synuclein Protein":{"IsPartOfPMID":"9726379","Synonym":["NACP"],"CurationStatus":"uncurated","SuperCategory":"Synuclein Protein","Id":"sao5651809446","Is part of":["Lewy Body"],"Definition":"Predominantly a presynaptic neuronal protein of unknown function, but can also be found in glial cells.  Expressed particularly in the neocortex, hippocampus, striatum, thalamus, and cerebellum. It is normally an unstructured protein yet it can aggregate to form incoluble fibrils in pathological conditions characterized by Lewy bodies.  It is the primary structural component of Lewy body fibrils and an alpha-synuclein fragment, known as the non-ABeta component (NAC) is found in amyloid plaques."}},{"Alpha-Synuclein RNA":{"CurationStatus":"uncurated","SuperCategory":"mRNA","Id":"sao2515005173","Definition":"The alpha-Synuclein mRNA is targeted when researchers target alpha-Synuclein gene expression."}},{"Alpha1A receptor":{"RelatedTo":"Epinephrine","Created":"2007-09-19","Synonym":["alpha1A; alpha 1A","A1A; Alpha 1A- adrenoreceptor; Alpha 1A-adrenoceptor; Alpha adrenergic receptor 1c; Alpha-1C adrenergic receptor; Alpha-1A adrenergic receptor","adrenoceptor 1A"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_7251","Has role":["Adrenoceptor receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system"],"DefiningCitation":"PMID 6308163","Abbrev":"A1AR","Definition":"Adrenergic receptor with high affinity binding to WB-4101."}},{"Alpha1B receptor":{"RelatedTo":"Epinephrine","Created":"2007-09-19","Synonym":["alpha1B","alpha 1B","A1B; Alpha 1B- adrenoreceptor; Alpha 1B-adrenoceptor;\tAlpha-1B adrenergic receptor","adrenoceptor 1B","ADRA1B"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_7143","Has role":["Adrenoceptor receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system"],"DefiningCitation":"PMID 6308163","Abbrev":"A1BR","Definition":"Alpha adrenergic receptor with a lower affinity for WB-4101."}},{"Alpha1D receptor":{"RelatedTo":"Epinephrine","Created":"2007-09-19","Synonym":["alpha1D; alpha 1D; A1D; Alpha 1D- adrenoreceptor; Alpha 1D-adrenoceptor; Alpha adrenergic receptor 1a; Alpha-1A adrenergic receptor; Alpha-1D adrenergic receptor","adrenoceptor 1D","ADRA1D"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_7241","Has role":["Adrenoceptor receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system"],"DefiningCitation":"PMID 7713154","Abbrev":"A1DR","Definition":"Alpha adrenergic receptor that is found in the rat aorta, and is genetically different from the other alpha1 receptors."}},{"Alpha2A receptor":{"PMID":"7938162","RelatedTo":["Epinephrine"],"Created":"2007-09-19","Synonym":["alpha2A; alpha 2A; A2A; Alpha-2 adrenergic receptor subtype C10; Alpha-2A adrenoceptor; Alpha-2A adrenoreceptor; Alpha-2AAR; Alpha-2A adrenergic receptor","ฮฑ2A adrenoreceptor"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_6235","Has role":["Adrenoceptor receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system","Adrenergic system"],"DefiningCitation":"Entrez Gene","Abbrev":"A2AR","Definition":"Alpha adrenergic receptor that is found in platelets and has a low affinity for prazosin. Alpha-2-adrenergic receptors include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. These receptors have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. Studies in mice revealed that both the alpha2A and alpha2C subtypes were required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons; the alpha2A subtype inhibited transmitter release at high stimulation frequencies. (Adapted from Entrez Gene)."}},{"Alpha2B receptor":{"PMID":"7938162","RelatedTo":["Epinephrine"],"Created":"2007-09-19","Synonym":"alpha2B; alpha 2B; A2B; Alpha-2 adrenergic receptor subtype C2; Alpha-2B adrenoceptor; Alpha-2B adrenoreceptor; Alpha-2B adrenergic receptor","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_7133","Has role":["Adrenoceptor receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system","Adrenergic system"],"DefiningCitation":"Entrez Gene","Abbrev":"A2BR","Definition":"This a subtype of the Alpha2 adrenergic receptor that is found in neonatal rat lung that has a high affinity for prazosin. Alpha-2-adrenergic receptors include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. These receptors have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. (Adapted from Entrez Gene)."}},{"Alpha2C receptor":{"PMID":"7938162","RelatedTo":["Epinephrine"],"Created":"2007-09-19","Synonym":["alpha2C; alpha 2C; A2C; Alpha-2 adrenergic receptor subtype C4; Alpha-2C adrenoceptor; Alpha-2C adrenoreceptor; Alpha-2C adrenergic receptor","ฮฑ2C adrenoreceptor"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nifext_7113","Has role":["Adrenoceptor receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system","Adrenergic system"],"DefiningCitation":"Entrez Gene","Abbrev":"A2CR","Definition":"The alpha-2C adrenergic receptor (ฮฑ2C adrenoreceptor), also known as ADRA2C, is an alpha-2 adrenergic receptor, and also denotes the human gene encoding it. Alpha-2-adrenergic receptors include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. These receptors have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. Studies in mouse revealed that both the alpha2A and alpha2C subtypes were required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons; the alpha2C subtype modulated neurotransmission at lower levels of nerve activity. (Adapted from Entrez Gene)."}},{"Alpha2D receptor":{"PMID":"7938162","RelatedTo":["Epinephrine"],"Synonym":["Alpha2D","Alpha 2D"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_99897","Has role":["Adrenoceptor receptor","Neurotransmitter Receptor"],"Is part of":["Catecholamine system","Adrenergic system"],"DefiningCitation":"Entrez Gene","Abbrev":"A2DR","Definition":"Some species other than humans express this fourth type of Alpha2-adrenergic receptor: ฮฑ2D-adrenergic receptor. (Adapted from Entrez Gene)."}},{"Alprazolam":{"RelatedTo":["Gamma-aminobutyric-acid receptor subunit alpha-2","Gamma-aminobutyric-acid receptor subunit alpha-5","Gamma-aminobutyric-acid receptor subunit alpha-4","Gamma-aminobutyric-acid receptor subunit alpha-3","Translocator protein","Gamma-aminobutyric-acid receptor subunit alpha-6"],"Synonym":["TUS-1","alprazolam","Alplax","Alpronax","Alviz","Bestrol","Cassadan","Constan","D 65MT","Esparon","Frontal","Intensol","Niravam","Restyl","Solanax","Tafil","Tranax","Trankimazin","Tranquinal","Xanax","Xanax XR"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2611","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00404","Definition":"A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of panic disorders, with or without agoraphobia, and in generalized anxiety disorders. (From AMA Drug Evaluations Annual, 1994, p238) Pharmacology: Alprazolam, a benzodiazepine, is used to treat panic disorder and anxiety disorder. Unlike chlordiazepoxide, clorazepate, and prazepam, alprazolam has a shorter half-life and metabolites with minimal activity. Like other triazolo benzodiazepines such as triazolam, alprazolam may have significant drug interactions involving the hepatic cytochrome P-450 3A4 isoenzyme. Clinically, all benzodiazepines cause a dose-related central nervous system depressant activity varying from mild impairment of task performance to hypnosis. Unlike other benzodiazepines, alprazolam may also have some antidepressant activity, although clinical evidence of this is lacking. Mechanism of action: Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Drug type: Approved. Illicit. Investigational. Small Molecule. Drug category: Anti-anxiety Agents. Benzodiazepines. GABA Modulators. Hypnotics and Sedatives"}},{"Alprenolol":{"RelatedTo":["Beta-1 adrenergic receptor","5-hydroxytryptamine 1A receptor"],"Synonym":["Alfeprol (Russian)","Alpheprol","Alprenololum (INN-Latin)","Apllobal","Aptine","Aptol Duriles","Gubernal","Regletin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:51211","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00866","Definition":"One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. (PubChem) Pharmacology: Alprenolol is a non-selective beta-blocker used in the treatment of hypertension, edema, ventricular tachycardias, and atrial fibrillation. Alprenolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Alprenolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Alprenolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, alprenolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action. Mechanism of action: Alprenolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, alprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. Drug type: Approved. Small Molecule. Drug category: Adrenergic beta-Antagonists. Anti-Arrhythmia Agents. Antiarrhythmic Agents. Antihypertensive Agents. Sympatholytics"}},{"Alprostadil":{"RelatedTo":["Prostaglandin E2 receptor","EP1 subtype","Prostaglandin E2 receptor"],"Synonym":["alprostadil","Alista","Alprostadil Prostoglandin E1","Alprox-TD","Befar","Caverject","Edex","Femprox","Muse","PGE1","Prink","Prostaglandin E1","Prostin VR","Prostin VR Pediatric","Topiglan"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00770","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00770","Definition":"Alprostadil is produced endogenously and causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In infants, it is used for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. In adults, it is used for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology. Pharmacology: Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora.As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops.This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow. Mechanism of action: Alprostadil causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In cyanotic congenital heart disease, alprostadil's actions result in an increased oxygen supply to the tissues. In infants with interrupted aortic arch or very severe aortic coarctation, alprostadil maintains distal aortic perfusion by permitting blood flow through the DA from the pulmonary artery to the aorta. In infants with aortic coarctation, alprostadil reduces aortic obstruction either by relaxing ductus tissue in the aortic wall or by increasing effective aortic diameter by dilating the DA. In infants with these aortic arch anomalies, systemic blood flow to the lower body is increased, improving tissue oxygen supply and renal perfusion. When administered by intracavernosal injection or as an intraurethral suppository, alprostadil acts locally to relax the trabecular smooth muscle of the corpora cavernosa and the cavernosal arteries. Swelling, elongation, and rigidity of the penis result when arterial blood rapidly flows into the corpus cavernosum to expand the lacunar spaces. The entrapped blood reduces the venous blood outflow as sinusoids compress against the tunica albuginea. Drug type: Approved. Investigational. Small Molecule. Drug category: Fibrinolytic Agents. Platelet Aggregation Inhibitors. Vasodilator Agents"}},{"Alseroxylon":{"RelatedTo":"Synaptic vesicular amine transporter","Synonym":[", Rautensin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00386","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00386","Definition":"A fat-soluble alkaloidal fraction extracted from the root of Rauwolfia serpentina, containing reserpine and other nonadrenolytic amorphous alkaloids; used as a sedative in psychoses, in mild hypertension, and as an adjunct to more potent hypotensive drugs. Pharmacology: Alseroxylon is a purified extract of Rauwolfia serpentina, containing reserpine and other amorphous alkaloids. Alseroxylon is an indole alkaloid antipsychotic and antihypertensive drug known to irreversibly bind to storage vesicles of neurotransmitters such as dopamine, norepinephrine, and serotonin. This leads to depletion of the neurotransmitters and subsequent depression in humans. Mechanism of action: The antihypertensive actions of alseroxylon are a result of its ability to deplete catecholamines from peripheral sympathetic nerve endings. Alseroxylon almost irreversibly blocks the accumulation of noradrenaline and dopamine into synaptic vesicles by inhibiting the Vesicular Monoamine Transporters (VMAT). Drug type: Approved. Small Molecule. Drug category: Adrenergic Uptake Inhibitors"}},{"Alteplase":{"RelatedTo":["Coagulation factor X","Fibrinogen alpha chain","Urokinase plasminogen activator surface receptor","Plasminogen activator inhibitor 2","Calnexin","Kallikrein-1","Annexin A2","Fibronectin","Laminin subunit alpha-5","Tetranectin","Keratin","type II cytoskeletal 8","Laminin subunit beta-1","Laminin subunit gamma-1","Laminin subunit alpha-1","Calreticulin","Low-density lipoprotein receptor-related protein 1"],"Synonym":["Tissue-type plasminogen activator precursor","t-PA","t-plasminogen activator","tPA"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00009","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00009","Definition":"Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells Pharmacology: Activase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It also produces limited conversion of plasminogen in the absence of fibrin. Mechanism of action: Cleaves the Arg-Val bond in plasminogen to produce active plasmin. Drug type: Approved. Biotech. Drug category: Thrombolytic Agents"}},{"Altered number of":{"CurationStatus":"uncurated","SuperCategory":"Has number of","Id":"PATO_0002083","Definition":"Having extra or fewer parts."}},{"Alternate placement":{"SuperCategory":"Regular spatial pattern","Id":"PATO_0001932","Definition":"Placed alternately one above the other."}},{"Alternate Representation Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_3001","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Curator":"BIRN-INCF Derived Data Task Force","Id":"nlx_149542","Has role":"DICOM administration attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"TBD."}},{"Alternating runs paradigm":{"Created":"8/15/2011 10:58","CurationStatus":"uncurated","Contributor":"Corey White","CAO_Id":"CAO_00944","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Alternating_runs_paradigm","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146169","Definition":"A type of task-switching paradigm in which two different tasks are presented in alternating runs or blocks"}},{"Alternation":{"SuperCategory":"Occurrence quality","Id":"PATO_0000999","Definition":"Successive change from one thing or state to another and back again."}},{"Alternative title":{"Synonym":["alt title"],"Created":"2007-10-11","CurationStatus":"uncurated","SuperCategory":"Citation record element","Id":"birnlex_2381"}},{"Altretamine":{"RelatedTo":"DNA","Synonym":["Altretaminum (INN-Latin)","HEXAMETHYLMELAMINE","HMM","HTM","HXM","Hemel","Hexalen"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00488","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00488","Definition":"An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. (PubChem) Pharmacology: Altretamine is a novel antineoplastic agent. The precise mechanism by which altretamine exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of altretamine and its metabolitics have been negative. Altretamine has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement of cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and in vivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown. Mechanism of action: The precise mechanism by which altretamine exerts its cytotoxic effect is unknown. Drug type: Approved. Small Molecule. Drug category: Antineoplastic Agents. Antineoplastic Agents, Alkylating"}},{"Alverine":{"Synonym":["Alverina (inn-spanish)","Alverine citrate","Alverinum (inn-latin)","Bis(gamma-phenylpropyl)ethylamine","Di(phenylpropyl)ethylamine","N,N-Bis(3-phenylpropyl)ethylamine","N-Ethyl-3,3'-diphenyldipropylamine","N-Ethyl-3-phenyl-N-(3-phenylpropyl)-1-propanamine","N-Ethyl-N-(3-phenylpropyl)benzenepropanamine","N-Ethyl-bis(3-phenylpropyl)amin","Phenopropamine","Phenpropamine","Antispasmin","Dipropylin","Dipropyline","Gamatran citrate","Profenil","Sestron","Spacolin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01616","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01616","Definition":"Alverine is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. It is used to  relieve cramps or spasms of the stomach and intestines. It is also useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain. Pharmacology: Alverine is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Diverticular disease is a condition in which small pouches form in the gut lining. These pouches can trap particles of food and become inflamed and painful. In irritable bowel syndrome the normal activity of the gut muscle is lost. The muscle spasms result in symptoms such as heartburn, abdominal pain and bloating, constipation or diarrhoea. By relaxing the gut muscle, alverine citrate relieves the symptoms of this condition. Alverine also relaxes the smooth muscle in the womb (uterus). It is therefore also used to treat painful menstruation, which is caused by muscle spasms in the uterus (dysmenorrhea). Mechanism of action: Not Available Drug type: Approved. Small Molecule. Drug category: Antispasmodics"}},{"Alveus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","PMID":["10906718","1430328","18551525","2464627","2540226","2540227","3514690","3522662","3793982","701493","8708010","8833116"],"CurationStatus":"uncurated","NeuronamesID":"168","Umlscui":"C0228247","SuperCategory":"Regional part of brain","Id":"birnlex_1510","Is part of":["Hippocampal formation"],"Definition":"Layer of white matter in hippocampus lying just deep to the stratum oriens layer, continuous with the fimbria of the hippocampus"}},{"ALX receptor":{"Synonym":"ALX","Created":"2007-09-19","SuperCategory":"Leukotriene and lipoxin receptor","Id":"nifext_7014"}},{"Alzheimers disease":{"Created":"2006-04-04","Synonym":["Alzheimer Dementia","Alzheimer","Alzheimer's","Alzheimer Type Dementia","Alzheimer Disease","Alzheimer's Disease","Alzheimer Type Senile Dementia","Alzheimer Senile Dementia"],"CurationStatus":"uncurated","Umlscui":"C0002395","SuperCategory":"Neurodegenerative disease","Curator":"BIRN OTF","Id":"birnlex_2092","Has role":"Tauopathy","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Abbrev":"AD","Definition":"A neurodegenerative disease resulting in the insidious onset of dementia. Impairment of memory, judgement, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (adapted from MSH)"}},{"Amacrine neuron":{"Synonym":"amacrine cell","CurationStatus":"uncurated","Comment":["I could not insert the term \"amacrine cell\".This cell should be the class of all amacrine cells recorded in NeuroLex","but we need to discuss the relationships","i.e."],"SuperCategory":"Neuron","Id":"nlx_158403","Has role":"Intrinsic neuron role","Species":"Vertebrata","Definition":"A neuron characterized by amacrine extensions. Discovered first by Herophilus (335-263 BC) in the retina. Considered initially without axon, now they are commonly found in nerve nets, where they may have an axon and/or dendrite.Adapted from Swanson, 2013."}},{"Amantadine":{"RelatedTo":["D(1A) dopamine receptor","Matrix protein 2"],"Synonym":["1-aminoadamantane","Adamantamine","Adamantanamine","Adamantylamine","Amantadine Base","Amantadine HCL","Amantidine","Aminoadamantane","Endantadine","Gen-Amantadine","Mantadine","Pk-Merz","Symadine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2618","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00915","Definition":"An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. (PubChem) Pharmacology: Amantadine is an antiviral drug which also acts as an antiparkinson agent, for which it is usually combined with L-DOPA when L-DOPA responses decline (probably due to tolerance). It is a derivate of adamantane, like a similar drug rimantadine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. It has been shown to cause an increase in dopamine release in the animal brain, and does not possess anticholinergic activity. Mechanism of action: The mechanism of its antiparkinsonic effect is not fully understood, but it appears to be releasing dopamine from the nerve endings of the brain cells, together with stimulation of norepinephrine response. The antiviral mechanism seems to be unrelated. The drug interferes with a viral protein, M2 (an ion channel), which is needed for the viral particle to become \"uncoated\" once it is taken inside the cell by endocytosis. Drug type: Approved. Small Molecule. Drug category: Analgesics, Non-Narcotic. Antiparkinson Agents. Antiviral Agents. Dopamine Agents"}},{"Ambenonium":{"RelatedTo":"Acetylcholinesterase","Synonym":["Ambenonum"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01122","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01122","Definition":"Ambenonium is a cholinesterase inhibitor used in the management of myasthenia gravis. (Wikipedia) Pharmacology: Ambenonium, similar to pyridostigmine and neostigmine, is used for the treatment of muscle weakness and fatigue in people with myasthenia gravis. It is postulated to exert its therapeutic effect by enhancing cholinergic function by inhibiting the hydrolysis of acetylcholine by acetylcholinesterase. Increased levels of acetylcholine has peripheral effects, as acetylcholine is also used in the brain, where it tends to cause excitatory actions. The glands that receive impulses from the parasympathetic part of the autonomic nervous system are also stimulated in the same way. This is why an increase in acetylcholine causes a decreased heart rate and increased production of saliva. Ambenonium is used less commonly than neostigmine or pyridostigmine but may be preferred in patients hypersensitive to the bromide ion. Ambenonium produces fewer muscarinic side effects than neostigmine, but more than pyridostigmine. Mechanism of action: Ambenonium exerts its actions against myasthenia gravis by competitive, reversible inhibition of acetylcholinesterase. The disease myasthenia gravis occurs when the body inappropriately produces antibodies against acetylcholine receptors, and thus inhibits proper acetylcholine signal transmission (when acetylcholine binds to acetylcholine receptors of striated muscle fibers, it stimulates those fibers to contract). Ambenonium reversibly binds acetylcholinesterase, and as acetylcholinesterase is responsible for the hydrolysis of acetylcholine, this inhibition increases levels of acetylcholine. In turn this facilitates transmission of impulses across the myoneural junction and effectively treats the disease. Drug type: Approved. Small Molecule. Drug category: Antiarrhythmic Agents. Antimyasthenics"}},{"Amcinonide":{"RelatedTo":["Annexin A1"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:31199","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00288","Definition":"Amcinonide is a corticosteroid. (Wikipedia) Pharmacology: Amcinonide is a topical corticosteroid. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Amcinonide reduces or inhibits the actions of chemicals in the body that cause inflammation, redness, and swelling. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. When in an ointment form, amcinonide also helps the skin maintain moisture. Mechanism of action: The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Amcinonide has affinity for the glucocorticoid receptor. It has weak affinity for the progesterone receptor, and virtually no affinity for the mineralocorticoid, estrogen, or androgen receptors. Drug type: Approved. Small Molecule. Drug category: Corticosteroids, topical"}},{"Amdinocillin":{"RelatedTo":"Penicillin-binding protein 2B","Synonym":["Amdinocillin mecillinam"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01163","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01163","Definition":"Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. (PubChem) Pharmacology: Amdinocillin is a novel, semisynthetic penicillin effective against many gram-negative bacteria. The antibacterial activity of amdinocillin is derived from its ability to bind specifically and avidly to Penicillin Binding Protein-2 (PBP 2). Amdinocillin is active alone against many gram-negative organisms. Pseudomonas and non-fermenting gram-negative bacteria, however, are usually resistant. Amdinocillin, in combination with many beta-lactams, exhibits marked synergy against many enterobacteriaceae. No such synergy can be demonstrated for gram-positive organisms or pseudomonas species. Amdinocillin is not beta-lactamase stable. Organisms which produce high levels of plasma-mediated beta-lactamase are resistant to the drug. Co-administration of probenecid results in markedly elevated plasma levels of amdinocillin and delays its excretion. Mechanism of action: Amdinocillin is a stong and specific antagonist of Penicillin Binding Protein-2 (PBP 2). Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Anti-Infective Agents, Urinary. Penicillins"}},{"American cockroach":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0242223","SuperCategory":"Periplaneta","Id":"birnlex_426"}},{"American lobster":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998232","SuperCategory":"Homarus","Id":"birnlex_629"}},{"Amiculum of dentate nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-18","NeuronamesID":"683","CurationStatus":"uncurated","Umlscui":"C0175487","SuperCategory":"Regional part of brain","Id":"birnlex_1044","Is part of":"Dentate nucleus","Abbrev":"amdt"}},{"Amifostine":{"RelatedTo":["Ectonucleotide pyrophosphatase/phosphodiesterase family member 1","Alkaline phosphatase"],"Synonym":["Amifostine Ethiofos","Aminopropylaminoethyl Thiophosphate","Apaetp","Ethiofos","Gammaphos","SAPEP","WR-1065","amifostine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2636","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01143","Definition":"A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. (PubChem) Pharmacology: Amifostine is an organic thiophosphate cytoprotective agent indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer or non-small cell lung cancer and also to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite, believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of radiation on normal oral tissues. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells. Mechanism of action: The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity. Drug type: Approved. Investigational. Small Molecule. Drug category: Radiation-Protective Agents"}},{"Amikacin":{"RelatedTo":["30S ribosomal protein S12"],"Synonym":["ANTIBIOTIC BB-K8","Amikacin Base","Amikacin Dihydrate","Amikacin Sulfate","Amikacina (INN-Spanish)","Amikacine (INN-French)","Amikacinum (INN-Latin)","BB-K8","amikacin","Amicacin","Amiglyde-V","Amikavet","Amikin"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2637","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00479","Definition":"A broad-spectrum antibiotic derived from kanamycin. It is reno- and oto-toxic like the other aminoglycoside antibiotics. (PubChem) Pharmacology: Amikacin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses. Mechanism of action: Aminoglycosides like Amikacin \"irreversibly\" bind to specific 30S-subunit proteins and 16S rRNA. Amikacin inhibits protein synthesis by binding to the 30S ribosomal subunit to prevent the formation of an initiation complex with messenger RNA. Specifically Amikacin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. Drug type: Approved. Investigational. Small Molecule. Drug category: Aminoglycosides. Anti-Bacterial Agents"}},{"Amiloride":{"RelatedTo":["Amiloride-sensitive sodium channel subunit beta","Amiloride-sensitive sodium channel subunit alpha","Amiloride-sensitive amine oxidase (copper-containing)","Amiloride-sensitive cation channel 2","neuronal","Amiloride-sensitive sodium channel subunit delta","Amiloride-sensitive sodium channel subunit gamma","Amiloride-sensitive cation channel 1","neuronal","Sodium/hydrogen exchanger 1"],"Synonym":["AMR","Amilorida (INN-Spanish)","Amiloride HCL","Amiloride hydrochloride","Amiloride hydrochloride hydrate","Amiloridum (INN-Latin)","Amyloride","Amipramidin","Amipramizid","Amipramizide","Amiprazidine","Guanamprazin","Guanamprazine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2639","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00594","Definition":"A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) Pharmacology: Amiloride, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents. It is an antihypertensive, potassium-sparing diuretic that was first approved for use in 1967 and helps to treat hypertension and congestive heart failure. The drug is often used in conjunction with thiazide or loop diuretics. Due to its potassium-sparing capacities, hyperkalemia (high blood potassium levels) are occasionally observed in patients taking amiloride. The risk is high in concurrent use of ACE inhibitors or spironolactone. Patients are also advised not to use potassium-containing salt replacements. Mechanism of action: Amiloride works by inhibiting sodium reabsorption in the distal convoluted tubules and collecting ducts in the kidneys by binding to the amiloride-sensitive sodium channels. This promotes the loss of sodium and water from the body, but without depleting potassium. Amiloride exerts its potassium sparing effect through the inhibition of sodium reabsorption at the distal convoluted tubule, cortical collecting tubule and collecting duct; this decreases the net negative potential of the tubular lumen and reduces both potassium and hydrogen secretion and their subsequent excretion. Amiloride is not an aldosterone antagonist and its effects are seen even in the absence of aldosterone. Drug type: Approved. Small Molecule. Drug category: Diuretics. Sodium channel blockers"}},{"Aminergic neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2009-07-13T04:06:57Z","Contributor":"djs93","SuperCategory":"Neuron","Id":"nlx_148084","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007368","Definition":"Any neuron (FBbt_00005106) that releases as a neurotransmitter, some amine (CHEBI:32952)."}},{"Amino Acid":{"Synonym":"Amino acids,","CurationStatus":"uncurated","SuperCategory":"Biomolecule","Id":"sao1511566913","Abbrev":"AA","Definition":"Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins (MSH)."}},{"Aminoalkylindole":{"Created":"2007-09-19","SuperCategory":"Biomolecule","Id":"nifext_5006"}},{"Aminocaproic Acid":{"RelatedTo":["Plasminogen","Tissue-type plasminogen activator"],"Synonym":["ACS","Aminocaproate","Aminocaproic","aminocaproic acid","Acepramin","Acepramine","Afibrin","Amicar","Amikar","Aminokapron","Atsemin","Caplamin","Capracid","Capramol","Capranol","Caprocid","Caprolisin","EACA","EACS","Epsamon","Epsicapron","Epsikapron","Epsilcapramin","Epsilcapramine","Hemocaprol","Hemopar","Hepin","Ipsilon"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00513","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00513","Definition":"An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. (PubChem) Pharmacology: Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Mechanism of action: Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin. Drug type: Approved. Investigational. Small Molecule. Drug category: Antifibrinolytic Agents"}},{"Aminoglutethimide":{"RelatedTo":"Cytochrome P450 19A1","Synonym":["Dl-Aminoglutethimide","P-Aminoglutethimide","Cytadren","Elipten"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00357","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00357","Definition":"An aromatase inhibitor that produces a state of \"medical\" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454) Pharmacology: Aminoglutethimide inhibits the enzymatic conversion of cholesterol to D5-pregnenolone, resulting in a decrease in the production of adrenal glucocorticoids, mineralocorticoids, estrogens, and androgens. Mechanism of action: Aminoglutethimide reduces the production of D5-pregnenolone and blocks several other steps in steroid synthesis, including the C-11, C-18, and C-21 hydroxylations and the hydroxylations required for the aromatization of androgens to estrogens, mediated through the binding of aminoglutethimide to cytochrome P-450 complexes. A decrease in adrenal secretion of cortisol is followed by an increased secretion of pituitary adrenocorticotropic hormone (ACTH), which will overcome the blockade of adrenocortical steroid synthesis by aminoglutethimide. The compensatory increase in ACTH secretion can be suppressed by the simultaneous administration of hydrocortisone. Since aminoglutethimide increases the rate of metabolism of dexamethasone but not that of hydrocortisone, the latter is preferred as the adrenal glucocorticoid replacement. Although aminoglutethimide inhibits the synthesis of thyroxine by the thyroid gland, the compensatory increase in thyroid-stimulating hormone (TSH) is frequently of sufficient magnitude to overcome the inhibition of thyroid synthesis due to aminoglutethimide. In spite of an increase in TSH, aminoglutethimide has not been associated with increased prolactin secretion. Drug type: Approved. Small Molecule. Drug category: Adrenergic Agents. Antineoplastic Agents. Antineoplastic Agents, Hormonal. Aromatase Inhibitors"}},{"Aminohippurate":{"Synonym":["Aminohippurate Sodium","Aminohippuric acid","Aminohippuric acid Sodium salt","PAH","Sodium p-aminohippurate","Sodium para-Aminohippurate","para-Aminohippurate"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00345","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00345","Definition":"The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. (PubChem) Pharmacology: Aminohippurate (p-aminohippuric acid, PAH, PAHA) is the glycine amide of p-aminobenzoic acid. It is filtered by the glomeruli and is actively secreted by the proximal tubules. At low plasma concentrations (1.0 to 2.0 mg/100 mL), an average of 90 percent of aminohippurate is cleared by the kidneys from the renal blood stream in a single circulation. It is ideally suited for measurement of ERPF since it has a high clearance, is essentially nontoxic at the plasma concentrations reached with recommended doses, and its analytical determination is relatively simple and accurate. Aminohippurate is also used to measure the functional capacity of the renal tubular secretory mechanism or transport maximum (TmPAH). This is accomplished by elevating the plasma concentration to levels (40-60 mg/100 mL) sufficient to saturate the maximal capacity of the tubular cells to secrete aminohippurate. Inulin clearance is generally measured during TmPAH determinations since glomerular filtration rate (GFR) must be known before calculations of secretory Tm measurements can be done. Mechanism of action: Aminohippurate is filtered by the renal glomeruli and secreted into the urine by the proximal tubules. By measuring the amount of drug in the urine it is possible to determine functional capacity and effective renal plasma flow. Drug type: Approved. Small Molecule. Drug category: Diagnostic aids. Indicators and Reagents"}},{"Aminolevulinic acid":{"RelatedTo":"Delta-aminolevulinic acid dehydratase","Synonym":["ALA","Aminolevulinate","delta-Aminolevulinic acid","Aladerm","Kerastick","Levulan"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00855","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00855","Definition":"A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. (PubChem) Pharmacology: The metabolism of aminolevulinic acid (ALA) is the first step in the biochemical pathway resulting in heme synthesis. Aminolevulinic acid is not a photosensitizer, but rather a metabolic precursor of protoporphyrin IX (PpIX), which is a photosensitizer. The synthesis of ALA is normally tightly controlled by feedback inhibition of the enzyme, ALA synthetase, presumably by intracellular heme levels. ALA, when provided to the cell, bypasses this control point and results in the accumulation of PpIX, which is converted into heme by ferrochelatase through the addition of iron to the PpIX nucleus. Mechanism of action: According to the presumed mechanism of action, photosensitization following application of aminolevulinic acid (ALA) topical solution occurs through the metabolic conversion of ALA to protoporphyrin IX (PpIX), which accumulates in the skin to which aminolevulinic acid has been applied. When exposed to light of appropriate wavelength and energy, the accumulated PpIX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light results in an excited state of the porphyrin molecule, and subsequent spin transfer from PpIX to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Photosensitization of actinic (solar) keratosis lesions using aminolevulinic acid, plus illumination with the BLU-UTM Blue Light Photodynamic Therapy Illuminator (BLU-U), is the basis for aminolevulinic acid photodynamic therapy (PDT). Drug type: Approved. Small Molecule. Drug category: Photosensitizing Agents"}},{"Aminophenazone":{"Synonym":["4-Dimethylaminoantipyrine","Aminopyrine","Dipyrine"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01424","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01424","Definition":"A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of agranulocytosis. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of cytochrome P-450 metabolic activity in liver function tests. (PubChem) Pharmacology: Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of agranulocytosis. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of cytochrome P-450 metabolic activity in liver function tests. Mechanism of action: Not Available Drug type: Approved. Small Molecule. Withdrawn. Drug category: Analgesics. Pyrazolones"}},{"Aminophylline":{"RelatedTo":["Adenosine A1 receptor","Adenosine A3 receptor"],"Synonym":["Aminophyllin","Aminophylline Anhydrous","Aminophylline Dihydrate","Aminophylline Dye Free","Aminocardol","Aminodur","Ammophyllin","Cardiofilina","Cardiomin","Cardophylin","Cardophyllin","Carena","Cariomin","Diaphylline","Diophllin","Diuxanthine","Dobo","Dura-Tab S,M","Aminophylline","Ethophylline","Etilen-Xantisan Tabl,","Eurphyllin","Euufillin","Genophyllin","Grifomin","Inophylline","Lasodex","Linampheta","Lixaminol","Metaphyllin","Metaphylline","Methophylline","Minaphil","Miofilin","Neophyiline","Norofilina","Peterphyllin","Phylcardin","Phyllindon","Phyllocontin","Phyllocontin-350","Rectalad Aminophylline","Rectalad-Aminophylline","Somophyllin","Somophyllin O","Somophyllin-O","Stenovasan","Syntophyllin","Theodrox","Theolamine","Theolone","Theophyldine","Theophyline Ethylenediamine","Theophyllamine","Theophyllaminum","Theophyllin Aethylendiamin","Theophyllin Ethylenediamine","Theophylline Ethylenediamine","Thephyldine","Truphylline","Variaphylline"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01223","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01223","Definition":"Aminophylline is a drug combination that contains theophylline and ethylenediamine in 2:1 ratio. (Wikipedia) Pharmacology: Aminophylline is the ethylenediamine salt of theophylline. Theophylline stimulates the CNS, skeletal muscles, and cardiac muscle. It relaxes certain smooth muscles in the bronchi, produces diuresis, and causes an increase in gastric secretion. Mechanism of action: Theophylline is structurally related to theobromine and caffeine. The precise mechanism of action of theophylline is not known. Drug type: Approved. Small Molecule. Drug category: Bronchodilator Agents. Cardiotonic Agents. Phosphodiesterase Inhibitors. Respiratory Smooth Muscle Relaxants"}},{"Aminosalicylic Acid":{"RelatedTo":["2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase","Phospholipase A2 VRV-PL-VIIIa"],"Synonym":["4-ASA","4-aminosalicylic acid","APAS","Amino-PAS","Aminosalicylate Sodium","P-Aminosalicylic Acid","PAS","PASK","Para-Amino Salicylic Acid","Para-aminosalicylic acid","Aminopar","Aminox","Apacil","Deapasil","Entepas","Ferrosan","Gabbropas","Hellipidyl","Kyselina P-Aminosalicylova","Neopasalate","Osacyl","PAS-C","Pamacyl","Pamisyl","Para-Pas","Paramycin","Parasal","Parasalicil","Parasalindon","Pasa","Pasalon","Pasara","Pascorbic","Pasdium","Pasem","Paser","Pasmed","Pasnodia","Pasolac","Propasa","Rezipas","Sanipirol-4"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00233","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00233","Definition":"An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid. (PubChem) Pharmacology: Aminosalicylic acid is an anti-mycobacterial agent used with other anti-tuberculosis drugs (most often isoniazid) for the treatment of all forms of active tuberculosis due to susceptible strains of tubercle bacilli. The two major considerations in the clinical pharmacology of aminosalicylic acid are the prompt production of a toxic inactive metabolite under acid conditions and the short serum half life of one hour for the free drug. Aminosalicylic acid is bacteriostatic against Mycobacterium tuberculosis (prevents the multiplying of bacteria without destroying them). It also inhibits the onset of bacterial resistance to streptomycin and isoniazid. Mechanism of action: There are two mechanisms responsible for aminosalicylic acid's bacteriostatic action against Mycobacterium tuberculosis. Firstly, aminosalicylic acid inhibits folic acid synthesis (without potentiation with antifolic compounds). The binding of para-aminobenzoic acid to pteridine synthetase acts as the first step in folic acid synthesis. Aminosalicylic acid binds pteridine synthetase with greater affinity than para-aminobenzoic acid, effectively inhibiting the synthesis of folic acid. As bacteria are unable to use external sources of folic acid, cell growth and multiplication slows. Secondly, aminosalicylic acid may inhibit the synthesis of the cell wall component, mycobactin, thus reducing iron uptake by M. tuberculosis. Drug type: Approved. Small Molecule. Drug category: Antitubercular Agents. Antituberculosis Agents"}},{"Amiodarone":{"RelatedTo":["Potassium voltage-gated channel subfamily H member 2","Beta-1 adrenergic receptor"],"Synonym":["Amiodarona (INN-Spanish)","Amiodarone Base","Amiodarone HCL","Amiodarone Hydrochloride","Amiodaronum (INN-Latin)","Aminodarone","Amio-Aqueous IV","Amiodarons","Aratac","Arycor","Cordarone","Cordarone Intravenous","Labaz","Pacerone"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2663","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01118","Definition":"An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. (PubChem) Pharmacology: Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects. Mechanism of action: The antiarrhythmic effect of amiodarone may be due to at least two major actions. It prolongs the myocardial cell-action potential (phase 3) duration and refractory period and acts as a noncompetitive a- and b-adrenergic inhibitor. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Arrhythmia Agents. Enzyme Inhibitors. Vasodilator Agents"}},{"Amitriptyline":{"RelatedTo":["Alpha-2A adrenergic receptor","Sodium-dependent noradrenaline transporter","Sodium-dependent serotonin transporter"],"Synonym":["Amitriprolidine","Amitriptylin","Amitriptyline HCL","Amitriptyline Hydrochloride","Amitryptiline","Amitryptyline","Amytriptiline","Adepress","Adepril","Amitid","Amitril","Damilan","Damilen","Elanil","Elavil","Endep","Flavyl","Hexathane","Horizon","Lantron","Laroxil","Laroxyl","Lentizol","Proheptadiene","Redomex","Saroten","Sarotex","Seroten","Sylvemid","Triptanol","Triptilin","Triptisol","Tryptanol","Tryptizol"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2666","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00321","Definition":"Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines. (PubChem) Pharmacology: Amitriptyline, a tertiary amine tricyclic antidepressant, is structurally related to both the skeletal muscle relaxant cyclobenzaprine and the thioxanthene antipsychotics such as thiothixene. It is extremely sedating, and thus improvement of sleep patterns can be the first benefit of treatment. Amitriptyline exhibits strong anticholinergic activity, cardiovascular effects including orthostatic hypotension, changes in heart rhythm and conduction, and a lowering of the seizure threshold. As with other antidepressants, several weeks of therapy may be required in order to realize the full clinical benefit of amitriptyline. Although not a labelled indication, amitriptyline is widely used in the management of chronic nonmalignant pain (e.g., post-herpetic neuralgia, fibromyalgia). Mechanism of action: Amitriptyline is metabolized to nortriptyline which inhibits the reuptake of norepinephrine and serotonin almost equally. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with the reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline. Drug type: Approved. Small Molecule. Drug category: Adrenergic Uptake Inhibitors. Analgesics, Non-Narcotic. Antidepressive Agents, Tricyclic"}},{"Amlexanox":{"RelatedTo":["Interleukin-3","Cysteinyl leukotriene receptor 1","Protein S100-A13"],"Synonym":["Amlexanox (USAN:INN:JAN)","Amlexanoxo (Spanish)","Amlexanoxum (Latin)","amlexanox","Amlenanox","Amoxanox","Aphthasol","Elics","OraDisc"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01025","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01025","Definition":"Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population. Pharmacology: Amlexanox is a mucoadhesive oral paste which has been clinically proven to abort the onset, accelerate healing and resolve the pain of aphthous ulcers (canker sores). It decreases the time ulcers take to heal. Because amlexanox decreases the healing time, it also decreases the pain you feel. Recent studies have also shown that the majority of ulcers can be prevented by application of the paste during the prodromal (pre-ulcerative) phase of the disease. Recurrent Aphthous Ulcers (RAU) also known as Recurrent Aphthous Stomatitis (RAS) is recognized as the most common oral mucosal disease known to man. Estimates suggest that 20% - 25% of the general population suffer at least one incidence of aphthous ulcers each year. Mechanism of action: As a benzopyrano-bipyridine carboxylic acid derivative, amlexanox has anti-inflammatory and antiallergic properties. It inhibits chemical mediatory release of the slow-reacting substance of anaphylaxis (SRS-A) and may have antagonistic effects on interleukin-3. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-Allergic Agents. Anti-inflammatory, Locally Applied. Antiulcer agent (topical)"}},{"Amlodipine":{"RelatedTo":["Carbonic anhydrase 1","Voltage-dependent calcium channel gamma-1 subunit"],"Synonym":["Amlodipine Benzenesulfonate","Amlodipine Besilate","Amlodipine Besylate","Amlodipine Free Base","Amlodipino (Spanish)","Amlodipinum (Latin)","Amlocard","Amlodis","Amvaz","Coroval","Lipinox","Lotrel"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00381","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00381","Definition":"A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of angina pectoris and hypertension. (PubChem) Pharmacology: Amlodipine, a calcium-channel blocker, is used alone or with benazepril, an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Amlodipine is similar to the peripheral vasodilator nifedipine and other members of the dihydropyridine class. Mechanism of action: Amlodipine is a calcium channel blocking agent. It inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. Another possible mechanism is that amlodipine inhibits vascular smooth muscle carbonic anhydrase I activity with consecutive pH increase which may be involved in intracelluar calcium influx through calcium channels. Drug type: Approved. Small Molecule. Drug category: Antianginals. Antihypertensive Agents. Calcium Channel Blockers. Vasodilator Agents"}},{"Ammon's horn of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"hippocampus","SuperCategory":"ABA mouse brain parcel","Id":"nlx_151337","ParcellationScheme":"ABA mouse brain parcellation scheme","Is part of":"Hippocampal region of ABA 2009","Species":"Mouse"}},{"Amniota":{"Created":"2007-06-03","CurationStatus":"pending_final_vetting","Umlscui":"C1004207","SuperCategory":"Tetrapoda","Id":"birnlex_264"}},{"Amobarbital":{"Synonym":["Isomytal","Amytal","amylobarbitone"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2673","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB01351","Definition":"A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565) Pharmacology: Not Available Mechanism of action: Amobarbital (like all barbiturates) works by binding to the GABAA receptor at either the alpha or the beta sub unit.  These are binding sites that are distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor.  This GABAA receptor binding decreases input resistance, depresses burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increases both the amplitude and decay time of inhibitory postsynaptic currents.  In addition to this GABA-ergic effect, barbiturates also block the AMPA receptor, a subtype of glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS.  Amobarbital also appears to bind neuronal nicotinic acetylcholine receptors. Drug type: Approved. Illicit. Small Molecule. Drug category: GABA Modulators. Hypnotics and Sedatives"}},{"Amodiaquine":{"RelatedTo":["Hemoglobin subunit alpha"],"Synonym":["Amodiaquin","Amodiaquine USP24","Amodiaquine","ring-closed","Basoquin","CAM-AQ1","CAM-AQI","Camochin","Camoquin","Camoquin HCL","Camoquinal","Camoquine","Flavoquin","Flavoquine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2674","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00613","Definition":"A 4-aminoquinoquinoline compound with anti-inflammatory properties. (PubChem) Pharmacology: Amodiaquine, a 4-aminoquinoline similar to chloroquine in structure and activity, has been used as both an antimalarial and an anti-inflammatory agent for more than 40 years. Amodiaquine is at least as effective as chloroquine, and is effective against some chloroquine-resistant strains, although resistance to amodiaquine has been reported. The mode of action of amodiaquine has not yet been determined. 4-Aminoquinolines depress cardiac muscle, impair cardiac conductivity, and produce vasodilatation with resultant hypotension. They depress respiration and cause diplopia, dizziness and nausea. Mechanism of action: The mechanism of plasmodicidal action of amodiaquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. Drug type: Approved. Small Molecule. Drug category: Amebicides. Anti-Inflammatory Agents, Non-Steroidal. Antimalarials"}},{"Amorphous":{"SuperCategory":"Morphology","Id":"PATO_0001332","Definition":"A morphology quality inhering in a bearer by virtue of its lacking distinct morphology."}},{"Amorphous Vesicle":{"CurationStatus":"uncurated","SuperCategory":"Vesicle","Id":"sao1531915298","Definition":"Category of non-SER vesicle described by Clooney et al. (2002) in dendrites, categorized by smooth membranes, electron-lucent interiors and irregular shapes.  Sometimes occurrs in clumps.  These vesicles contained gold taken up from the extracellular space, suggesting that they may be part of the endosomal pathway."}},{"Amount":{"SuperCategory":"Quantitative","Id":"PATO_0000070"}},{"Amoxapine":{"RelatedTo":["Sodium-dependent noradrenaline transporter"],"Synonym":["Amoxepine","Ascendin","Asendis","Defanyl","Demolox"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00543","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00543","Definition":"The N-demethylated derivative of the antipsychotic agent loxapine that works by blocking the reuptake of norepinephrine, serotonin, or both. It also blocks dopamine receptors. (PubChem) Pharmacology: Amoxapine is a tricyclic antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzodiazepines, dibenzocycloheptenes, and dibenzoxepines. It has a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of nor-epinephirine and serotonin and blocked the response of dopamine receptors to dopamine Amoxapine is not a monoamine oxidase inhibitor. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine Mechanism of action: Amoxapine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT). Drug type: Approved. Small Molecule. Drug category: Adrenergic Uptake Inhibitors. Antidepressive Agents, Second-Generation. Dopamine Antagonists. Neurotransmitter Uptake Inhibitors. Serotonin Uptake Inhibitors"}},{"Amoxicillin":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":["AMC","Amoxicilina (INN-Spanish)","Amoxicillin Trihydrate","Amoxicillin anhydrous","Amoxicilline (INN-French)","Amoxicillinum (INN-Latin)","Amoxycillin","Amoxycillin Trihydrate","D-Amoxicillin","p-Hydroxyampicillin","AMPC","Actimoxi","Amoclen","Amolin","Amopen","Amopenixin","Amoxi","Amoxi-Mast","Amoxibiotic","Amoxiden","Amoxil","Amoxivet","Anemolin","Aspenil","Biomox","Bristamox","Cemoxin","Clamoxyl","Delacillin","Dispermox","Efpenix","Flemoxin","Hiconcil","Histocillin","Ibiamox","Imacillin","Lamoxy","Metafarma capsules","Metifarma capsules","Moxacin","Moxal","Ospamox","Pamoxicillin","Piramox","Polymox","Robamox","Sawamox PM","Sumox","Tolodina","Trimox","Unicillin","Utimox","Vetramox","Wymox"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2676","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01060","Definition":"A broad-spectrum semisynthetic antibiotic similar to ampicillin except that its resistance to gastric acid permits higher serum levels with oral administration. (PubChem) Pharmacology: Amoxicillin is a moderate-spectrum antibiotic active against a wide range of Gram-positive, and a limited range of Gram-negative organisms. It is usually the drug of choice within the class because it is better absorbed, following oral administration, than other beta-lactam antibiotics. Amoxicillin is susceptible to degradation by -lactamase-producing bacteria, and so may be given with clavulanic acid to increase its susceptability. The incidence of -lactamase-producing resistant organisms, including E. coli, appears to be increasing. Amoxicillin is sometimes combined with clavulanic acid, a -lactamase inhibitor, to increase the spectrum of action against Gram-negative organisms, and to overcome bacterial antibiotic resistance mediated through -lactamase production. Mechanism of action: Amoxicillin binds to penicillin-binding protein 1A (PBP-1A) located inside the bacterial cell well. Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that amoxicllin interferes with an autolysin inhibitor. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Penicillins"}},{"AMPA-type glutamate-gated cationic channel":{"Created":"2007-09-19","Synonym":["AMPA receptor","AMPA"],"CurationStatus":"uncurated","SuperCategory":"Glutamate-gated cationic channel","Id":"nifext_5251","Has role":["Glutamate receptor"],"Definition":"Cell surface proteins that bind glutamate and directly gate ion channels in cell membranes. AMPA receptors were originally discriminated from other glutamate receptors by their affinity for the agonist AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid). They are probably the most common mediators of fast excitatory synaptic transmission in the central nervous system. Several subtypes have been cloned, and for some types the traditional distinction from kainate receptors may not apply (MSH)."}},{"Amperometric electrode recording protocol":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Micro-electrode recording protocol","Id":"birnlex_2275","Has role":"\tElectrophysiology concept"}},{"Amphetamine":{"RelatedTo":["Alpha-2A adrenergic receptor","Alpha-1A adrenergic receptor","Sodium-dependent dopamine transporter","Cocaine- and amphetamine-regulated transcript protein"],"Synonym":["(+/-)-Benzedrine","(+/-)-Desoxynorephedrine","(+/-)-beta-Phenylisopropylamine","1-Methyl-2-phenylethylamine","1-Phenyl-2-aminopropane","3-Methoxy-a-methylbenzeneethanamine","3-Methoxyamphetamine","3-Methoxyphenylisopropylamine","Amfetamine","Amphetamine Sulfate","DL-alpha-Methylphenethylamine","Fenylo-izopropylaminyl","Methamphetamine HCL","Phenylisopropylamine","(1-(3-Methoxyphenyl)-2-propyl)amine","alpha-Methylbenzeneethaneamine","beta-Aminopropylbenzene","beta-phenyl-isopropylamine","dl-1-Phenyl-2-aminopropane","dl-Amphetamine","dl-Benzedrine","m-Methoxy-a-methylphenethylamine","m-Methoxyamphetamine","Actedron","Adipan","Allodene","Anorexide","Anorexine","Benzebar","Benzedrine","Benzolone","Desoxyn","Dexampex","Dexedrine","Dextrostat","Elastonon","Fenamin","Ferndex","Finam","Isoamycin","Isoamyne","Isomyn","Mecodrin","Methampex","Norephedrane","Novydrine","Oktedrin","Ortedrine","Paredrine","Percomon","Phenamine","Phenedrine","Profamina","Propisamine","Psychedrine","Raphetamine","Rhinalator","Simpatedrin","Simpatina","Sympamin","Sympamine","Sympatedrine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2679","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00182","Definition":"Amphetamine is a chiral compound. The racemic mixture can be divided into its optical antipodes: levo- and dextro-amphetamine. Amphetamine is the parent compound of its own structural class, comprising a broad range of psychoactive derivatives, e.g., MDMA (Ecstasy) and the N-methylated form, methamphetamine. Amphetamine is a homologue of phenethylamine. Pharmacology: Amphetamine and dextroamphetamine, non-catechloamine sypathomimetic agents, are used in combination to treat attention-deficit hyperactivity disorder (ADHD) or narcolepsy. Adderall consists of equivalent amounts of amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate. Mechanism of action: Amphetamines stimulate the release of norepinephrine from central adrenergic receptors. At higher dosages, they cause release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems. Amphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect. Drug type: Approved. Illicit. Small Molecule. Drug category: Adrenergic Agents. Adrenergic Uptake Inhibitors. Amphetamines. Central Nervous System Stimulants. Dopamine Agents. Dopamine Uptake Inhibitors. Sympathomimetics"}},{"Amphetamine-Related Disorder":{"Synonym":["Amphetamine Abuse"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Substance-Related Disorder","Id":"birnlex_12709","Definition":"Disorders related or resulting from use of amphetamines (MeSH)."}},{"Amphibia":{"Created":"2007-06-03","CurationStatus":"pending_final_vetting","Umlscui":"C0002668","SuperCategory":"Tetrapoda","Id":"birnlex_394"}},{"Amphiesmenoptera":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","SuperCategory":"Endopterygota","Id":"birnlex_164"}},{"Amphotericin B":{"RelatedTo":"Ergosterol biosynthetic protein 28","Synonym":["AMPH-B","Amphortericin B","Amphotericine B","Liposomal Amphotericin B","amphotericin B","ABLC","Abelcet","AmB","AmBisome","Ampho-Moronal","Amphocin","Amphotec","Amphotericin","Amphozone","Fungilin","Fungisone","Fungizone","Fungizone Intravenous","HSDB 3008 IAB","Halizon","IAB","LNS-AmB","Mysteclin-F","SinuNase"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00681","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00681","Definition":"Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses. Pharmacology: Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses. Mechanism of action: Amphotericin B is fungistatic or fungicidal depending on the concentration obtained in body fluids and the susceptibility of the fungus. The drug acts by binding to sterols in the cell membrane of susceptible fungi with a resultant change in membrane permeability allowing leakage of intracellular components. Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of amphotericin B and the azoles. Amphotericin B, a polyene, binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death. Drug type: Approved. Investigational. Small Molecule. Drug category: Amebicides. Anti-Bacterial Agents. Antifungal Agents. Antiprotozoal Agents"}},{"Ampicillin":{"RelatedTo":"Penicillin-binding proteins 1A/1B","Synonym":["Aminobenzylpenicillin","Ampicilina (INN-Spanish)","Ampicillin Acid","Ampicillin Anhydrate","Ampicillin Anhydrous","Ampicillin Base","Ampicillin Sodium","Ampicillin Trihydrate","Ampicillin (Usan:Ban:Inn:Jan)","Ampicillina (Dcit)","Ampicilline","Ampicilline (INN-French)","Ampicillinum (INN-Latin)","Anhydrous Ampicillin","Bayer 5427","D-Ampicillin","AB-PC","Ab-Pc Sol","Acillin","Adobacillin","Alpen","Amblosin","Amcill","Amfipen","Amfipen V","Amipenix S","Ampen","Ampi","Ampi-Bol","Ampi-Co","Ampi-Tab","Ampichel","Ampicil","Ampicillin A","Ampicin","Ampifarm","Ampikel","Ampimed","Ampipenin","Ampipenin","Nt3","Ampiscel","Ampisyn","Ampivax","Ampivet","Amplacilina","Amplin","Amplipenyl","Amplisom","Amplital","Ampy-Penyl","Austrapen","BRL","Binotal","Bonapicillin","Britacil","Campicillin","Cimex","Copharcilin","D-Cillin","Delcillin","Deripen","Divercillin","Doktacillin","Duphacillin","Geocillin","Grampenil","Guicitrina","Guicitrine","Lifeampil","Morepen","Norobrittin","Novo-Ampicillin","Nuvapen","Olin Kid","Omnipen","Omnipen-N","Orbicilina","Pen A","Pen Ampil","Pen a Oral","Penbristol","Penbritin","Penbritin Paediatric","Penbritin Syrup","Penbritin-S","Penbrock","Penicline","Penimic","Pensyn","Pentrex","Pentrexl","Pentrexyl","Pfizerpen A","Pfizerpen-A","Polycillin","Polycillin-N","Ponecil","Princillin","Principen","Principen '125'","Principen '250'","Principen '500'","Qidamp","Racenacillin","Ro-Ampen","Rosampline","Roscillin","Semicillin","Semicillin R","Servicillin","Sk-Ampicillin","Spectrobid","Sumipanto","Supen","Synpenin","Texcillin","Tokiocillin","Tolomol","Totacillin","Totacillin-N","Totalciclina","Totapen","Trifacilina","Ultrabion","Ultrabron","Vampen","Viccillin","Viccillin S"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:28971","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00415","Definition":"Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic. (PubChem) Pharmacology: Ampicillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \"penicillin\" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Ampicillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ampicillin results from the inhibition of cell wall synthesis and is mediated through Ampicillin binding to penicillin binding proteins (PBPs). Ampicillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Mechanism of action: By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Ampicillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Ampicillin interferes with an autolysin inhibitor. Drug type: Approved. Small Molecule. Drug category: Anti-Bacterial Agents. Penicillins"}},{"Amplifier":{"CurationStatus":"uncurated","Comment":"Adapted from WPI http://www.wpiinc.com/index.php/Virtue-Mart/vmchk.html","SuperCategory":"Measurement device","Id":"nlx_27076","Has role":"Instrument role","Definition":"Amplifiers are used in intracellular and extracellular recording, epithelial voltage clamps, specialty instruments for micro-pressure measurement and bio-potential discrimination, and work with electrodes and transducers."}},{"Amplitude":{"SuperCategory":"Quality of a single process","Id":"PATO_0000080","Definition":"A physical monadic quality of occurent quality inhering in a bearer by virtue of the size of its maximum displacement from the 'normal' position, when periodic motion is taking place."}},{"Amprenavir":{"RelatedTo":"HIV-1 protease","Synonym":["AMP","AMV","APV","VX-478","Agenerase","Prozei"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:40050","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00701","Definition":"Amprenavir is a protease inhibitor used to treat HIV infection. Pharmacology: Amprenavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Amprenavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. Mechanism of action: Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Drug type: Approved. Small Molecule. Drug category: Anti-HIV Agents. Antibiotics, Antitubercular. HIV Protease Inhibitors"}},{"Ampulla caudalis":{"Synonym":"terminal ventricle","SynonymPMID":"11241868","CurationStatus":"uncurated","SuperCategory":"Regional part of spinal cord","Id":"nlx_151879","OrganismPMID":"11241868","Is part of":"Spinal cord central canal","Species":["Vertebrata"],"DefinitionPMID":"11241868","Definition":"Caudal dilation of the spinal cord central canal. In lower vertebrates, it represents the major route by which cerebral spinal fluid enters the blood stream."}},{"Amsacrine":{"RelatedTo":["Potassium voltage-gated channel subfamily H member 2","DNA topoisomerase 2-alpha"],"Synonym":["Acridinyl Anisidide","M-AMSA","MAMSA","AMSA P-D","Amsidine","Amsidyl"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2687","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00276","Definition":"Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects. (PubChem) Pharmacology: Amsacrine is an aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects. Mechanism of action: Amsacrine binds to DNA through intercalation and external binding. It has a base specificity for A-T pairs. Rapidly dividing cells are two to four times more sensitive to amsacrine than are resting cells. Amsacrine appears to cleave DNA by inducing double stranded breaks. Amsacrine also targets and inhibits topoisomerase II. Cytotoxicity is greatest during the S phase of the cell cycle when topoisomerase levels are at a maximum. Drug type: Approved. Small Molecule. Drug category: Antineoplastic Agents. Intercalating Agents"}},{"Amydala of WHS11":{"Synonym":"Amygdala","CurationStatus":"uncurated","SuperCategory":"Waxholm 2011 parcellation scheme region","Id":"nlx_143678","Is part of":"Telencephalon of WHS11"}},{"Amygdala":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["amygdaloid nucleus","amygdaloid body","archistriatum"],"CurationStatus":"uncurated","Is_part_of":"Basal nuclear complex","Has role":"PONS reference structure","Created":"2006-10-05","NeuronamesID":"219","Umlscui":"C0002708","ExampleImage":["Physiol Rev 2003 Jul 83(3) 803-34"],"SuperCategory":"Regional part of brain","Id":"birnlex_1241","Is part of":["Telencephalon","Basal forebrain"],"Definition":"Subcortical brain region lying anterior to the hippocampal formation in the temporal lobe and anterior to the temporal horn of the lateral ventricle in some species.  It is usually subdivided into several groups.  Functionally, it is not considered a unitary structure (MM)."}},{"Amygdala basolateral nuclear complex nonpyramidal PV basket cell":{"Located in":"Basolateral nuclear complex ","AxonProjectionLaterality":"ipsilateral","CurationStatus":"uncurated","MolecularConstituents":"Parvalbumin","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel","GABA A-gated anionic channel"],"Has role":"Intrinsic neuron role","OriginOfAxon":"soma and sometimes dendrite","LocationOfAxonArborization":"none","CellSomaSize":"Medium soma","SpineDensityOnDendrites":"Smooth","Neurotransmitter":"GABA","LocationOfLocalAxonArborization":["Basolateral nuclear complex"],"SuperCategory":"Neuron","Id":"nlx_149090","AxonMyelination":"myelinated","CellSomaShape":"Multipolar","Species":"Mammal","Definition":"Multipolar nonpyramidal interneuron whose axon forms multiple synaptic contacts with the somata of numerous neighboring pyramidal cells. It is one of several parvalbumin-containing interneuronal subpopulations.    "}},{"Amygdala basolateral nuclear complex nonpyramidal PV chandelier cell":{"Located in":"Basolateral nuclear complex ","AxonProjectionLaterality":"ipsilateral","Synonym":"axo-axonic interneuron","CurationStatus":"uncurated","MolecularConstituents":"Parvalbumin","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel","GABA A-gated anionic channel"],"Has role":"Intrinsic neuron role","OriginOfAxon":"soma and sometimes dendrite","LocationOfAxonArborization":"None","CellSomaSize":"Medium soma","SpineDensityOnDendrites":"Smooth","Neurotransmitter":"GABA","LocationOfLocalAxonArborization":"Basolateral nuclear complex ","SuperCategory":"Neuron","Id":"nlx_149091","AxonMyelination":"myelinated","CellSomaShape":"Multipolar","Species":["Mammal"],"Definition":"Multipolar nonpyramidal interneuron whose axon forms multiple synaptic contacts with the axon initial segments of numerous neighboring pyramidal cells. It is one of several parvalbumin-containing interneuronal subpopulations.    "}},{"Amygdala basolateral nuclear complex nonpyramidal SOM neuron":{"Located in":"Basolateral nuclear complex ","AxonProjectionLaterality":"ipsilateral","BranchingMetrics":"bitufted","CurationStatus":"uncurated","MolecularConstituents":"Somatostatin","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel","GABA A-gated anionic channel","GABA B"],"Has role":"Intrinsic neuron role","OriginOfAxon":"soma and sometimes dendrite","LocationOfAxonArborization":["Substantia innominata"],"CellSomaSize":"Medium soma","SpineDensityOnDendrites":"spiny low density","Neurotransmitter":"GABA","LocationOfLocalAxonArborization":"Basolateral nuclear complex","SuperCategory":"Neuron","Id":"nlx_149093","AxonMyelination":"unmyelinated","CellSomaShape":"Fusiform","Species":"Mammal","Definition":"Somatostatin-containing nonpyramidal neuron whose axon forms synaptic contacts with the distal dendrites and spines of neighboring pyramidal cells. Although generally considered an interneuron, at least some of these cells have distant axonal projections to the substantia innominata or entorhinal cortex. A subpopulation expresses neuropeptide Y.  "}},{"Amygdala basolateral nuclear complex pyramidal neuron":{"Located in":"Basolateral nuclear complex","Synonym":["Pyramidal cell basolateral amygdalar nucleus"],"CurationStatus":"uncurated","NeurotransmitterReceptorsPMID":"10103117","CellSomaSize":"Large soma","LocationOfAxonArborization":["Cerebral cortex","hippocampus","striatum","basal forebrain","amygdala"],"SpineDensityOnDendrites":"spiny high density","Created":"2007-09-05","LocationOfLocalAxonArborization":"intranuclear","Neurotransmitter":"Glutamate","CellSomaShapePMID":"4638299","SuperCategory":"Neuron","CellSomaShape":"Pyramidal","Species":"Mammal,","AxonProjectionLaterality":"bilateral","MolecularConstituents":"Calcium calmodulin protein kinase II","Comment":"Change the label to Amygdala basolateral nucleus pyramidal neuron","CellSomaShapeOther":["Pyramidal-like"],"Has role":"Principal neuron role","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel","NMDA-type glutamate-gated cationic channel","GABA A-gated anionic channel"],"CellSomaSizePMID":"6185547,6664494","OriginOfAxon":"soma","Abbrev":"PN","EditorialNote":"http://www.nature.com/mp/journal/v14/n9/full/mp200983a.html","NeurotransmitterPMID":"7911130","ExampleImage":"Amygdala basolateral nucleus pyramidal neuron.JPG,","Id":"nifext_152","AxonMyelination":"myelinated","DefinitionPMID":"12843409","Definition":"These neurons make up ~80-85% of neurons in the basolateral nuclear complex of the amygdala. Unlike cortical pyramidal cells, they are not arranged with parellel apical dendrites but are randomly organized."}},{"Amygdala intercalated nuclei small spiny neuron":{"Located in":"Intercalated amygdaloid nuclei","AxonProjectionLaterality":"ipsilateral","Synonym":"paracapsular intercalated cell (ITC)","CurationStatus":"uncurated","NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel","NMDA-type glutamate-gated cationic channel","GABA A-gated anionic channel","D1 receptor"],"Has role":"Principal neuron role","OriginOfAxon":"soma and sometimes dendrite","Abbrev":"ITC","LocationOfAxonArborization":["Central amygdaloid nucleus"],"CellSomaSize":"Small soma","SpineDensityOnDendrites":"spiny high density","Neurotransmitter":"GABA","LocationOfLocalAxonArborization":"Intercalated amygdaloid nuclei","SuperCategory":"Neuron","Id":"nlx_149095","AxonMyelination":"myelinated","CellSomaShape":"Spherical","Species":"Mammal","Definition":"Small spiny principal neurons of the intercalated nuclei. These nuclei are clusters of neurons surrounding rostral portions of the basolateral nuclear complex. Some of these clusters are located adjacent to the external capsule or intermediate capsule (paracapsular intercalated nuclei)."}},{"Amygdala lateral central nucleus medium spiny neuron":{"Located in":"Central amygdaloid nucleus ","AxonProjectionLaterality":"ipsilateral","CurationStatus":"uncurated","MolecularConstituents":["Corticotropin releasing factor","Neurotensin","Somatostatin"],"NeurotransmitterReceptors":["AMPA-type glutamate-gated cationic channel","NMDA-type glutamate-gated cationic channel","GABA A-gated anionic channel"],"Has role":"Principal neuron role","OriginOfAxon":"soma and sometimes dendrite","LocationOfAxonArborization":["Bed nucleus of stria terminalis","Substantia innominata"],"CellSomaSize":"Medium soma","SpineDensityOnDendrites":"spiny high density","Neurotransmitter":"GABA","LocationOfLocalAxonArborization":"Central amygdaloid nucleus ","SuperCategory":"Neuron","Id":"nlx_149094","AxonMyelination":"myelinated","CellSomaShape":"Spherical","Species":"Mammal","Definition":"Medium-sized, multipolar, principal neuron found in lateral portions of the central nucleus. It has very spiny dendrites and closely resembles the medium spiny neuron of the adjacent striatum. "}},{"Amygdala of CIVM postnatal rat brain atlas":{"AtlasImage":["amygdala p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151532","Is part of":"Subpallium of CIVM postnatal rat brain atlas","Definition":"The amygdala is most easily segmented in the coronal plane of a diffusion-weighted image (DWI). This structure may be completely indistinguishable from surrounding regions on T2-weighted MRI. The rostral aspect of the amygdala begins as a light (low diffusivity) region just ventral to the dark (high diffusivity), ellipsoid, diagonal domain at roughly the level of the optic chiasm. Moving caudally, the lateral border of the amygdala is distinguishable from the adjacent cortex based on the dark appearance of layer 2 of the piriform cortex. The medial extent is easily identified based on the dark border created by the lateral hypothalamus and diagonal domain. The dorsal border of the amygdala with the striatum is defined by the start of the striations that define the caudate/putamen. The border with the hippocampus is equally straightforward due to the dark appearance of the alveus. The caudal border of the amygdala is a circular bulge of dark tissue on the ventral-most part of the allocortex (the posteromedial cortical amygdaloid nucleus), which emerges at around the level of the genu of the corpus callosum."}},{"Amygdala of Macaque":{"CurationStatus":"uncurated","SuperCategory":"Amygdala","Id":"nlx_12298","Species":"Macaque"}},{"Amygdala of PHT00":{"Synonym":"amygdala","PublicationDate":"2000","ISBN":"123582555","SuperCategory":"Amygdala of Macaque","Id":"nlx_br_927{{PONS brain region","Curator":"CoCoMac","Authors":["George Paxinos","Xu-Feng Huang"],"Is part of":"Subcortical structures of PHT00","Species":"Macaque","DefiningCitation":"ISBN 0123582555","Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"Amyg"}},{"Amygdalo-entorhinal transition area of RHA11":{"AtlasImage":"Amygdalo Entorhinal area.jpg,","CurationStatus":"graph position temporary","Comment":["RHA gives a few regions that overlap with this one in other terminologies"],"Curator":"Maryann Martone,","PublicationLink":"http://cmbn-approd01.uio.no/zoomgen/hippocampus/Structures/AmygdaloEntorhinal.do","Abbrev":"AE","CytoDefiningCriteria":["The lamination of this field is less developed than in the remainder of entorhinal fields. Layer I is very broad and has a scalloped border with layer II. Layers II and III merge","and are made up of small-sized cells. There is a distinct tendency for cells in layers II and III to form clusters","leaving broad gaps in between. Layer V is characterized by the presence of a population of slightly larger neurons"],"EditorialNote":"In the description of entorhinal cortex from the RHA, they do not list this as one of the cytoarchitectural fields of EC, but in the hierarchy, they list is under the entorhinal cortex (http://cmbn-approd01.uio.no/zoomgen/hippocampus/structureindexB.do), so I have included it here.","DefiningCriteria":"cyto-architecture","SuperCategory":"RHA11 hippocampal parcellation scheme region","Id":"nlx_152001","Is part of":"Entorhinal cortex of RHA11","ParcellationScheme":"RHA11 hippocampal parcellation scheme","Species":["Long Evans Rat"],"ParcellationSchemePMID":"21519393","Definition":"Cytoarchitectural field located between the ventral-intermediate entorhinal area (VIE) and the amygdalohippocampal transition area. The former is caudal and the latter is anterior to AE. Laterally, AE borders with the dorsal-intermediate entorhinal area (DIE), while medially it abuts on the periamygdaloid cortex."}},{"Amyl Nitrite":{"Synonym":["3-Methylbutanol nitrite","3-Methylbutyl nitrite","Amilnitrit","Amilnitrite","Amyl nitrit","Amyl nitrite I","Amyl nitrosum","IPN","Isoamyl nitrite","Isopentyl nitrite","Nitramyl","3-methylbutyl ester","Nitrous acid","isopentyl ester","Pentanoli nitris","Pentyl nitrite","Aspiral","Vaporole","3-methylbutyl nitrite","C5H11NO2","amyl nitrite","snappers"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Alkyl nitrite","Curator":"ab","Id":"CHEBI:2691","Has role":["Drug","Drug of abuse role"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB01612","Definition":"Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Like other alkyl nitrites, amyl nitrite is bioactive in mammals, being a vasodilator which is the basis of its use as a prescription medicine. As an inhalant, it also has psychoactive effect which has led to illegal drug use. Pharmacology: Amyl nitrite, in common with other alkyl nitrites, is a potent vasodilator. It expands blood vessels, resulting in lowering of the blood pressure. Alkyl nitrite functions as a source of nitric oxide, which signals for relaxation of the involuntary muscles. Physical effects include decrease in blood pressure, headache, flushing of the face, increased heart rate, dizziness, and relaxation of involuntary muscles, especially the blood vessel walls and the anal sphincter. There are no withdrawal symptoms. Mechanism of action: Amyl nitrite's antianginal action is thought to be the result of a reduction in systemic and pulmonary arterial pressure (afterload) and decreased cardiac output because of peripheral vasodilation, rather than coronary artery dilation. As an antidote (to cyanide poisoning), amyl nitrite promotes formation of methemoglobin, which combines with cyanide to form nontoxic cyanmethemoglobin. Drug type: Approved. Small Molecule. Drug category: Vasodilator Agents"}},{"Amylin":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5135"}},{"Amyloid Aggregate":{"SuperCategory":"Protein Aggregate","Id":"sao4785563283","Definition":"Insoluble fibrous protein aggregation sharing specific structural traits."}},{"Amyloid Fibril":{"SuperCategory":"Fibril","Id":"sao1342297498","Definition":"A fibril composed of amyloid protein."}},{"Amyloid Precursor Protein":{"Synonym":["APP amyloid beta (A4) precursor protein","Amyloid beta A4 protein"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"sao1143333050","Abbrev":"APP","Definition":"A membrane protein expressed in many tissues and concentrated in the synapses of neurons. It is implicated as a regulator of synapse formation and neural plasticity.  Its proteolysis generates amyloid beta."}},{"Amyloid Protein":{"SuperCategory":"Protein","Id":"sao7278684532","Definition":"Fibrous protein with insoluble fibrils that generally resist proteolytic digestion."}},{"Amylose composition":{"SuperCategory":"Composition","Id":"PATO_0001539","Definition":"A composition quality inhering in a bearer by virtue of the quantities or relative ratios of amylose in the inhering entity."}},{"Amyotrophic Lateral Sclerosis":{"Created":"2007-10-05","Synonym":["Lou Gehrig's Disease","Gehrig's Disease","Maladie de Charcot"],"CurationStatus":"uncurated","SuperCategory":"Motor Neuron Disease","Id":"birnlex_12566","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts (MeSH)."}},{"Anabolic agent":{"CurationStatus":"uncurated","SuperCategory":"Molecule role","Id":"CHEBI:36413","Definition":"A compound which stimulates anabolism and inhibits catabolism. Anabolic agents stimulate the development of muscle mass, strength, and power."}},{"Anabolic steroid":{"Synonym":["anabolic steroids","steroids","anabolic-androgenic steroid"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"CHEBI:50786","Has role":["Drug of abuse role","Anabolic agent"],"Abbrev":"AAS"}},{"Anadoridoidea":{"Created":"2008-02-05","CurationStatus":"pending_final_vetting","Umlscui":"C1228817","SuperCategory":"Doridina","Id":"birnlex_7282"}},{"Anaerobic":{"SuperCategory":"Sensitivity to oxygen","Id":"PATO_0001456","Definition":"A quality inhering in a bearer by virtue of its independence from oxygen."}},{"Anaerobic (for occurrence)":{"SuperCategory":"Sensitivity of occurrent to oxygen","Id":"PATO_0001460","Definition":"A quality inhering in a biological process by virtue of the process unfolding in a location without oxygen."}},{"Anagrelide":{"RelatedTo":"cGMP-inhibited 3',5'-cyclic phosphodiesterase A","Synonym":["Anagrelide HCL","Anagrelide Hydrochloride","BL-4162A","Agrylin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00261","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00261","Definition":"Anagrelide is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It also has been used in the treatment of chronic myeloid leukemia. (Wikipedia) Pharmacology: Anagrelide is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It works by inhibiting the maturation of megakaryocytes into platelets. The exact mechanism of action is unclear, although it is known to be a potent (IC50 "}},{"Anakinra":{"RelatedTo":["Interleukin-1 receptor type I","Interleukin-1 beta"],"Synonym":["ICIL-1RA","IL-1RN","IL-1ra","IL1 inhibitor","IRAP","Interleukin-1 receptor antagonist protein precursor"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00026","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00026","Definition":"Recombinant human interleukin-1 receptor antagonist. Has an extra Met at N-terminus, expressed in E. coli. 153 residues, MW"}},{"Analysis service resource":{" limit":"1000","CurationStatus":"uncurated","SuperCategory":"Production service resource"," format":"CSV","Id":"nlx_res_20090420","Definition":"A resource that provides a service, which transforms any input into data, such as producing gene expression profiles of a sample of tissue, or interpretation of EEG data. For example, the NIH blueprint core facility (La Jolla Core facility) can run certain types of experiments for researchers who do not wish to purchase equipment or develop expertise in the field. Viewing this as an input/output relationship the input would be a physical entity such as a mouse and the output would be data."}},{"Anaphylatoxin C3a":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5266"}},{"Anaphylatoxin C5a":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5023"}},{"Anaphylatoxin receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5584"}},{"Anaphylatoxin receptor - unspecified 1":{"Created":"2007-09-19","SuperCategory":"Anaphylatoxin receptor","Id":"nifext_5585"}},{"Anaphylatoxin receptor - unspecified 2":{"Created":"2007-09-19","SuperCategory":"Anaphylatoxin receptor","Id":"nifext_6245"}},{"Anaphylatoxin receptor - unspecified 3":{"Created":"2007-09-19","SuperCategory":"Anaphylatoxin receptor","Id":"nifext_6592"}},{"Anaplastic":{"CurationStatus":"uncurated","SuperCategory":"Morphology","Id":"PATO_0002092","Definition":"A morphology quality inhering in a neoplastic cell by virtue of the bearer's exhibiting breakdown of cell-cell interaction maintaining tissue architecture, proliferative dysregulation and bizarre modification to nucleus size and shape."}},{"Anaspidea":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998097","SuperCategory":"Opisthobranchia","Id":"birnlex_551"}},{"Anastrozole":{"RelatedTo":"Cytochrome P450 19A1","Synonym":["Anastrozol","anastrozole","Anastrole"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01217","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01217","Definition":"Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens. Pharmacology: Anastrozole is a potent and selective non-steroidal aromatase inhibitor indicated for the treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. Many breast cancers have estrogen receptors and growth of these tumors can be stimulated by estrogens. In post-menopausal women, the principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues, such as adipose tissue, with further conversion of estrone to estradiol. Many breast cancers also contain aromatase; the importance of tumor-generated estrogens is uncertain. Treatment of breast cancer has included efforts to decrease estrogen levels by ovariectomy premenopausally and by use of anti-estrogens and progestational agents both pre- and post-menopausally, and these interventions lead to decreased tumor mass or delayed progression of tumor growth in some women. Anastrozole is a potent and selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone. Mechanism of action: Anastrozole selectively inhibits aromatase. The principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues. Therefore, aromatase inhibition leads to a decrease in circulatin estrogen, leading to a decreased tumor mass or delayed progression of tumor growth in some women. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents. Antineoplastic Agents, Hormonal. Aromatase Inhibitors"}},{"Anatomic Region Modifier Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_2220","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149543","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence that refines the anatomic region of interest in this image. Required if Primary Anatomic Structure Sequence (0008,2228) is not sent. Only a single Item shall be permitted in this Sequence."}},{"Anatomic Region Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_2218","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149614","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Sequence that identifies the anatomic region of interest in this image. Only a single Item shall be permitted in this Sequence."}},{"Anatomic Structure":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_2208","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149545","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Anatomic Structure Space or Region Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0008_2229","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149546","Has role":"Image interpretation attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Anatomic structure, space or region that has been exposed to ionizing radiation. The sequence may have zero or one Items."}},{"Anatomical cavity":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Anatomical entity","PublicationLink":"http://sig.uw.edu/fma#Anatomical_cavity","Id":"birnlex_1011","Definition":"Anatomical space which contains portions of one or more body substances and is bounded by the internal surface of one maximally connected anatomical structure or two or more adjacent anatomical structures. Examples: pharyngeal recess space, nasal cavity, cavity of serous sac, lumen of stomach, lumen of artery, fornix of vagina. (FMA)"}},{"Anatomical entity":{"Created":"2006-09-07","EditorialNote":"We are changing the definition of this category from material entity to independent continuant, as we do not believe that non-experts can distinguish among material and immaterial entities.  The meaning usually depends on the context, e.g., a sulcus (a space) can be used as a proxy for the gray matter lying within its depths or as a landmark.","Synonym":["anatomical object","anatomical objects","Supramolecular part of organism"],"CurationStatus":"graph position temporary","SuperCategory":"Independent continuant","Curator":"Maryann Martone","Id":"birnlex_6","Definition":"Organismal continuant entity which is enclosed by the bona fide boundary of an organism or is an attribute of its structural organization. Examples: cell, heart, head, peritoneal cavity, apex of lung, anatomical term, sagittal plane (FMA)."}},{"Anatomical Location":{"CurationStatus":"uncurated","SuperCategory":"Quality","Id":"sao7122682114","Definition":"Spatial association relationship which describes the containment, adjacency, and anatomical coordinates of physical anatomical entities.  Examples: anatomical containment, anatomical adjacency, anatomical coordinate (FMA)."}},{"Anatomical pathology":{"CurationStatus":"uncurated","SuperCategory":"Pathology","Id":"nlx_inv_100604","Definition":"Branch of pathology."}},{"Anatomical Pattern":{"SuperCategory":"Quality","Id":"sao732945962"}},{"Anatomy":{"Synonym":"Anatomist","CurationStatus":"uncurated","SuperCategory":"Scientific_discipline","Id":"nlx_inv_100605","Definition":"branch of biology and Medicine that studies primarily the internal structure and design of the structure of living things. It is a general term that includes human anatomy, animal anatomy (zootomy) and plant anatomy (phytotomy). Anatomy is divided into various sub specialties in some of its facets anatomy is closely related to Embryology, Histology, comparative anatomy and comparative embryology, through common roots in evolution.Anatomy is subdivided into gross anatomy (or macroscopic anatomy) and microscopic anatomy. Gross anatomy (also called topographical anatomy, regional anatomy, or anthropotomy) is the study of anatomical structures that can be seen by unaided vision with the naked eye. Microscopic anatomy is the study of minute anatomical structures assisted with microscopes, which includes histology (the study of the organization of tissues), and cytology (the study of cells).The history of anatomy has been characterized, over time, by a continually developing understanding of the functions of organs and structures in the body including the clinical understanding of how damage to these structures effects other functions in the body. Methods have also advanced dramatically, advancing from examination of animals through dissection of cadavers (dead human bodies) to technologically complex techniques developed in the 20th century including X-ray technology, Sonogram and MRI technology.Anatomy should not be confused with anatomical pathology (also called morbid anatomy or histopathology), which is the study of the gross and microscopic appearances of diseased organs. - definition adapted from Wikipedia"}},{"Anchor Point":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0014","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149547","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"FL","Definition":"Location of a point in the image or Specified Displayed Area to which the Unformatted Text Value (0070,0006) is related, in Anchor Point Annotation Units (0070,0004), given as columnrow. Column is the horizontal offset and row is the vertical offset. "}},{"Anchor Point Annotation Units":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0004","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149548","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Units of measure for the axes of the text anchor point annotation."}},{"Anchor Point Visibility":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0070_0015","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149549","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Flag to indicate whether or not a visible indication (such as a line or arrow) of the relationship between the text and the anchor point is to be displayed. Required if Anchor Point (0070,0014) is present."}},{"Anesthetic drug":{"CurationStatus":"uncurated","SuperCategory":"Drug","Id":"nlx_17889"}},{"Aneuploid":{"SuperCategory":"Ploidy","Id":"PATO_0001385","Definition":"A ploidy quality inhering in a bearer by virtue of containing a non-integral multiple of the monoploid number, due to extra or missing chromosomes."}},{"Angio Flag":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_0025","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149550","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Angio Image Indicator. Primary image for Angio processing."}},{"Angiotensin":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5025"}},{"Angiotensin receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5740"}},{"Angle Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0020_0018","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149551","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"TBD (retired)."}},{"Angular":{"SuperCategory":"Shape","Id":"PATO_0001977","Definition":"Having several salient angles on the margin."}},{"Angular acceleration":{"SuperCategory":"Movement quality","Id":"PATO_0001350","Definition":"A physical quality inhering in a bearer by virtue of the rate of change of its angular velocity."}},{"Angular gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","RelatedTo":"inferior parietal cortex","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"91","Umlscui":"C0152305","SuperCategory":"Regional part of brain","Id":"birnlex_1376","Species":"Human","Definition":"Part of inferior parietal lobule formed by the cortex surrounding the upturned end of the superior temporal sulcus (Nolte, The Human Brain, 6th ed, 2009, pg 659)"}},{"Angular placement":{"Synonym":["orientation","angular magnitude","angle","amount of rotation"],"CurationStatus":"uncurated","SuperCategory":"Relational spatial quality","Id":"PATO_0000133","Definition":"A relational spatial quality that is the placement of two entities which is defined by the angle between two axes, or an axis and another object."}},{"Angular Position":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1141","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149552","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"TBD (retired)."}},{"Angular Step":{"ValueRepresentation":"DS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1144","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149553","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"DS","Definition":"The angular scan arc step between views of the TOMO acquisition, in degrees."}},{"Angular sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","NeuronamesID":"26","CurationStatus":"uncurated","SuperCategory":"Superficial feature part of parietal cortex","Id":"birnlex_4012","Abbrev":"AS","Definition":"The term angular sulcus (H) refers to a superficial feature of the parietal lobe. It is the portion of the superior temporal sulcus that extends into the angular gyrus (Ono-90). (NN)"}},{"Angular velocity":{"SuperCategory":"Movement quality","Id":"PATO_0001413","Definition":"A physical quality inhering in a bearer by virtue of the rate of its angular movement about an axis; the angle rotated in a given time."}},{"Angular View Vector":{"ValueRepresentation":"US","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0054_0090","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149554","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"An array which contains the angular view number for each frame. Required if the value of the Frame Increment Pointer (0028,0009) includes the Tag for Angular View Vector (0054,0090)."}},{"Anidulafungin":{"RelatedTo":"Beta-1,3-glucan synthase","Synonym":["anidulafungin"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00362","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00362","Definition":"Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. (Wikipedia) Pharmacology: Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3--D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis. Mechanism of action: Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3--D-glucan, an essential component of the fungal cell wall. Drug type: Approved. Investigational. Small Molecule. Drug category: Antibiotics, Antifungal"}},{"Anileridine":{"RelatedTo":"Mu-type opioid receptor","Synonym":["Anileridina (INN-Spanish)","Anileridinum (INN-Latin)","Phthalylsulfathiazole","Sulfathalidine","Adopol","Alidine","Apidol","Apodol","Leritin","Leritine"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00913","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00913","Definition":"Anileridine is a synthetic opioid and strong analgesic medication. It is a narcotic pain reliever used to treat moderate to severe pain. Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effects are also caused by actions in the CNS. Pharmacology: Anileridine, a potent analgesic, is an analog of pethidine. Anileridine is useful for the relief of moderate to severe pain. It may also be used as an analgesic adjunct in general anesthesia in the same manner as meperidine to reduce the amount of anesthetic needed, to facilitate relaxation, and to reduce laryngospasm. In addition, anileridine exerts mild antihistaminic, spasmolytic and antitussive effects. Anileridine's main pharmacologic action is exerted on the CNS. Respiratory depression, when it occurs, is of shorter duration than that seen with morphine or meperidine when equipotent analgesic doses are used. Mechanism of action: Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids such as anileridine close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. Drug type: Approved. Illicit. Small Molecule. Drug category: Analgesics. Narcotics. Opiate Agonists"}},{"Animal Biobank":{"Synonym":"Animal Biobanks","CurationStatus":"uncurated","SuperCategory":"Biobank","Id":"nlx_143632","Species":"Non-human animal","Abbrev":"Animal Biobank","Definition":"A cryogenic storage facility used to archive biological samples from non-human animals for use in research and experiments. Ranging in size from individual refrigerators to warehouses, animal biobanks are maintained by institutions such as universities and nonprofit organizations. (Adapted from Wikipedia)"}},{"Animal model":{"CurationStatus":"graph position temporary","Comment":["I think that animal model is a role"],"SuperCategory":"Role","Curator":"Maryann Martone","PublicationLink":"http://purl.bioontology.org/ontology/MESH/D023421","Id":"nlx_157943","Xref":"MeSH:D023421","Definition":"Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing (adapted from MeSH via BioPortal:  http://purl.bioontology.org/ontology/MESH/D023421)"}},{"Animal naming task":{"Created":"8/15/2011 11:05","CurationStatus":"uncurated","Contributor":"Corey White","CAO_Id":"CAO_00946","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Animal_naming_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146171","Definition":"animals are presented, usually pictorially, and participants are asked to name them aloud"}},{"Animal physiology":{"CurationStatus":"uncurated","SuperCategory":"Physiology","Id":"nlx_inv_100606","Definition":"Branch of physiology concerned with animals."}},{"Animal strain":{"Synonym":"Strain,","CurationStatus":"uncurated","SuperCategory":"Taxonomic rank","Id":"birnlex_7103","Definition":"Animals produced by the mating of littermates or siblings over multiple generations. The resultant strain of animals is virtually identical genotypically. Highly inbred animal lines allow the study of certain traits in a relatively pure form. (Segen, Dictionary of Modern Medicine, 1992) (MSH)"}},{"Animal Temp Control":{"SuperCategory":"Physiology Instrument","Comment":"Adapted from WPI http://www.wpiinc.com/index.php/Virtue-Mart/vmchk.html","Id":"nlx_39801","Has role":"Instrument role","Definition":"low noise heating system maintains animal body temperature during experimental procedures such as electrophysiological recordings where minimal electromagnetic interference is required."}},{"Animation software":{"CurationStatus":"uncurated","SuperCategory":"Data visualization software","Id":"nlx_inv_090901","Definition":"A resource that provides an application or program that is used to rapidly display a sequence of images of 2-D or 3-D artwork or model positions in order to create an illusion of movement.NIRTC definition: Software application visualization using 'Animation'."}},{"Anion":{"CurationStatus":"uncurated","SuperCategory":"Ion","Id":"CHEBI:22563","Definition":"A monoatomic or polyatomic species having one or more elementary charges of the electron."}},{"Anionic cys-loop ligand-gated ion channel":{"Created":"2007-09-19","SuperCategory":"Cys-loop ligand-gated ion channel","Id":"nifext_5240"}},{"Anisindione":{"RelatedTo":"Vitamin K-dependent gamma-carboxylase","Synonym":["Anisin indandione","Miradon"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01125","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01125","Definition":"Anisindione is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K  mediated gamma-carboxylation of precursor proteins. Pharmacology: Anisindione is a synthetic anticoagulant and an indanedione derivative. It is prescribed only if you cannot take coumarin-type anticoagulants such as coumadin as anisindione is a powerful drug with serious potential side effects. Anticoagulants decrease the clotting ability of the blood and therefore help to prevent harmful clots from forming in the blood vessels. These medicines are sometimes called blood thinners, although they do not actually thin the blood. They also will not dissolve clots that already have formed, but they may prevent the clots from becoming larger and causing more serious problems. Mechanism of action: Like phenindione, to which it is related chemically, anisindione exercises its therapeutic action by reducing the prothrombin activity of the blood. Anisindione prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin Kmediated gamma-carboxylation of precursor proteins. Anisindione has no direct thrombolytic effect and does not reverse ischemic tissue damage, although it may limit extension of existing thrombi and prevent secondary thromboembolic complications. Drug type: Approved. Small Molecule. Drug category: Anticoagulants"}},{"Anisotropine Methylbromide":{"RelatedTo":["Cholinergic system","Muscarinic acetylcholine receptor M3","Muscarinic acetylcholine receptor M1"],"Synonym":["Anisotropine methobromide","Endovalpin","Lytispasm","Methyloctatropine bromide","Octatropine"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:2739","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00517","Definition":"Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion. Pharmacology: Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion. Mechanism of action: Quaternary ammonium compounds such as anisotropine methylbromide inhibit the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These postganglionic receptor sites are present in the autonomic effector cells of the smooth muscle, cardiac muscle, sinoatrial and atrioventricular nodes, and exocrine glands. Drug type: Approved. Small Molecule. Drug category: Anticholinergics. Parasympatholytics"}},{"Anistreplase":{"RelatedTo":["Coagulation factor X","Fibrinogen alpha chain","Urokinase plasminogen activator surface receptor","Plasminogen activator inhibitor 2","Calnexin","Kallikrein-1","Annexin A2","Fibronectin","Laminin subunit alpha-5","Tetranectin","Keratin","type II cytoskeletal 8","Laminin subunit beta-1","Laminin subunit gamma-1","Laminin subunit alpha-1","Calreticulin","Low-density lipoprotein receptor-related protein 1"],"Synonym":["Tissue-type plasminogen activator precursor","t- PA","t-plasminogen activator","tPA"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00029","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00029","Definition":"Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins. Pharmacology: Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction. Mechanism of action: Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots. Drug type: Approved. Biotech. Drug category: Thrombolytic Agents"}},{"ANKTM1":{"Synonym":"ankyrin-like with transmembrane domains 1","Created":"2007-09-06","SuperCategory":"Transient receptor potential channel","Id":"nifext_3163"}},{"Annectant gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"135","Umlscui":"C0694596","SuperCategory":"Regional part of brain","Id":"birnlex_1391","Is part of":"Occipital lobe","Species":"Human"}},{"Annelida":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":["C0322464"],"SuperCategory":"Annelida/Echiura/Pogonophora group","Id":"birnlex_354"}},{"Annotation Flag":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:2000_0065","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149555","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"TBD (retired)."}},{"Annotation Group Number":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0040_A180","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149556","Has role":"Processed image attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"A number identifying the associated annotations."}},{"Annotation Sequence":{"RelatedTo":"BIRN-INCF Derived Data Project","SuperCategory":"DICOM term","Id":"nlx_149557","Has role":"BIRN-INCF Derived Data Project","Is part of":"Resource:DICOM standard","Definition":"no def needed"}},{"Anode Target Material":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_1191","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149558","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"The primary material in the anode of the X-Ray source."}},{"Anomura":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998251","SuperCategory":"Pleocyemata","Id":"birnlex_637"}},{"Anoxia":{"SuperCategory":"Tissue state","Id":"nlx_202","Definition":"A condition in which tissues are severely or totally deprived of oxygen."}},{"Ansa lenticularis":{"EditorialNote":"Brainmaps.org lists the ansa lenticularis as an avian and primate term.","CurationStatus":"graph position temporary","SuperCategory":"Regional part of brain","Curator":"Maryann Martone","Id":"nlx_87326","Is part of":["Telencephalon"],"Species":"Primate","Abbrev":"al","DefinitionPMID":"ISBN: 978-0323041317","Definition":"White matter bundle containing part of the projection of the globus pallidus to the thalamus, forming a compact, conspicuous bundle running beneath the internal capsule and hooking around its medial edge (Nolte, The Human Brain, 6th ed., 2009, pg 659)"}},{"Ansa lenticularis of PHT00":{"Synonym":"ansa lenticularis","CurationStatus":"uncurated","ISBN":"123582555","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"al","PartiallyOverlapsWith":["Ansa lenticularis"],"PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_75","ParcellationScheme":["Paxinos"],"Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Ansiform lobule of ABA 2009":{"PartiallyOverlapsWith":"Ansiform lobule","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153088","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Ansoparamedian fissure":{"Synonym":["Fissura Inferior Posterior"],"CurationStatus":"uncurated","SuperCategory":"Superficial feature part of the cerebellum","Id":"nlx_anat_20081256","Abbrev":"apmf","Definition":"Fissure between cerebellar hemispheric lobules VIIBi and VIIBii."}},{"ANT-1":{"SuperCategory":"Adenine Nucleotide Transporter","Id":"sao607850352"}},{"ANT-2":{"SuperCategory":"Adenine Nucleotide Transporter","Id":"sao369353782"}},{"Antagonist role":{"RelatedTo":"Drug","Synonym":["Antagonist","Receptor antagonist","antagoniste","antagonists"],"CurationStatus":"uncurated","SuperCategory":"Pharmacological_role","Id":"CHEBI:48706","Definition":"Substance that attaches to and blocks cell receptors that normally bind naturally occurring substances. - adapted from ChEBI"}},{"Antenna lobe of Manduca":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_151563","Species":"Manduca","Definition":"The Antennal lobe is the first olfactory processing center in the insect brain (similar to the olfactory bulb in vertebrates).Manduca is a moth genus of the Sphingidae (hawkmoth) family. The Carolina Sphinx (Manduca sexta) is often used in biological research. http://en.wikipedia.org/wiki/Manduca"}},{"Antennal commissure":{"Has_role":"Fly_Anatomy_Ontology","Innervates":"adult antennal lobe","Synonym":"VAC2","SuperCategory":"Commissure","Id":"nlx_147690","Is part of":"Adult deuterocerebrum","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00003979","hasDBXref":"VFB:FBbt_00003979","Definition":"Commissure consisting of about 2500 axons located anterior and ventral to the fan-shaped body which connects the two antennal lobes at their postero-dorsal corners."}},{"Antennal lobe (Honey bee) interneuron":{"Located in":"Antennal lobe","AxonProjectionLaterality":"ipsilateral","BranchingMetrics":"unipolar","DendriteLocation":"antennal lobe glomerulus","Synonym":"Antennal lobe local interneuron","CurationStatus":"graph position temporary","Comment":["Is the \"glomerulus\" referenced in the axon specific field referencing a generic glomerulus or the \"antennal lobe glomerulus\"?  Right now"],"Curator":["Maryann Martone"],"Has role":"Intrinsic neuron role","OriginOfAxon":"dendrite","Abbrev":["LIN"],"LocationOfAxonArborization":"none","CellSomaSize":"Medium soma","SpineDensityOnDendrites":"spiny low density","Neurotransmitter":["GABA","Histamine"],"LocationOfLocalAxonArborization":"glomerulus","SuperCategory":"Neuron","AxonMyelination":"unmyelinated","Id":"nlx_151565","CellSomaShape":"Spherical","Species":["Honey bee"],"Definition":"Interglomerular local interneurons in the antennal lobe of the honey bee, Apis mellifera. Homoglomerular and heteroglomerular innervation patterns. Total of 4000 neurons, about two third GABA immunoreactive. Other transmitters possibly histamine and glutamate."}},{"Antennal lobe (Honey bee) principal neuron":{"Located in":"antennal lobe rind","AxonProjectionLaterality":"ipsilateral","BranchingMetrics":"unipolar","DendriteLocation":"Antennal lobe of honey bee","Synonym":"Antennal lobe principal neuron","CurationStatus":"graph position temporary","NeurotransmitterReceptors":["Acetylcholine-gated channel (nicotinic)"],"Has role":"Principal neuron role","OriginOfAxon":"dendrite","Abbrev":["ACT neurons"],"LocationOfAxonArborization":["mushroom body"],"CellSomaSize":"Medium soma","SpineDensityOnDendrites":"spiny high density","RelatedTo":"projection neuron","EditorialNote":"The only projection given for this is to the antennal lobe, outer border, the same place as the soma.  As it is a principal neuron, I assume that it projects to other regions.","Neurotransmitter":"Acetylcholine,","LocationOfLocalAxonArborization":"aglomerular layer of antennal lobe","SuperCategory":"Neuron","AxonMyelination":"unmyelinated","Id":"nlx_151564","CellSomaShape":"Spherical","Species":["Honey bee"],"Definition":"Projection neuron of the honey bee, Apis mellifera,whose soma is located on the rind of the antennal lobe.The axons of uniglomerular projection neurons project to the mushroom body calyx and to the lateral horn in the protocerebral lobe.The axons of the multiglomerular projction neurons project to the protocebral lobe only."}},{"Antennal lobe (Manduca) interneuron":{"Located in":"antennal lobe","Synonym":"multiglomerular local interneuron","CurationStatus":"uncurated","MolecularConstituents":"Neuropeptide","Has role":"Intrinsic neuron role","NeurotransmitterReceptors":["Acetylcholine-gated channel (nicotinic)"],"OriginOfAxon":"no axon","CellSomaSize":"Large soma","Neurotransmitter":"GABA","SuperCategory":"Neuron","Id":"nlx_151689","CellSomaShape":"Spherical","Species":"Manduca sexta","Definition":"local interneuron in the tobacco hornworm moth, in neuronal cell groups at the border of the antennal lobe (mainly lateral group) that express various neuropeptides in subsets of LNs"}},{"Antennal lobe (Manduca) principal neuron":{"Located in":"antennal lobe","AxonProjectionLaterality":"ipsilateral","Synonym":"uniglomerular projection neuron,medial-antenno-protocerebral-tract projection neuron,inner-antennocerebral-tract projection neuron","CurationStatus":"uncurated","NeurotransmitterReceptors":["Acetylcholine-gated channel (nicotinic)"],"Has role":"Principal neuron role","AbbrevPMID":"19737085","OriginOfAxon":"dendrite","Abbrev":["uPN","uPN (m-APT)"],"LocationOfAxonArborization":["lateral protocerebrum"],"CellSomaSize":"Medium soma","SpineDensityOnDendrites":"spiny low density","SynonymPMID":"3197087","Neurotransmitter":"Acetylcholine,","LocatedInPMID":"3197087","SuperCategory":"Neuron","AxonMyelination":"unmyelinated","Id":"nlx_151688","CellSomaShape":"Spherical","Species":"Manduca sexta","Definition":"uniglomerular principal neuron in the antennal lobe of the tobacco hornworm moth, in neuronal cell groups on the border of the antennal lobe, mainly medial and anterior cell groups.  It likely uses acetylcholine as a transmitter.  The axon projects to lateral protocerebrum with collaterals in the mushroom body."}},{"Antennal olfactory receptor neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2009-07-06T03:51:32Z","Synonym":"antennal ORN","Contributor":"djs93","SuperCategory":"Adult olfactory receptor neuron","Id":"nlx_148073","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00007352","Fasciculates_with":"adult antennal nerve","Definition":"Odorant receptor neuron (ORN) whose dendrite transduces signals from some antennal sensillum. The axons of these neurons fasciculate in the antennal nerve and innervate the antennal lobe."}},{"Anteriolateral neurosecretory cell":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Neurosecretory cell","Id":"nlx_147720","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00004010","hasDBXref":"VFB:FBbt_00004010"}},{"Anterior amygdalar area of ABA 2009":{"PartiallyOverlapsWith":"Anterior amygdalar area","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153428","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior amygdaloid area":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":["anterior amygaloid area","anterior amygdalar area"],"CurationStatus":"uncurated","PartiallyOverlapsWith":"anterior amygdaloid area of PHT00","NeuronamesID":"221","Umlscui":"C0175215","SuperCategory":"Regional part of brain","Id":"birnlex_2698","OrganismPMID":"19129928","Is part of":"Corticomedial nuclear complex","Species":"Mammal,","Abbrev":"AA"}},{"Anterior ascending limb of lateral sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"68","Umlscui":"C0262186","SuperCategory":"Sulcus","Id":"birnlex_1330","Is part of":["Lateral sulcus"],"DefiningCitation":"http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID"}},{"Anterior calcarine sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":["Sulcus calcarinus anterior"],"CurationStatus":"uncurated","NeuronamesID":"26","Umlscui":"C0262187","SuperCategory":"Sulcus","Id":"birnlex_1072","Is part of":"Calcarine sulcus","Abbrev":"accs"}},{"Anterior Cerebral Artery Infarction":{"Synonym":["Anterior Cerebral Artery Stroke","Anterior Cerebral Artery Circulation Infarction","ACA Infarction","Heubner Artery Infarction","Anterior Cerebral Artery Syndrome"],"Created":"2007-10-08","CurationStatus":"uncurated","SuperCategory":"Cerebral Infarction","Id":"birnlex_12792","DefiningCitation":["Adams et al.","Principles of Neurology","6th ed"],"Definition":"An infarction in the vascular distribution of the anterior cerebral artery which supplies the majority of the medial surface of the cerebral hemispheres, and provides branches (including Heubner's artery) to the anterior limb of the internal capsule, head of the CAUDATE NUCLEUS, and anterior GLOBUS PALLIDUS. Clinical manifestations may include contralateral lower extremity weakness and sensory loss. Bilateral anterior cerebral artery infarctions are associated with abulia, PARAPLEGIA, and URINARY INCONTINENCE (MeSH)."}},{"Anterior cingulate area dorsal part layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  dorsal part  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152999","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area dorsal part layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  dorsal part  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153072","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area dorsal part layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  dorsal part  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153052","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area dorsal part layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  dorsal part  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153770","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area dorsal part of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  dorsal part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153512","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152928","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153667","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153476","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153756","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153153","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area ventral part layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  ventral part  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153467","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area ventral part layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  ventral part  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153043","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area ventral part layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  ventral part  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153134","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area ventral part layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  ventral part  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152950","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate area ventral part of ABA 2009":{"PartiallyOverlapsWith":"Anterior cingulate area  ventral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153644","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior cingulate cortex":{"Created":"2006-10-08","Synonym":"anterior cingulate","CurationStatus":"uncurated","PartiallyOverlapsWith":"Anterior cingulate gyrus,","ExampleImage":"File:File:AnteriorCingulateCortex-1-.gif","SuperCategory":"Regional part of brain","Curator":"Bill Bug","Id":"birnlex_936","Is part of":["Cingulate cortex"],"Definition":"The frontal part of the cingulate cortex that resembles a collar form around the corpus callosum. It includes both the ventral and dorsal areas of the cingulate cortex. http://en.wikipedia.org/wiki/File:Gray727.svg"}},{"Anterior cingulate gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","CurationStatus":"uncurated","NeuronamesID":"143","Umlscui":"C0175190","SuperCategory":"Regional part of brain","Id":"birnlex_1603","Is part of":"Cingulate gyrus","Species":"Human","Abbrev":"ACG"}},{"Anterior column of fornix":{"CurationStatus":"uncurated","Umlscui":"C0175236","SuperCategory":"Regional part of brain","Id":"birnlex_731","Is part of":"Fornix"}},{"Anterior commissure":{"Created":"2006-07-15","CurationStatus":"uncurated","Umlscui":"C0152335","SuperCategory":"Commissure","Id":"birnlex_1557","Is part of":["Telencephalon"],"Definition":"A forebrain white matter structure consisting of a  large fiber bundle, connecting the two cerebral hemispheres across the middle line, located in front of the columns of the fornix. On sagittal section it is oval in shape, its long diameter being vertical and measuring about 5 mm. Its fibers can be traced lateralward and backward on either side beneath the corpus striatum into the substance of the temporal lobe. It serves in this way to connect the two temporal lobes, but it also contains decussating fibers from the olfactory tracts. (http://en.wikipedia.org/wiki/Anterior_commissure)]]"}},{"Anterior commissure anterior part":{"Created":"2006-07-15","CurationStatus":"uncurated","Umlscui":"C0175209","SuperCategory":"Regional part of brain","Curator":["Allan_MacKenzie-Graham"],"Id":"birnlex_969","Is part of":"Anterior commissure,","Definition":"The part of the anterior commissure that contains fibers interconnecting the anterior olfactory nucleus in each hemisphere.  The fibers extend from the commissural region of the anterior commissure anteriorly into the olfactory bulb.  Within the commissural portion, the fibers lie in the anterior portion, but cannot be easily distinguished from the posterior fibers on gross dissection.  (Adapted from Heimer, 1996)"}},{"Anterior Commissure of CIVM postnatal rat brain atlas":{"AtlasImage":["ac p0.png"],"CurationStatus":"uncurated","SuperCategory":"CIVM postnatal rat brain atlas parcellation scheme region","Id":"nlx_151545","Is part of":"Major White Matter Structures of CIVM postnatal rat brain atlas","Definition":"The anterior commissure is very easily segmented on horizontal T2w MRI. The dense white matter of the anterior commissure is much darker than surrounding tissue on T2w MRI and the entire structure can be segmented using a simple seeded threshold (magic wand) tool. The posterior limbs tend to be slightly lighter than the anterior limbs, but are still readily distinguishable from surrounding tissue."}},{"Anterior commissure of WHS11":{"AtlasImage":"Anterior commissure of WHS11.png,","PartiallyOverlapsWith":"anterior commissure","CurationStatus":"uncurated","SuperCategory":"Waxholm 2011 parcellation scheme region","Id":"nlx_143692","ParcellationScheme":"Waxholm 2011 parcellation scheme","Is part of":"Telencephalon of WHS11","Species":"Mouse","Definition":"Delineation of anterior commissure in Waxholm mouse atlas based on T1, T2* and T2W volumes.  As seen in sagittal at the midline: In T1 image round feature with lower intensity of surround structures. Traced specific intensity through slices.  Examples:  transverse 240, sagittal 256"}},{"Anterior commisure":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_144088","Is part of":"Basal forebrain","Abbrev":"AC"}},{"Anterior crossvein campaniform sensillum neuron":{"Has_role":"Fly_Anatomy_Ontology","Created":"2010-03-17T12:13:24Z","Synonym":"sensillum campaniformium of anterior crossvein neuron","Contributor":"sr544","SuperCategory":"Eo neuron","Id":"nlx_148482","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00100120","Fasciculates_with":"L3 nerve","Definition":"Neuron associated with the wing anterior crossvein sensillum (Murray et al., 1984)."}},{"Anterior fascicle sensory neuron":{"Has_role":"Fly_Anatomy_Ontology","SuperCategory":"Sensory neuron (FBbt Term)","Id":"nlx_146718","FBBT_Link":"http://www.virtualflybrain.org/site/tools/anatomy_finder/index.htm?id","FBbt_Id":"FBbt_00001998","Fasciculates_with":"intersegmental nerve","Definition":"Any sensory neuron (FBbt_00005124) that fasciculates with some intersegmental nerve (FBbt_00001997)."}},{"Anterior forebrain":{"PMID":"16927265,17626267","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_10637","Is part of":"Forebrain"}},{"Anterior Funiculus":{"CurationStatus":"uncurated","SuperCategory":"Funiculi","Id":"nlx_379","Is part of":"Spinal cord white matter"}},{"Anterior group of the dorsal thalamus of ABA 2009":{"PartiallyOverlapsWith":"Anterior group of the dorsal thalamus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153317","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior horizontal limb of lateral sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","DefiningCriteria":"topography","CurationStatus":"uncurated","NeuronamesID":"69","Umlscui":"C0262190","SuperCategory":"Sulcus","Id":"birnlex_1327","Is part of":["Lateral sulcus"],"Species":"Human"}},{"Anterior horn of lateral ventricle":{"Created":"2006-07-15","CurationStatus":"uncurated","Umlscui":"C1281033","SuperCategory":"Regional part of brain","Id":"birnlex_1279","Is part of":"Lateral ventricle","Definition":"Part of the lateral ventricle that extends anteriorly into the frontal lobes, bordered by the head of the caudate nucleus on the lateral side (Adapted from Heimer, 1996)"}},{"Anterior hypothalamic area of ABA 2009":{"SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153108","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior hypothalamic commissure":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","EditorialNote":"Check to see whether this is a decussation or a commissure, according to the CUMBO definitions","Synonym":"Anterior hypothalamic decussation of Ganser","NeuronamesID":"373","CurationStatus":"graph position temporary","Umlscui":"C0175337","SuperCategory":"Commissure","Id":"birnlex_1424","Is part of":["White matter"],"Abbrev":"ahc"}},{"Anterior hypothalamic nucleus anterior part of ABA 2009":{"PartiallyOverlapsWith":"Anterior hypothalamic nucleus  anterior part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153704","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior hypothalamic nucleus central part of ABA 2009":{"PartiallyOverlapsWith":"Anterior hypothalamic nucleus  central part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153780","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior hypothalamic nucleus dorsal part of ABA 2009":{"PartiallyOverlapsWith":"Anterior hypothalamic nucleus  dorsal part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153079","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior hypothalamic nucleus of ABA 2009":{"PartiallyOverlapsWith":"Anterior hypothalamic nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153519","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior hypothalamic nucleus posterior part of ABA 2009":{"PartiallyOverlapsWith":"Anterior hypothalamic nucleus  posterior part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153048","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior hypothalamic region":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-09","Synonym":"Anterior hypothalamus","NeuronamesID":"359","CurationStatus":"uncurated","Umlscui":"C0020653","SuperCategory":"Regional part of brain","Is_part_of":"Hypothalamus","Id":"birnlex_1005","Abbrev":"AHR"}},{"Anterior hypothalamus":{"PMID":"2461972,2461973,3597828,61213,730854,10754510,2148751,9527538,7860792,762273,16705678,3102567,2754028,19637308,6757282,7593751","Synonym":"Anterior hypothalamic","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_91346","Is part of":"Hypothalamus"}},{"Anterior limb of internal capsule":{"CurationStatus":"uncurated","NeuronamesID":"199","SuperCategory":"Regional part of brain","Id":"nlx_144257","Is part of":"Internal capsule","Species":"Primate","Definition":"Portion of internal capsule lying between the lenticular nucleus and the head of the caudate nucleus."}},{"Anterior lobe of the cerebellum":{"Created":"2006-07-15","Synonym":["spinocerebellum"],"CurationStatus":"uncurated","NeuronamesID":"650","SuperCategory":"Lobe parts of the cerebellar cortex","Curator":"BIRN OTF","PublicationLink":["anterior cerebellar lobe","anterior lobe of cerebellum","spinocerebellum"],"Id":"birnlex_1118","Is part of":"Cerebellum,","Abbrev":"ALCb"}},{"Anterior median eminence":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","NeuronamesID":"386","CurationStatus":"uncurated","Umlscui":"C0175323","SuperCategory":"Regional part of brain","Id":"birnlex_1264","Is part of":"Median eminence","Abbrev":"AME"}},{"Anterior median fissure":{"Synonym":"Anterior median fissure of spinal cord","CurationStatus":"uncurated","SuperCategory":"Sulcus","Id":"nlx_152094","Is part of":"Spinal cord"}},{"Anterior median oculomotor nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-07-15","NeuronamesID":"488","CurationStatus":"uncurated","Umlscui":"C0175382","SuperCategory":"Regional part of brain","Id":"birnlex_1445","Is part of":"Oculomotor nuclear complex","Abbrev":"AM3"}},{"Anterior middle temporal sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","CurationStatus":"uncurated","NeuronamesID":"114","Umlscui":"C0694593","SuperCategory":"Sulcus","Id":"birnlex_998","Is part of":"Temporal lobe","Species":"Human","Abbrev":"amt"}},{"Anterior nuclear group":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-03","Synonym":["anterior nucleus of thalamus","nuclei anterior thalami","nuclei thalamicus anterior","nuclei anteriores thalami","nuclei anteriores (thalami)","anterior thalamus"],"CurationStatus":"uncurated","NeuronamesID":"285","Umlscui":"C0228316","SuperCategory":"Regional part of brain","Id":"birnlex_1692","Is part of":"Thalamus,","Abbrev":"ANG","Definition":"Mostly gray regional part of anterior thalamic region, consisting of the anterior medial, anterior dorsal and anterior lateral thalamic nuclei in primates.  In rodents, it consists of anterior medial and anterior ventral divisions, with several subdivisions of each, according to Paxinos (MM: 2006-10-26)"}},{"Anterior nucleus of hypothalamus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","Synonym":"Anterior hypothalamic area","CurationStatus":"uncurated","NeuronamesID":"369","Umlscui":"C0020653","Comment":["This hierarchy needs some examination","particularly in clarifying the relationship between these classical structures from NeuroNames vs atlases like the Allen Brain Atlas.  I don't feel qualified to state overlaps relationships without some additional research.  NeuroNames has Anterior hypothalamic region --> anterior hypothalamic area","which is a synonym of anterior hypothalamic nucleus.  ABS 2009 does not have an anterior hypothalamic region","and has both an anterior hypothalamic area and an anterior hypothalamic nucleus.  However","in the current version of the Allen Reference Atlas (accessed April 5","2014)","the anterior hypothalamic area is grayed out"],"SuperCategory":"Regional part of brain","Id":"birnlex_1226","Is part of":"Anterior hypothalamic region"}},{"Anterior nucleus of hypothalamus central part":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1119","Is part of":"Anterior nucleus of hypothalamus","Abbrev":["AHNc"]}},{"Anterior nucleus of hypothalamus dorsal part":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1139","Is part of":"Anterior nucleus of hypothalamus","Abbrev":"AHNd"}},{"Anterior nucleus of hypothalamus posterior part":{"Created":"2007-08-19","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1125","Is part of":"Anterior nucleus of hypothalamus","Abbrev":["AHNp"]}},{"Anterior occipital sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["sulcus annectans","sulci occipitales superiores","ascending limb of the inferior temporal sulcus","Sulcus occipitalis anterior"],"NeuronamesID":"124","CurationStatus":"uncurated","Umlscui":"C0262194","SuperCategory":"Sulcus","Id":"birnlex_4023","Is part of":"Occipital lobe","Abbrev":"aocs"}},{"Anterior olfactory nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","CurationStatus":"uncurated","TomoDefiningCriteria":["The structure can be found behind the olfactory bulb in all vertebrates. Since in many primates the bulb is located at the end of a long stalk below the frontal cortex","the AON is often difficult to locate and may appear only as islands of cells in the stalk rather than a clearly defined ring. In the macaque monkey"],"Abbrev":["AON"],"IsPartOfPMID":"16229895","Created":"2006-10-05","TopoDefiningCriteriaPMID":"16229895","NeuronamesID":"262","PartiallyOverlapsWith":"Anterior olfactory nucleus of PHT00","Umlscui":"C0175225","SuperCategory":"Nucleus of CNS","Id":"birnlex_1085","Is part of":["Telencephalon"],"Species":"Vertebrata","Definition":"Laminated structure lying caudal to the olfactory bulb in all vertebrates.  Based on Nissl stains, the AON has been divided into two basic zones: \"pars externa,\" a thin ring of cells that encircles the rostral end of the olfactory peduncle, and the remainder, sometimes referred to as \"pars cruralis\" or \"pars principalis\"","DefinitionPMID":"16229895"}},{"Anterior olfactory nucleus dorsal part of ABA 2009":{"PartiallyOverlapsWith":"Anterior olfactory nucleus  dorsal part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153687","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior olfactory nucleus external part of ABA 2009":{"PartiallyOverlapsWith":"Anterior olfactory nucleus  external part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153664","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior olfactory nucleus lateral part of ABA 2009":{"PartiallyOverlapsWith":"Anterior olfactory nucleus  lateral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153424","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior olfactory nucleus layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Anterior olfactory nucleus  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153032","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior olfactory nucleus layer 2 of ABA 2009":{"PartiallyOverlapsWith":"Anterior olfactory nucleus  layer 2","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153199","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior olfactory nucleus medial part of ABA 2009":{"PartiallyOverlapsWith":"Anterior olfactory nucleus  medial part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153474","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior olfactory nucleus of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Anterior olfactory nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153369","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Olfactory bulb of ABA 2009","Species":"Mouse"}},{"Anterior olfactory nucleus pars externa":{"CytoDefiningCriteria":["A thin band of tightly packed cells oriented in a oblique coronal plane"],"CytoDefiningCriteriaPMID":"16229895","DefiningCriteria":"cyto-architecture","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_152598","Is part of":"Anterior olfactory nucleus","DefinitionPMID":"16229895","Definition":"One of two main divisions of the anterior olfactory nucleus, comprising a thin ring of cells that encircles the rostral end of the olfactory peduncle"}},{"Anterior olfactory nucleus pars principalis":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_152597","Is part of":"Anterior olfactory nucleus"}},{"Anterior olfactory nucleus posteroventral part of ABA 2009":{"PartiallyOverlapsWith":"Anterior olfactory nucleus  posteroventral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153541","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior Paravermal Cortex":{"CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_144122"}},{"Anterior parieto-occipital sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":["Sulcus parieto-occipitalis anterior"],"CurationStatus":"uncurated","NeuronamesID":"34","Umlscui":"C0262195","SuperCategory":"Sulcus","Id":"birnlex_1079","OrganismPMID":"9549495","Is part of":"Cerebral cortex","Species":["Macaque"],"Abbrev":"apos"}},{"Anterior parolfactory sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2008-03-02","Synonym":["Paraolfactory sulci","Sulcus parolfactorius anterior","Set of paraolfactory sulci"],"CurationStatus":"uncurated","NeuronamesID":"18","Umlscui":"C0262196","SuperCategory":"Sulcus","Id":"birnlex_4039","Is part of":"Telencephalon","Abbrev":"aps"}},{"Anterior perforated substance":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","EditorialNote":"Should consider whether this is a superficial feature or not","Synonym":"substantia perforata anterior","CurationStatus":"graph position temporary","NeuronamesID":"264","Umlscui":"C0162436","TomoDefiningCriteria":["Lies on the basal surface and bounded by the olfactory trigone rostrally","the diagonal band medially and caudally and the prepiriform cortex laterally.  It is characterized by many perforations caused by small blood vessels entering the gray matter (Meyer et al.","J. Comp. Neurol 284: 405"],"SuperCategory":"Regional part of brain","Id":"birnlex_1096","Species":"Human,","Definition":"Regional part of telencephalon lying on the basal surface and bounded by the olfactory trigone rostrally, the diagonal band medially and caudally and the prepiriform cortex laterally.  It is characterized by many perforations caused by small blood vessels entering the gray matter (Meyer et al., J. Comp. Neurol 284: 405, 1989)."}},{"Anterior piriform cortex":{"PMID":"632378,14991564,20235162,6863605,15924345,6200519,6200518,2906072,15282713,16320252,6853766,6306065","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_12056","Is part of":"Prepyriform area"}},{"Anterior preoptic area":{"PMID":"3047186,12012424,11116217,1691747,12373783","SuperCategory":"Brain Subdivisions based on automated term selection","Id":"nlx_12412","Is part of":"Preoptic area"}},{"Anterior pretectal nucleus":{"CurationStatus":"uncurated","NeuronamesID":"1116","SuperCategory":"Regional part of brain","Id":"nlx_144456","Is part of":"Pretectum","Species":"Mammal"}},{"Anterior pretectal nucleus of ABA 2009":{"PartiallyOverlapsWith":"Anterior pretectal nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153450","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior quadrangular lobule":{"Created":"2006-07-15","CurationStatus":"uncurated","SuperCategory":"Lobular parts of the cerebellar cortex","Id":"birnlex_913"}},{"Anterior spinocerebellar tract":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Synonym":["ventral spinocerebellar tract"],"Pages":"209","CurationStatus":"uncurated","ISBN":"0-89004-106-7","EfferentProjections":"Anterior Paravermal Cortex","Authors":"Masao Ito","Title":"The Cerebellum and neural control","AfferentProjections":"Lumbar spinal cord","Abbrev":"vsc","Created":"2006-10-08","NeuronamesID":"805","Umlscui":"C0175561","SuperCategory":"Nerve tract","Id":"birnlex_848","Is part of":["Spinocerebellar tract"],"Definition":"White matter tract that runs through the ventrolateral surface of the spinal cord.  It enters the cerebellum through the superior cerebellar peduncle.  It arises from cell bodies located in the intermediate and ventral gray matter in the lower half of the spinal cord (Heimer, L:  The Human Brain and Spinal Cord, 1995, pg 370).  It crosses the midline at the segmental level and recrosses in the cerebellum.  Its terminals are distributed in the cerebellar anterior lobe, preferentially in the ipsilateral intermediate cortex.  Rostrally, it extends to lobule II.  The equivalent pathway from the cervical cord is the rostral spinocerebellar tract (Heimer, L:  The Human Brain and Spinal Cord, 1995, pg 370)"}},{"Anterior subcentral sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":["inferior precentral dimple"],"CurationStatus":"uncurated","NeuronamesID":"3328","SuperCategory":"Sulcus","Id":"birnlex_1332","Is part of":"Frontal lobe","Species":"Macaque","DefiningCitation":"http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID","Abbrev":"asd","Definition":"A branch from the lateral fissure into the precentral gyrus of the frontal lobe caudal to the diagonal sulcus "}},{"Anterior superior frontal sulcus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","NeuronamesID":"1065886326","CurationStatus":"uncurated","SuperCategory":"Sulcus","Id":"birnlex_1338","Is part of":"Superior frontal sulcus"}},{"Anterior tegmental nucleus of ABA 2009":{"PartiallyOverlapsWith":"Anterior tegmental nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153166","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterior to":{"Synonym":["preceding","anterior"],"SuperCategory":"Relational spatial quality","Id":"PATO_0001632","Definition":"A relational spatial quality where an entity is located toward the front of an organism relative to another entity."}},{"Anterior transverse temporal area 41":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-08","Synonym":["Brodmann's area 41","principle auditory receptive areas"],"CurationStatus":"uncurated","PartiallyOverlapsWith":"anterior transverse temporal gyrus","NeuronamesID":"77","SuperCategory":"Brodmann partition scheme region","Curator":"Bill Bug","Id":"birnlex_1582","ParcellationScheme":"Brodmann (1909) cortical parcellation scheme human","Species":"Human","Definition":"A subdivision of the cytoarchitecturally defined temporal region of cerebral cortex. It occupies the anterior transverse temporal gyrus (H) in the bank of the lateral sulcus on the dorsal surface of the temporal lobe. Cytoarchitecturally it is bounded medially by the parainsular area 52 (H) and laterally by the posterior transverse temporal area 42 (H) (Brodmann-1909).  Adapted from Brain Info"}},{"Anterior transverse temporal gyrus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2006-10-05","Synonym":["great transverse gyrus of Heschl","anterior transverse convolution of Heschl"],"CurationStatus":"uncurated","NeuronamesID":"116","Umlscui":"C0262198","SuperCategory":"Regional part of brain","Id":"birnlex_1657","Is part of":"Temporal lobe","Species":["Human"]}},{"Anterior-posterior diameter":{"SuperCategory":"Diameter","Id":"PATO_0002041","Definition":"Diameter that is along the anterior-posterior axis."}},{"Anterior-posterior polarity":{"Synonym":"rostral-caudal polarity","SuperCategory":"Polarity (PATO 0001769)","Id":"PATO_0002024","Definition":"Polarity that is along the anterior-posterior axis."}},{"Anterioralized":{"SuperCategory":"Malformed","Id":"PATO_0000615","Definition":"A malformed quality in which the gross morphology contains only what are normally anterior structures."}},{"Anteriorly rotated":{"SuperCategory":"Rotation","Id":"PATO_0001601"}},{"Anterodorsal nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-04","Synonym":["nucleus thalamicus anterodorsalis","nucleus anterior thalami dorsalis","nucleus anterior dorsalis","nucleus anterodorsalis","nucleus anterodorsalis (Hassler)","anterodorsal nucleus of the thalamus","nucleus anterosuperior","anterodorsal thalamic nucleus","nucleus anterodorsalis thalami"],"NeuronamesID":"286","CurationStatus":"uncurated","Umlscui":"C0228318","SuperCategory":"Regional part of brain","Id":"birnlex_1358","Is part of":"Anterior nuclear group,","Abbrev":"AD"}},{"Anterodorsal nucleus of ABA 2009":{"PartiallyOverlapsWith":"Anterodorsal nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153123","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterodorsal nucleus of medial geniculate body":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-05","Synonym":["anterodorsal nucleus of medial geniculate complex","pars anterodorsalis"],"NeuronamesID":"2090221698","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"birnlex_1600","Is part of":"Medial geniculate body","Abbrev":"ADMG"}},{"Anterodorsal preoptic nucleus":{"CurationStatus":"uncurated","NeuronamesID":"1790","SuperCategory":"Regional part of brain","Id":"nlx_144455","Is part of":"Preoptic area"}},{"Anterodorsal preoptic nucleus of ABA 2009":{"PartiallyOverlapsWith":"Anterodorsal preoptic nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153605","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterodorsal to":{"SuperCategory":"Anterior to","Id":"PATO_0001915","Definition":"A relational spatial quality in which an entity is located toward the front and upper surface of an organism relative to another entity."}},{"Anterograde tracing role":{"CurationStatus":"uncurated","SuperCategory":"Tracing role","Id":"nlx_25113","Definition":"Role of a substance that is used for tract tracing studies in the nervous system that is taken up by cell bodies and transported towards the axon terminals"}},{"Anterolateral visual area layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Anterolateral visual area  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153796","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterolateral visual area layer 4 of ABA 2009":{"PartiallyOverlapsWith":"Anterolateral visual area  layer 4","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152906","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterolateral visual area layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Anterolateral visual area  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153029","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterolateral visual area layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Anterolateral visual area  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153279","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterolateral visual area layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Anterolateral visual area  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153739","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anterolateral visual area of ABA 2009":{"PartiallyOverlapsWith":"Anterolateral visual area","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153101","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteromedial nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-04","Synonym":["nucleus anteromedialis thalami","nucleus thalamicus anteromedialis","anteromedial thalamic nucleus","nucleus anterior medialis thalami","nucleus anterior thalami medialis","nucleus anteromedialis (Hassler)","nucleus anteromedialis","nucleus anterior medialis"],"NeuronamesID":"287","CurationStatus":"uncurated","Umlscui":"C0228319","SuperCategory":"Regional part of brain","Id":"birnlex_1365","Is part of":"Anterior nuclear group","Abbrev":"AM"}},{"Anteromedial nucleus dorsal part of ABA 2009":{"PartiallyOverlapsWith":"Anteromedial nucleus  dorsal part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153266","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteromedial nucleus of ABA 2009":{"PartiallyOverlapsWith":"Anteromedial nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153141","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteromedial nucleus ventral part of ABA 2009":{"PartiallyOverlapsWith":"Anteromedial nucleus  ventral part","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153018","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteromedial visual area layer 1 of ABA 2009":{"PartiallyOverlapsWith":"Anteromedial visual area  layer 1","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153045","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteromedial visual area layer 4 of ABA 2009":{"PartiallyOverlapsWith":"Anteromedial visual area  layer 4","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153242","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteromedial visual area layer 5 of ABA 2009":{"PartiallyOverlapsWith":"Anteromedial visual area  layer 5","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153377","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteromedial visual area layer 6a of ABA 2009":{"PartiallyOverlapsWith":"Anteromedial visual area  layer 6a","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153609","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteromedial visual area layer 6b of ABA 2009":{"PartiallyOverlapsWith":"Anteromedial visual area  layer 6b","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152986","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteromedial visual area of ABA 2009":{"PartiallyOverlapsWith":"Anteromedial visual area","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153421","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteroventral cochlear nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":["anterior part of anterior cochlear nucleus","anteroventral auditory nucleus"],"NeuronamesID":"720","CurationStatus":"uncurated","Umlscui":"C0926557","SuperCategory":"Regional part of brain","Id":"birnlex_2572","Is part of":"Ventral cochlear nucleus,","Abbrev":["AVCo"]}},{"Anteroventral nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-04","Synonym":["nucleus thalamicus anteroventralis","anteroventral thalamic nucleus","nucleus anteroinferior","nucleus anteroventralis thalami","anteroventral nucleus of the thalamus","nucleus anterior ventralis","nucleus anterior thalami ventralis","nucleus anteroventralis"],"NeuronamesID":"288","CurationStatus":"uncurated","Umlscui":"C0752050","SuperCategory":"Regional part of brain","Id":"birnlex_1372","Is part of":"Anterior nuclear group,","Abbrev":"AV"}},{"Anteroventral nucleus of thalamus of ABA 2009":{"PartiallyOverlapsWith":"Anteroventral nucleus of thalamus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153004","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteroventral periventricular nucleus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","CurationStatus":"uncurated","NeuronamesID":"365","Umlscui":"C0262200","SuperCategory":"Regional part of brain","Id":"birnlex_1401","Is part of":"Anterior hypothalamic region","Abbrev":"AVPe"}},{"Anteroventral periventricular nucleus of ABA 2009":{"PartiallyOverlapsWith":"Anteroventral periventricular nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153603","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteroventral preoptic nucleus":{"PMID":"8946289,1374435","Synonym":"anteroventral preoptic nuclei","CurationStatus":"uncurated","SuperCategory":"Regional part of brain","Id":"nlx_17240","Is part of":"Preoptic area"}},{"Anteroventral preoptic nucleus of ABA 2009":{"PartiallyOverlapsWith":"Anteroventral preoptic nucleus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153534","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Anteroventral to":{"SuperCategory":"Anterior to","Id":"PATO_0001917","Definition":"A relational spatial quality where an entity is located toward the front and abdomen of an organism relative to another entity."}},{"Anteverted":{"SuperCategory":"Oriented","Id":"PATO_0001474","Definition":"An oriented quality inhering in a bearer by virtue of its axis being positioned forward."}},{"Anti saccade paradigm":{"Synonym":"Anti-saccades paradigm","Created":"2006-06-01","CurationStatus":"uncurated","SuperCategory":"Eye Saccade paradigm","Id":"birnlex_2173","Definition":"A behavioral paradigm in which subjects fixate a target and are instructed to make a saccade in the opposite direction of a stimulus (modified from Brain Map by OTF)"}},{"Anti-Muellerian hormone type-2 receptor":{"Synonym":"anti-Muellerian hormone type II receptor ,\"AMH type II receptor\" ,\"MIS type II receptor\" ,\"MISRII\" ,\"MRII\" ,\"AMHR2\" ,\"AMHR\"","CurationStatus":"uncurated","Comment":"Category","SuperCategory":"Protein","Id":"PRO:000000009","Definition":"A protein that is a translation product of the AMHR2 gene or a 1:1 ortholog thereof. (PRO:CNA)"}},{"Antibody":{"Created":"2006-05-15","Synonym":["antibodies"],"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"birnlex_2110","Has role":["Protein specific probe"],"Xref":["PAR:1279 (Protein Affinity Reagent Ontology)"],"Abbrev":"Ab","Definition":"An antibody is any of the structurally related proteins that function as immunoglobulins. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity."}},{"Antibody supplier":{" limit":"1000","Synonym":"Antibody repository","CurationStatus":"uncuratedThis table also available in {{#ask: [[Has role::Category:Antibody supplier]]","SuperCategory":"Reagent supplier"," format":"csv{{#ask: [[Has role::Category:Antibody supplier]]","Id":"birnlex_2480_2","Definition":"A material resource provider, such as a vendor or noncommercial entity, that provides access to antibodies."}},{"Anticonvulsant drug":{"CurationStatus":"uncurated","Id":"CHEBI:35623"}},{"Antidepressant drug":{"Synonym":"Antidpressant","CurationStatus":"uncurated","SuperCategory":"Drug","Id":"CHEBI:35469","Definition":"A mood-stimulating drug used primarily in the treatment of affective disorders and related conditions."}},{"Antihemophilic Factor":{"RelatedTo":["Prothrombin","Coagulation factor X","Coagulation factor IX","Vitamin K-dependent protein C","Vitamin K-dependent protein S","Calnexin","von Willebrand factor","78 kDa glucose-regulated protein","Calreticulin","Low-density lipoprotein receptor-related protein 1","Phytanoyl-CoA dioxygenase","peroxisomal","Asialoglycoprotein receptor 2","ERGIC-53 protein"],"Synonym":["AHF","Coagulation factor VIII precursor","Procoagulant component","antihemophilic factor","Advate","Alphanate","Bioclate","Helixate","Helixate FS","Hemofil M","Humate-P","Hyate:C","Koate-HP","Kogenate","Kogenate FS","Monarc-M","Monoclate-P","ReFacto"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00025","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00025","Definition":"Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells Pharmacology: Antihemophilic Factor binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade. Mechanism of action: Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia). Drug type: Approved. Biotech. Investigational. Drug category: Coagulants. Thrombotic Agents"}},{"Antioxidant":{"CurationStatus":"uncurated","SuperCategory":"Molecule role","Id":"CHEBI:22586","Definition":"A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides."}},{"Antipsychotic drug":{"Synonym":["antipsychotic"],"CurationStatus":"uncurated","SuperCategory":"Drug","Id":"nlx_30993","Definition":"are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect."}},{"Antisaccade-prosaccade task":{"Created":"8/15/2011 11:21","CurationStatus":"uncurated","Contributor":"Corey White","CAO_Id":"CAO_00798","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Antisaccade-prosaccade_task","SuperCategory":"Behavioral Experimental Paradigm","Id":"nlx_146020","Definition":"Subjects view a fixation point and a visual target is presented.  Subjects are instructed to make a saccade away from the target (antisaccade) or to the target (prosaccade)."}},{"Antithymocyte globulin":{"RelatedTo":"T-cell surface glycoprotein CD1a","Synonym":["Thymoglobulin","Genzyme)"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00098","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00098","Definition":"Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells. Pharmacology: This immunosuppressive product, obtained by immunization of rabbits with human thymocytes, contains cytotoxic antibodies directed against antigens expressed on human T-lymphocytes. This reduces the host immune response against tissue transplants or organ allografts. Mechanism of action: Binds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis. Drug type: Approved. Biotech. Drug category: Immunomodulatory Agents"}},{"Antrozous":{"Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C1271536","SuperCategory":"Vespertilionidae","Id":"birnlex_640"}},{"Anucleate":{"SuperCategory":"Nucleate quality","Id":"PATO_0001405","Definition":"A nucleate quality inhering a bearer by virtue of having no nucleus."}},{"Anura":{"Synonym":"Salientia","Created":"2007-08-04","CurationStatus":"pending_final_vetting","Umlscui":"C0003459","SuperCategory":"Batrachia","Id":"birnlex_601"}},{"Anxiety Disorder":{"Synonym":["Neurotic Anxiety State"],"Created":"2007-10-05","CurationStatus":"uncurated","SuperCategory":"Mental Disorder","Id":"birnlex_12671","Definition":"Persistent and disabling ANXIETY (MeSH)."}},{"Anxiety Status Inventory":{"Created":"2008-03-14","Related disease":"Anxiety","CurationStatus":"uncurated","Umlscui":"C0451594","SuperCategory":"Rating scale","Id":"birnlex_3007","Has role":"Affective assessment","Species":"Human","DefiningCitation":["Zung","W.W.K. (1971). A rating instrument for anxiety disorders. Psychosomatics","8","6"],"Abbrev":"ASI","Definition":"The ASI is an assessment of anxiety, consists of 20 somatic and affective symptoms of anxiety. Each item is rated on severity from 1 to 4, where 1 indicates none and 4 indicates severe. The raw score range is from 20 - 80.  This is converted to a percentage, by dividing the raw score by 80 and multiplying by 100. Low scores or percentages indicate low levels of anxiety and high scores indicate high levels of anxiety."}},{"Aotidae":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB)., This is currently listed as an unconfirmed Family taxon name in GBIF. The fact GBIF lists this Familys Genuses under Cebidae is reflected in this classes asserted disjoints.","Created":"2007-08-02","CurationStatus":"raw_import","SuperCategory":"Platyrrhini","Id":"birnlex_353"}},{"Aotus":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB)., As the Family listed in NCBI Tax (Aotidae) is currently listed as an unconfirmed Family taxon name in GBIF, GBIF lists this genus under the Cebidae family.","Synonym":"owl monkey","Created":"2007-08-02","CurationStatus":"raw_import","Umlscui":"C1265472","SuperCategory":"Aotidae","Id":"birnlex_365"}},{"Aotus azarai":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB)., As the Family listed in NCBI Tax (Aotidae) is currently listed as an unconfirmed Family taxon name in GBIF, GBIF lists this genus under the Cebidae family.","Synonym":["Southern night monkey"],"Created":"2007-08-02","CurationStatus":"raw_import","Umlscui":"C1003294","SuperCategory":"Aotus","Id":"birnlex_375"}},{"Aotus trivirgatus":{"EditorialNote":"This class is not intended to present a normative, comprehensive, taxonomic hierarchy, but rather is provided as an approximate indication of the phylogenetic relatedness amongst the taxonomic groups nested under it (BB)., As the Family listed in NCBI Tax (Aotidae) is currently listed as an unconfirmed Family taxon name in GBIF, GBIF lists this genus under the Cebidae family.","Created":"2007-08-20","CurationStatus":"raw_import","Umlscui":"C0003518","SuperCategory":"Aotus","Id":"birnlex_360"}},{"Apache License":{"Created":"2007-10-11","Synonym":["Apache License 2.0"],"CurationStatus":"uncurated","SuperCategory":"Open-source license","Id":"birnlex_2349","Xref":"NITRC_605","Definition":"A free software license authored by the Apache Software Foundation (ASF) which requires preservation of the copyright notice and disclaimer, but is not a copyleft license. It allows use of the source code for the development of proprietary software in addition to free, open source software.  (From http://en.wikipedia.org/wiki/Apache_License)http://www.apache.org/licenses/LICENSE-2.0.html"}},{"Apelin":{"Created":"2007-09-19","SuperCategory":"Peptide","Id":"nifext_5026"}},{"Apelin receptor":{"Created":"2007-09-19","SuperCategory":"G-protein coupled receptor","Id":"nifext_5967"}},{"Apex of cervical spinal cord dorsal horn":{"Synonym":"Apex of cervical spinal cord posterior horn","Created":"2007-08-18","CurationStatus":"raw_import","Umlscui":"C0228612","SuperCategory":"Regional part of cervical spinal cord dorsal horn","Id":"birnlex_1714"}},{"Apex of cochlea":{"Created":"2007-08-25","CurationStatus":"uncurated","Umlscui":"C1184827","SuperCategory":"Regional part of body","Id":"birnlex_2523","Is part of":"Cochlea"}},{"Apex of lumbar spinal cord dorsal horn":{"EditorialNote":"UML has duplicate concept (C1282146).","Synonym":"Apex of lumbar spinal cord posterior horn","Created":"2007-08-18","CurationStatus":"raw_import","Umlscui":"C0228647","SuperCategory":"Regional part of lumbar spinal cord dorsal horn","Id":"birnlex_811"}},{"Apex of spinal cord dorsal horn (birnlex 2670)":{"Created":"2007-08-18","Synonym":"Apex of spinal cord posterior horn","CurationStatus":"uncurated","SuperCategory":"Regional part of spinal cord dorsal horn (birnlex 2671)","Id":"birnlex_2670"}},{"Apex of the cochlear canal":{"Created":"2007-08-28","CurationStatus":"raw_import","Umlscui":"C0458765","SuperCategory":"Regional part of cochlear canal","Id":"birnlex_2555"}},{"Apex of thoracic spinal cord dorsal horn":{"EditorialNote":"UML has duplicate concept (C1288553).","Synonym":"Apex of thoracic spinal cord posterior horn","Created":"2007-08-18","CurationStatus":"raw_import","Umlscui":"C0228629","SuperCategory":"Regional part of thoracic spinal cord dorsal horn","Id":"birnlex_1427"}},{"Apical Dendrite":{"SuperCategory":"Dendrite","Id":"sao273773228"}},{"Apical Pole Of Neuron":{"SuperCategory":"Site","Id":"sao1877927224","Definition":"Portion of a cell soma closest to the point where the apical dendrite emerges."}},{"Apical-basal polarity":{"SuperCategory":"Polarity (PATO 0001769)","Id":"PATO_0002023","Definition":"Polarity that is along an apical-basal axis."}},{"Apidae":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0600167","SuperCategory":"Apoidea","Id":"birnlex_419"}},{"Apinae":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1028360","SuperCategory":"Apidae","Id":"birnlex_427"}},{"Apini":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1094230","SuperCategory":"Apinae","Id":"birnlex_435"}},{"Apis":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0323350","SuperCategory":"Apini","Id":"birnlex_442"}},{"Apis mellifera carnica":{"Created":"2007-08-03","Synonym":"Apis mellifera","CurationStatus":"uncurated","SuperCategory":"Honey bee","Id":"birnlex_154","Definition":"Honey beeApis mellifera"}},{"APJ receptor":{"Synonym":"APJ","Created":"2007-09-19","SuperCategory":"Apelin receptor","Id":"nifext_5968"}},{"Aplastic":{"Synonym":"Undeveloped","SuperCategory":"Hypoplastic","Id":"PATO_0001483","Definition":"Absence of an organ or tissue coupled with persistence of the organ/tissue primordium, which fails to develop completely."}},{"Aplastic growth":{"Synonym":["dysgenesis"],"SuperCategory":"Growth quality of occurrent","Id":"PATO_0002019","Definition":"Growth quality of occurrent in which the growth of an organism, structure, or group of organisms does not occur."}},{"Aplysia":{"Created":"2007-08-03","CurationStatus":"http://purl.org/nbirn/birnlex/ontology/annotation/BIRNLex_annotation_properties.owl#pending_final_vetting","Umlscui":"C0003577","SuperCategory":"Aplysiidae"," format":"ul","Curator":["Bill Bug[[Category:Aplysiidae]]* Externally Sourced Definition: [[externallySourcedDefinition::* An opisthobranch mollusk of the order Anaspidea. It is used frequently in studies of nervous system development because of its large identifiable neurons. Aplysiatoxin and its derivatives are not biosynthesized by Aplysia","but acquired by ingestion of Lyngbya (seaweed) species. (MSH) * genus of motile gastropods with a poorly developed or missing shell; used in neurobiology studies because it possesses a simple nervous system with large"],"Id":"birnlex_464"}},{"Aplysia buccal 15":{"CellSomaSize":"Medium soma","PMID":"2881988","CurationStatus":"uncurated","Neurotransmitter":["Acetylcholine"],"SuperCategory":"Neuron","Id":"nlx_152508","Species":["Aplysia californica"],"Definition":"Accessory radular closure (ARC) muscle motor neuron."}},{"Aplysia buccal 20":{"Located in":["Aplysia buccal ganglia"],"CurationStatus":"uncurated","Neurotransmitter":"Dopamine","FiringPatterns":"bursting","SuperCategory":"Neuron","Id":"nlx_152107","Species":"Aplysia californica,","Abbrev":"B20","Definition":"pattern initiating neuron. Biases feeding motor patterns to rejection type."}},{"Aplysia buccal 30":{"Located in":["Aplysia buccal ganglia"],"PMID":"15254087","CurationStatus":"uncurated","SuperCategory":"Neuron","Id":"nlx_152511","Species":["Aplysia californica"],"Abbrev":"B30","Definition":"aplysia buccal neuron that is active during protraction phase and promotes the expression of ingestion type activity motor patterns."}},{"Aplysia buccal 31":{"Located in":"Aplysia buccal ganglia,","CellSomaSize":"Small soma","PMID":"3385489","Synonym":["Aplysia buccal 31"],"CurationStatus":"uncurated","FiringPatterns":"Plateau potentials","SuperCategory":"Neuron","Id":"nlx_152516","Species":"Aplysia californica,","Abbrev":["B31/32","B31"],"Definition":"Initiates feeding motor patterns. Active during the protraction phase of feeding motor patterns."}},{"Aplysia buccal 4":{"Located in":"Aplysia buccal ganglia","Synonym":"Aplysia buccal 5","CurationStatus":"uncurated","Neurotransmitter":"Acetylcholine,","SuperCategory":"Neuron","Id":"nlx_152070","Species":"Aplysia californica,","Abbrev":["B4, B5"],"Definition":"Sensory motor neuron of the buccal ganglia."}},{"Aplysia buccal 51":{"Located in":"Aplysia buccal ganglia,","CurationStatus":"uncurated","Pages":"539 - 558","FiringPatterns":"Plateau potentials","JournalVolume":"63","Authors":"Plummer MR and Kirk MD","Title":["Premotor neurons B51 and B52 in the buccal ganglia of aplysia californica: Synaptic connections","effects on ongoing motor rythms"],"Abbrev":"B51","PublicationDate":"1990","SuperCategory":"Neuron","PublicationName":"J Neurophysiol","Id":"nlx_152108","JournalNumber":"3","Species":"Aplysia californica,","Definition":"Active during the retraction phase of feeding motor patterns. Biases feeding motor patterns towards ingestion like."}},{"Aplysia buccal 61":{"Located in":"Aplysia buccal ganglia,","CellSomaSize":"Medium soma","PMID":"8035232","Synonym":["Aplysia buccal 62"],"CurationStatus":"uncurated","FiringPatterns":"Regular spiking","SuperCategory":"Neuron","Id":"nlx_152510","Species":"Aplysia californica,","Abbrev":"B61","Definition":"Intrinsic muscle 2 motor neuron. Mediates protraction of the radula."}},{"Aplysia buccal 8":{"Located in":"Aplysia buccal ganglia,","CellSomaSize":"Large soma","PMID":"8263840","CurationStatus":"uncurated","FiringPatterns":"Regular spiking","SuperCategory":"Neuron","Id":"nlx_152509","SpontaneousFiringPatterns":"Regular firing","Species":"Aplysia californica,","Abbrev":"B8","Definition":"Motor neuron that innervates the I4 muscle to mediate radular closure."}},{"Aplysia buccal ganglia":{"CurationStatus":"uncurated","EfferentProjections":"Aplysia Cerebral ganglia","SuperCategory":"Regional part of brain","Id":"nlx_152072","Species":"Aplysia californica,","AfferentProjections":"Aplysia Cerebral ganglia","Definition":"This ganglia mediates feeding behavior.  Neurons within this ganglia produce either ingestion or rejection rhythmic patterned activity."}},{"Aplysia californica":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998099","SuperCategory":"Aplysia","Id":"birnlex_470"}},{"Aplysia Cerebral ganglia":{"CurationStatus":"uncurated","EfferentProjections":"Aplysia buccal ganglia","SuperCategory":"Regional part of brain","Id":"nlx_152110","Species":["Aplysia californica"],"AfferentProjections":"Aplysia buccal ganglia"}},{"Aplysia cerebral ganglion metacerebral cell":{"Located in":"Cerebral ganglia","Located_in":"cerebral ganglion","EditorialNote":"http://neuronbank.org/wiki/index.php/Aplysia_cerebral_ganglia","Synonym":["Giant Serotonergic Neuron"],"CurationStatus":"uncurated","Neurotransmitter":"Serotonin","ExampleImage":"Aplysia cerebral ganglion metacerebral cell.jpg,","SuperCategory":"Neuron","Id":"nlx_cell_20090313","Species":"Aplysia","Abbrev":"MCC","Definition":"Largest Serotonergic Neuron in the anterior portion of the cerebral ganglion of Aplysia.  This neuron has axons that project to the buccal ganglion."}},{"Aplysiidae":{"Synonym":["Dolabellidae"],"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998098","SuperCategory":"Aplysioidea","Id":"birnlex_458"}},{"Aplysioidea":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1228801","SuperCategory":"Anaspidea","Id":"birnlex_452"}},{"Apocrita":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0998568","SuperCategory":"Hymenoptera","Id":"birnlex_503"}},{"Apogastropoda":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1228774","SuperCategory":"Orthogastropoda","Id":"birnlex_453"}},{"Apoidea":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0004923","SuperCategory":"Aculeata","Id":"birnlex_410"}},{"Apolipoprotein":{"CurationStatus":"uncurated","SuperCategory":"Protein","Id":"nlx_mol_090902"}},{"Apolipoprotein E":{"Synonym":"Apo-E; Apolipoprotein E precursor; Apolipoprotein E","CurationStatus":"uncurated","SuperCategory":"Apolipoprotein","Id":"nlx_mol_090903"}},{"Apolipoprotein J":{"CurationStatus":"uncurated","SuperCategory":"Apolipoprotein","Id":"nlx_mol_090904"}},{"Apomorphine":{"RelatedTo":["D(1A) dopamine receptor","D(1B) dopamine receptor","D(4) dopamine receptor","D(3) dopamine receptor","D1 dopamine receptor-interacting protein calcyon"],"Synonym":["Apomorfin","Apomorphine Hydrochloride Hemihydrate","Apomorphinium Chloride Hemihydrate","Apormorphine","L-Apomorphine","VR-040","VR-400","VR004","apomorphine","APOKYN","Ixense"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:48538","Has role":["Drug"],"DefiningCitation":"http://www.drugbank.ca/drugs/DB00714","Definition":"A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. (PubChem) Pharmacology: Apomorphine is a type of dopaminergic agonist, a morphine derivative which primarily affects the hypothalamic region of the brain. Drugs containing this substance are sometimes used in the treatment of Parkinson's disease or erectile dysfunction. In higher doses it is a highly effective emetic. Mechanism of action: The precise mechanism of action of apomorphine as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D2-type receptors within the brain. Apomorphine has been shown to improve motor function in an animal model of Parkinson's disease. In particular, apomorphine attenuates the motor deficits induced by lesions in the ascending nigrostriatal dopaminergic pathway with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in primates. Drug type: Approved. Investigational. Small Molecule. Drug category: Antidyskinetics. Antiparkinson Agents. Dopamine Agonists"}},{"Apoptotic":{"SuperCategory":"Structure","Id":"PATO_0000638"}},{"Appalachian brook crayfish":{"EditorialNote":"Note this is given as unspecified with a Kingdom: Unknown in BGIF.","Synonym":"Cambarus bartoni","Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1688715","SuperCategory":"Cambarus","Id":"birnlex_250"}},{"Appetitive activity":{"Created":"2007-03-06","EditorialNote":"I'm not sure that the examples given here are consistent with the synonym \"eating\".  Rather, these activities are part of and activity that is \"feeding/eating\". So I deleted them.  I would also favor moving \"feeding\" to the preferred label and getting rid of \"appetitive activity\"","Synonym":["eating"],"CurationStatus":"uncurated","SuperCategory":"Behavioral activity","Id":"birnlex_1881"}},{"Appetitive function":{"Created":"2007-03-06","CurationStatus":"uncurated","SuperCategory":"Behavioral system function","Id":"birnlex_1888","Definition":"Explorative or goal-directed behavior (http://www.springerreference.com/docs/search?query"}},{"Applicable Frame Range":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0028_6102","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149559","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"US","Definition":"Each pair of numbers in this multivalued attribute specify a beginning and ending frame number inclusive of a range where this particular mask operation is valid. Discontinuous ranges are represented by multiple pairs of numbers."}},{"Applicable Safety Standard Description":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:0018_9175","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149561","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Name and Version of the applicable standard."}},{"Application programming interface":{"Created":"2007-10-09","CurationStatus":"uncurated","SuperCategory":"Data access protocol","Id":"birnlex_2235","Abbrev":"API"}},{"Application Setup Check":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:3008_0116","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149562","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Results of check-wire travel through all channels of current Application Setup."}},{"Application Setup Manufacturer":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0238","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149563","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"Manufacturer of Application Setup."}},{"Application Setup Name":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0236","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149564","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"User-defined name for Application Setup."}},{"Application Setup Number":{"ValueRepresentation":"IS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0234","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149565","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"IS","Definition":"Identification number of the Application Setup. The value of Application Setup Number (300A,0234) shall be unique within the RT Plan in which it is created."}},{"Application Setup Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0230","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149566","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of Application Setups for current RT Plan. One or more items may be included in this sequence."}},{"Application Setup Type":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0232","CurationStatus":"uncurated","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149567","Has role":"Imaging protocol attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Type of Application Setup."}},{"Applicator Description":{"ValueRepresentation":"LO","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_010A","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149568","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LO","Definition":"User-defined description for Applicator."}},{"Applicator ID":{"ValueRepresentation":"SH","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0108","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149569","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SH","Definition":"User or machine supplied identifier for Applicator. Required if Applicator Sequence (300A,0107) is sent."}},{"Applicator Sequence":{"ValueRepresentation":"SQ","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0107","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149570","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"SQ","Definition":"Introduces sequence of Applicators associated with Beam. Only a single item shall be permitted in this sequence."}},{"Applicator Type":{"ValueRepresentation":"CS","RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:300A_0109","Comment":"DICOM specific term","SuperCategory":"DICOM term","Id":"nlx_149571","Has role":"Imaging hardware attribute","Is part of":"Resource:DICOM standard","Value_Representation":"CS","Definition":"Type of Applicator. Required if Applicator Sequence (300A,0107) is sent."}},{"Apraclonidine":{"RelatedTo":"Alpha-2A adrenergic receptor","Synonym":["Apraclonidina (INN-Spanish)","Apraclonidinum (INN-Latin)","P-Aminoclonidine Hydrochloride","Aplonidine","Iopidine"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00964","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00964","Definition":"Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. Pharmacology: Apraclonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. Mechanism of action: Apraclonidine is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Apraclonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Drug type: Approved. Small Molecule. Drug category: Adrenergic alpha-Agonists. Antiglaucomic Agents. EENT Drugs. Ophthalmics"}},{"Aprepitant":{"RelatedTo":"Substance-P receptor","Synonym":["MK-0517","MK-869","aprepitant","fosaprepitant"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00673","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00673","Definition":"Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). Pharmacology: Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). Mechanism of action: Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with Aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that Aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroidethasone and inhibits both the acute and delayed phases of cisplatin induced emesis. Drug type: Approved. Investigational. Small Molecule. Drug category: Antiemetics"}},{"APV":{"PMID":"6111052","Synonym":["AP5","(2R)-amino-5-phosphonovaleric acid","(2R)-amino-5-phosphonopentanoate"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"nlx_94485","Has role":["Antagonist role","Drug"],"Definition":"selective NMDA receptor antagonist that competitively inhibits the ligand (glutamate) binding site of NMDA receptors. - from Wikipedia"}},{"Aquaporin 4":{"SuperCategory":"Protein","Id":"sao1548226791","Abbrev":"AQP4"}},{"Arachidonic acid":{"Synonym":"(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid","CurationStatus":"uncurated","SuperCategory":"Fatty acid","Id":"CHEBI:15843"}},{"Arachnoid membrane":{"Synonym":["Arachnoid mater"],"SuperCategory":"Leptomeninx","Id":"nlx_anat_090208","Definition":"One of two leptomeningeal membranes covering the brain and spinal cord.  The arachnoid membrane lies under the dura mater and above the pial membrane.  It closely hugs the outside surface of the brain in many places, but does not extend into sulci in gyrencephalic species."}},{"Arbitrary":{"RelatedTo":"BIRN-INCF Derived Data Project","DICOMID":"DICOM:4000_0010","Comment":"general term","SuperCategory":"DICOM term","Id":"nlx_149572","Has role":"Imaging data attribute","Is part of":"Resource:DICOM standard","Value_Representation":"LT","Definition":"TBD (retired)."}},{"Arbor Vitae":{"CurationStatus":"uncurated","ExampleImage":"File:File:CerebellumRegion ArborVitae.jpg","SuperCategory":"Regional part of cerebellar white matter","Id":"nlx_anat_20090101","Is part of":["Cerebellar white matter"],"Definition":"The white matter contained within the cerebellum, lying deep to the granule cell layer in the cerebellar cortex, excluding the parts of the cerebellar peduncles that extend outside of the cerebellum.  The deep cerebellar nuclei are embedded within the arbor vitae."}},{"Arbutamine":{"RelatedTo":"Beta-1 adrenergic receptor","CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:50580","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01102","Definition":"Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately . Pharmacology: Not Available Mechanism of action: Arbutamine is a synthetic catecholamine with positive chronotropic and inotropic properties. The chronotropic (increase in heart rate) and inotropic (increase in force of contraction) effects of arbutamine serve to mimic exercise by increasing cardiac work (producing stress) and provoke myocardial ischemia in patients with compromised coronary arteries. The increase in heart rate caused by arbutamine is thought to limit regional subendocardial perfusion, thereby limiting tissue oxygenation. In functional assays, arbutamine is more selective for beta-adrenergic receptors than for alpha-adrenergic receptors. The beta-agonist activity of arbutamine provides cardiac stress by increasing heart rate, cardiac contractility, and systolic blood pressure. The degree of hypotension that occurs for a given chronotropic activity is less with arbutamine than, for example, with isoproterenol because alpha receptor activity is retained. Drug type: Approved. Small Molecule. Drug category: Adrenergic beta-Agonists. Cardiotonic Agents"}},{"Arched":{"SuperCategory":"Concave","Id":"PATO_0001594","Definition":"Forming or resembling an arch."}},{"Archosauria":{"Created":"2007-06-03","CurationStatus":"pending_final_vetting","Umlscui":"C0999075","SuperCategory":"Sauria","Id":"birnlex_218"}},{"Arcitumomab":{"RelatedTo":"Carcinoembryonic antigen-related cell adhesion molecule 1","Synonym":["IMMU-4","anti-Carcinoembryonic Antigen Monoclonal Antibody Fab' Fragment","arcitumomab"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00113","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00113","Definition":"Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight of ~54,000 Daltons. Pharmacology: Binds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors Mechanism of action: Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors. Drug type: Approved. Biotech. Investigational. Drug category: Diagnostic Agents. Imaging Agents"}},{"ArcLight":{"CurationStatus":"uncurated","SuperCategory":"Fluorescent protein","Id":"nlx_152495","Has role":"Fluorescent protein voltage sensor","DefinitionPMID":"22958819"}},{"Arcopallium":{"Synonym":"archistriatum; Arcopallium","CurationStatus":"uncurated{{PONS brain region","SuperCategory":"Regional part of brain","Id":"nlx_144487","Is part of":"Pallium","Abbrev":"A"}},{"Arctia":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C0323251","SuperCategory":"Arctiinae","Id":"birnlex_563"}},{"Arctiinae":{"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1090493","SuperCategory":"Tiger moths","Id":"birnlex_556"}},{"Arcuate hypothalamic nucleus of ABA 2009":{"CurationStatus":"uncurated","PartiallyOverlapsWith":"Arcuate nucleus of hypothalamus","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_152922","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Is part of":"Periventricular zone of ABA 2009","Species":"Mouse"}},{"Arcuate nucleus of hypothalamus":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-19","AtlasImage":"Brainmaps_INF.jpg,","Synonym":["arcuate periventricular nucleus","Infundibular hypothalamic nucleus"],"CurationStatus":"uncurated","NeuronamesID":"378","Umlscui":"C0003741","SuperCategory":"Regional part of brain","Id":"birnlex_1638","Is part of":"Intermediate hypothalamic region","Species":"Mammal","Abbrev":"ArcH"}},{"Arcuate nucleus of medulla":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","Synonym":["nucleus arciformis pyramidalis","arcuate nucleus"],"CurationStatus":"uncurated","NeuronamesID":"772","Umlscui":"C0228544","SuperCategory":"Regional part of brain","Id":"birnlex_2635","Is part of":"Medulla oblongata","Abbrev":"ArcM"}},{"Arcuate sulcus":{"CurationStatus":"uncurated","NeuronamesID":"2379","SuperCategory":"Sulcus","Id":"nlx_153910","Is part of":"Frontal lobe","Species":"Macaque","Definition":"Composite sulcus of the frontal lobe of the macaque. Located on the dorsolateral surface, it consists of the superior ramus of the arcuate sulcus (macaque), the inferior ramus of the arcuate sulcus and the spur of the arcuate sulcus (macaque) (http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID"}},{"Ardeparin":{"RelatedTo":"Heparin cofactor 2","SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB00407","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00407","Definition":"Ardeparin (brand name Normiflo) is an anticoagulant. It is used for prevention of deep vein thrombosis. (Wikipedia) Pharmacology: Ardeparin, an anticoagulant, is a fractionated heparin. It acts at multiple sites in the normal coagulation system to inhibit reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Mechanism of action: Ardeparin binds to antithrombin III, accelerating its activity and inactivating factor Xa and thrombin, thereby inhibiting thrombosis. Ardeparin also binds to heparin cofactor II, inhibiting thrombin. Ardeparin does not effect prothrombin time (PT) assays and may prolong activated partial thromboplastin time (APTT). Ardeparin has double the anti-factor Xa activity of anti-factor IIa activity, compared to unfractionated heparin which has approximately equal anti-factor Xa activity and anti-factor IIa activity. Drug type: Approved. Small Molecule. Drug category: Anticoagulants. Fibrinolytic Agents"}},{"Area":{"SuperCategory":"2-D extent","Id":"PATO_0001323","Definition":"A 2-D extent inhering in a bearer by virtue of its two dimensional extent."}},{"Area 4 of cortex primary motor of PHT00":{"Synonym":"area 4 of cortex (primary motor)","CurationStatus":"uncurated","ISBN":"123582555","Comment":"//appears as \"4\" in PHT00","Curator":"CoCoMac{{PONS brain region","Authors":["George Paxinos","Xu-Feng Huang"],"Title":"The Rhesus Monkey Brain in Stereotaxic Coordinates","Abbrev":"4","PartiallyOverlapsWith":"primary motor cortex","PublicationDate":"2000","SuperCategory":"PHT00 macaque brain parcel","Id":"nlx_br_145","Is part of":"Isocortex of PHT00","ParcellationScheme":["Paxinos"],"Species":"Macaque","DefiningCitation":"ISBN 0123582555"}},{"Area density":{"SuperCategory":"Density (PATO 0001019)","Id":"PATO_0001351","Definition":"A density quality which is equal to the mass exerting an influence on a given area."}},{"Area postrema":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-08-28","CurationStatus":"uncurated","NeuronamesID":"769","Umlscui":["C1289468"],"SuperCategory":"Circumventricular organ","Id":"birnlex_2636","Is part of":"Medulla oblongata,","Abbrev":"AP"}},{"Area postrema of ABA 2009":{"PartiallyOverlapsWith":"Area postrema","SuperCategory":"ABA 2009 mouse brain parcel","Id":"nlx_153728","ParcellationScheme":"ABA 2009 adult mouse brain parcellation scheme","Organism":"mouse"}},{"Area prostriata of DMVH2003":{"CurationStatus":"uncurated","ChemoDefiningCriteriaPMID":"12509875","CytoDefiningCriteria":["accentuated layer 2","wide and lightly stained layer 3 and poorly developed layer 4","along with a poorly defined border between layers 5 and 6 (see fig 3","4","5 and 7).  An anterior and posterior part were distinguished based on layer 4"],"CytoDefiningCriteriaPMID":"12509875","DefiningCriteria":"cyto-architecture","PartiallyOverlapsWith":"prostriate area","ChemoDefiningCriteria":["Slightly higher density of parvalbumin+ cells and neuropil in the anterior portion compared to the adjacent parasubiculum","but lower compared to area 29i and to the posterior portion of the parastriate area.  The difference between the parastriate area and area 18 is most clearly defined in SMI-32 stained sections"],"SuperCategory":"Regional part of brain","Id":"nlx_149262","ParcellationScheme":"DMVH2003 parcellation scheme","Is part of":"Cingulo-parahippocampal isthmus of DMVH2003","OrganismPMID":"12509875","ParcellationSchemePMID":"12509875","Species":"Macaque,","Definition":"Cytoarchitecturally defined region within the isthmus of the cingulate cortex located posterior to the parasubiculum of the isthmus, bordering area 17 posteriorly, further divided into an anterior and posterior portion based on cytoarchitectureal and immunocytochemical criteria","DefinitionPMID":"12509875"}},{"Area X":{"NeuronamesLink":"http://braininfo.rprc.washington.edu/Scripts/hiercentraldirectory.aspx?ID","Created":"2007-03-03","EditorialNote":"Synonyms derived both from UMLS and from NN, with NN given precedence (BB: 2007-03-03).","Synonym":["superior part","nucleus ventrooralis internus","nucleus ventralis oralis","pars posterior (Dewulf)","nucleus ventrooralis internus (Hassler)","area X of Olszewski","nucleus lateralis intermedius mediodorsalis situs ventralis medialis"],"NeuronamesID":"325","CurationStatus":"uncurated","Umlscui":"C0262201","SuperCategory":"Regional part of brain","Id":"birnlex_1379","Is part of":"Ventral lateral nucleus"}},{"Arformoterol":{"RelatedTo":"Beta-2 adrenergic receptor","Synonym":["(R,R)-formoterol","arformoterol"],"SuperCategory":"Molecular entity","Comment":"taken from DrugBank","Id":"DB01274","Curator":"ab","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01274","Definition":"Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Pharmacology: Arformoterol, the (R,R)-enantiomer of formoterol, is a selective long-acting beta2-adrenergic receptor agonist (beta2-agonist) that has two-fold greater potency than racemic formoterol (which contains both the (S,S) and (R,R)-enantiomers). The (S,S)-enantiomer is about 1,000-fold less potent as a beta2-agonist than the (R,R)-enantiomer. Mechanism of action: While it is recognized that beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, data indicate that there are also beta2-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including arformoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3,5-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-response. Drug type: Approved. Investigational. Small Molecule. Drug category: Adrenergic beta-Agonists. Bronchodilator Agents"}},{"Argatroban":{"RelatedTo":"Prothrombin","Synonym":"argatroban,","CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:48720","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB00278","Definition":"Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. In 2002, it was approved for use during percutaneous coronary interventions in patients who have or at risk for developing HIT. (Wikipedia) Pharmacology: Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Argatroban is highly selective for thrombin with an inhibitory constant (Ki) of 0.04 M. At therapeutic concentrations, Argatroban has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein).Argatroban is capable of inhibiting the action of both free and clot-associated thrombin. Mechanism of action: Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Drug type: Approved. Investigational. Small Molecule. Drug category: Anticoagulants. Platelet Aggregation Inhibitors"}},{"Arhynchobdellida":{"Synonym":["Arhynchobdellae"],"Created":"2007-08-03","CurationStatus":"pending_final_vetting","Umlscui":"C1001462","SuperCategory":"Hirudinea","Id":"birnlex_172"}},{"Aripiprazole":{"RelatedTo":["5-hydroxytryptamine 1A receptor","5-hydroxytryptamine 2A receptor"],"Synonym":["OPC 31","OPC-14597","aripiprazole","Abilify"],"CurationStatus":"uncurated","Comment":"taken from DrugBank","SuperCategory":"Molecular entity","Curator":"ab","Id":"CHEBI:31236","Has role":"Drug","DefiningCitation":"http://www.drugbank.ca/drugs/DB01238","Definition":"Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors. Pharmacology: Aripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. Mechanism of action: Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5- HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors and moderate affinity for the serotonin reuptake pump. Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors. Aripiprazole functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptor. Drug type: Approved. Investigational. Small Molecule. Drug category: Antipsychotic Agents. Antipsychotics"}},{"Armina":{"Created":"2008-02-05","CurationStatus":"pending_final_vetting","Umlscui":"C1085235","SuperCategory":"Arminidae","Id":"birnlex_7278"}},{"Armina californica":{"Created":"2008-02-05","CurationStatus":"pending_final_vetting","SuperCategory":"Armina","Id":"birnlex_7279"}},{"Armina lovenii":{"Synonym":"Armina loveni","Created":"2008-02-05","CurationStatus":"pending_final_vetting","Umlscui":"C1028709","SuperCategory":"Armina","Id":"birnlex_7280"}},{"Arminidae":{"Created":"2008-02-05","CurationStatus":"pending_final_vetting","Umlscui":"C1028708","SuperCategory":"Euarminoidea","Id":"birnlex_7276"}},{"Arminina":{"Synonym":"Arminacea","Created":"2008-02-05","CurationStatus":"pending_final_vetting","Umlscui":"C1028703","SuperCategory":"Nudibranchia","Id":"birnlex_7275"}},{"Aroclor 1016":{"Synonym":["1,1'-Biphenyl","3,3',5-trichloro-","3,3',5-Trichlorophnel","Arochlor 1016","Aroclor 1016","Chlorodiphenyl (41% Cl)"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0051","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0051","Abbrev":"C12H7Cl3","Definition":"Organic Compound;Coolant;Plasticizer;Polychlorinated Biphenyl;Aromatic Hydrocarbon;Organochloride; Aroclor 1016 is a commercial mixture of PCBs with an average chlorine content of 41.5%. It is composed of mainly trichlorobiphenyls (54.67%), and also includes mono-, bi-, tetra-, and pentachlorinated homologs."}},{"Aroclor 1221":{"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0048","Has role":["Toxin"],"DefiningCitation":"http://t3db.org/toxins/T3D0048","Abbrev":"C12H4Cl6","Definition":"Organic Compound;Coolant;Plasticizer;Polychlorinated Biphenyl;Aromatic Hydrocarbon;Organochloride; Aroclor 1221 is a commercial mixture of PCBs with an average chlorine content of 21%. It is composed of mainly monochlorobiphenyls (60.06%), and also includes bi-, tri, tetra-, and pentachlorinated homologs."}},{"Aroclor 1242":{"Synonym":["2,2',4,4'-Tetrachloro-1,1'-Biphenyl","2,2',4,4'-Tetrachlorobiphenyl","2,2',4,4'-Tetrachlorodiphenyl","2,4,2',4'-Tetrachlorobiphenyl","2,2',4,4'-Tetrachloro-Biphenyl","Chlorierte biphenyle","chlorgehalt 42%","Chlorodiphenyl (42% Cl)","Chlorodiphenyl (42% chlorine)","Clorodifenili cloro 42%","Diphenyle chlore 42% de chlore","Gechloreerdedifenyl"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0029","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0029","Abbrev":"C12H6Cl4","Definition":"Organic Compound;Coolant;Plasticizer;Polychlorinated Biphenyl;Aromatic Hydrocarbon;Organochloride; Aroclor 1242 is a commercial mixture of PCBs with an average chlorine content of 41.5%. It is composed of mono- to hexachlorinated homologs."}},{"Aroclor 1248":{"Synonym":["3,3',5,5'-Tetrachloro-1,1'-Biphenyl","3,3',5,5'-Tetrachlorodiphenyl","3,5,3',5'-Tetrachlorobiphenyl","Aroclor 1248","3,3',5,5'-Tetrachloro-Biphenyl","Kanechlor 400"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0027","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0027","Abbrev":"C12H6Cl4","Definition":"Organic Compound;Coolant;Plasticizer;Polychlorinated Biphenyl;Aromatic Hydrocarbon;Organochloride; Aroclor 1248 is a commercial mixture of PCBs with an average chlorine content of 48%. It is composed of mono- to heptachlorinated homologs."}},{"Aroclor 1254":{"Synonym":["2,2',3,3',4-pentachloro-1,1'-Biphenyl","2,2',3,3',4'-Pentachlorobiphenyl","2,2',3,4,5-Pentachlorobiphenyl","2,3,4,2',3'-Pentachlorobiphenyl","Chlorierte biphenyle chlorgehalt 54%","Chlorodiphenyl (54% Chlorine)","Clorodifenili cloro 54%","Diphenyle chlore 54% de chlore","PCB","PCB's (54% Cl)","Polychlorinated biphenyl"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0013","Has role":"Toxin","DefiningCitation":"http://t3db.org/toxins/T3D0013","Abbrev":"C12H5Cl5","Definition":"Organic Compound;Coolant;Plasticizer;Polychlorinated Biphenyl;Aromatic Hydrocarbon;Organochloride; Aroclor 1254 is a commercial mixture of PCBs with an average chlorine content of 54%. It is composed of mainly pentachlorobiphenyls (71.44%) and hexachlorobuphenyls (21.97%) and also includes mono-, bi-, tri, tetra-, hexa, and nonachlorinated homologs."}},{"Aroclor 1260":{"Synonym":["2,2',3,3',4,4'-hexachloro-1,1'-Biphenyl","2,2',3,3',4,4'-Hexachlorobiphenyl","2,3,4,2',3',4'-Hexachlorobiphenyl","Chlorodiphenyl (60% Cl)","Clophen A 60","Phenoclor DP6"],"CurationStatus":"uncurated","SuperCategory":"Molecular entity","Id":"T3D0014","Has role":"Toxin","Is part of":"Polychlorinated biphenyl","DefiningCitation":"http://t3db.org/toxins/T3D0014","Abbrev":"C12H4Cl6","Definition":"is a commercial mixture of PCBs with an average chlorine content of 60%. It is composed of mainly pentachlorobiphenyls (43.35%) and hexachlorobuphenyls (38.54%) and also includes mono-, bi-, tri, tetra-, hexa-, octa- and nonachlorinated homologs."}},{"Aromatic L-Amino Acid Decarboxylase":{"RelatedTo":["Dopamine","L Dopa","Dopaminergic system"],"Synonym":"DOPA decarboxylase; DDC; Dopa decarboxylase; Dopa-decarboxylase; DOPA-decarboxylase; Aromatic L-amino acid decarboxylase; EC 4.1.1.28;","CurationStatus":"uncurated","SuperCategory":"Protein","Id":"PRO:000006342","Has role":"Synthetic Enzyme,","Is part of":["Catecholamine system"],"DefiningCitation":["PRotein Ontology; \"Principles of Neuropsychopharmacology\" Feldman","Meyer"],"Abbrev":"AADC","Definition":"A protein that is a translation product of the DDC gene or a 1:1 ortholog thereof. It is a synthetic enzyme that is involved in the second step of the catecholamine synthesis, in which it converts L-DOPA to dopamine via the removal of the carboxyl group from the alpha-carbon on the side chain, with the subsequent liberation of free carbon dioxide. This process also involves the co-factor Pyridoxal phosphate. AADC acts on a variety of aromatic amino acids besides DOPA. (Adapted from \"Principles of Neuropsychopharmacology\" and PRotein Ontology)."}},{"Arousal":{"Created":"8/15/2011 7:49","CurationStatus":"uncurated","Contributor":"Corey White","CAO_Id":"CAO_00134","Cognitive_Atlas_Link":"http://www.cognitiveatlas.org/concept/Arousal","SuperCategory":"Motivational state","Id":"nlx_145345","Definition":"physiological readiness for activity."}},{"Array tomography":{"PMID":"17610815","CurationStatus":"uncurated","SuperCategory":"Microscopic imaging assay","Id":"nlx_152219","DefiningCitation":["Micheva and Smith"],"DefinitionPMID":"17610815","Definition":"Imaging assay that employs methods for constructing and repeatedly staining and imaging ordered arrays of ultrathin (50\u2013200 nm), resin-embedded serial sections on glass microscope slides, using fluorescence and electron microscopic imaging, followed by 3D reconstruction."}},{"Arrested":{"Synonym":"incomplete","SuperCategory":"Duration","Id":"PATO_0000297","Definition":"A duration which ends earlier than the natural end time."}}]}